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Summary 
Cystic fibrosis (CF; mucoviscidosis) is the most common inherited disease in the western 
population and lung disease due to respiratory infections is the leading cause of death in CF. 
Routine clinical diagnostics are focusing on the detection of only a modest number of 
microbial pathogens but recent studies suggest that pulmonary infections in CF patients are 
polymicrobial. Thus, this thesis aimed to contribute to a more profound understanding of the 
microbial communities present in the airways of adult CF patients. For this purpose, sputum 
samples were collected from 56 patients and analyzed with culture-independent methods, 
such as single-strand conformation polymorphism (SSCP) fingerprinting and Illumina 
sequencing. From a smaller subcohort, samples were repeatedly collected and the temporal 
dynamics of microbial communities analyzed. However, spatial heterogeneity of microbial 
communities in the CF lung and in sputum samples are known to potentially bias the 
diagnostic accuracy of conventional methods based on sputum, therefore, a rapid and non-
invasive breath analytical method was developed to detect microbial biomarkers (volatile 
organic compounds; VOCs) in exhaled air of the infected host and the feasibility of the 
method was tested in a CF outpatient clinic. 
Only culture-independent methods revealed the broad spectrum of microorganisms associated 
with sputum from CF patients. Profiling of bacterial communities was performed and revealed 
no strong correlation between lung function and individual relative abundances of single 
species. In a polymicrobial perspective, however, distinct and persistent subgroups of 
bacterial communities could be defined by the individual compositions of species. In contrast 
to bacteria, an unexpected high richness of fungi was detected. Likewise, high fluctuation 
rates in species numbers were observed over time and between different patients, suggesting 
rather low colonization abilities of fungi in CF airways. For the breath analytical diagnostic 
approach, it was at first demonstrated that VOCs released by microorganism allowed 
discrimination of pathogens in vitro. The microbial-specific compounds observed in vitro 
were not detected in the exhaled breath of infected patients in vivo; however, the individual 
VOCs compositions monitored in exhaled breath allowed distinction between CF patients and 
controls.  
Overall, this thesis supports the hypothesis of polymicrobial consortia being involved in 
pulmonary infections and provides for the first time an overview of the entire microbiome in a 
broader CF cohort, including fungi and bacteria. Furthermore, the potential of exhaled VOCs 
analysis to identify patients with certain pulmonary infections was demonstrated which may 
facilitate rapid and highly accurate diagnosis in the future.        
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Zusammenfassung 
Zystische Fibrose (CF; Mukoviszidose) ist die häufigste erbliche Stoffwechselerkrankung in 
der europiden Bevölkerung. Die führende Todesursache bei CF ist eine durch Infektionen 
hervorgerufene Schädigung der Lunge. Während die klinische mikrobiologische Diagnostik 
noch auf einer relativ kleinen Anzahl Krankheitserreger spezialisiert ist, deuten aktuelle 
wissenschaftliche Studien auf polymikrobielle Lungeninfektionen als häufigste Todesursache 
hin. Ziel der vorliegenden Arbeit war es daher die mikrobiologischen Lebensgemeinschaften 
in den Atemwegen von adulten CF-Patienten zu analysieren. Sputumproben von 56 Patienten 
wurden mit molekularen, kulturunabhängigen Methoden untersucht, hierzu zählen 
molekulares "Fingerprinting" und die Sequenziertechnik von Illumina. Von einer kleineren 
Subkohorte wurden wiederholt Sputumproben gesammelt, um die Dynamik der 
mikrobiologischen Gemeinschaften zu analysieren. Bei einer auf Sputumproben basierenden 
Diagnostik können jedoch räumliche Heterogenitäten in den mikrobiologischen 
Gemeinschaften der Lunge sowie in den Proben selbst zu einem unvollständigen Befund 
führen. Daher wurde zusätzlich ein diagnostisches Verfahren zur Atemluftanalytik entwickelt 
um mikrobielle Biomarker (flüchtige organische Verbindungen; VOCs) nachzuweisen. Die 
Durchführbarkeit des Verfahrens wurde in der CF-Ambulanz getestet.  
Die molekularen Analysen identifizierten ein breites Spektrum an Mikroorganismen im 
Sputum und ermöglichten die Untersuchung der genauen Zusammensetzung der 
unterschiedlichen bakteriellen Gemeinschaften. Eine Korrelation zwischen Lungenfunktion 
und der relativen Häufigkeit einzelner Arten wurde nicht festgestellt. Jedoch konnten 
verschiedene, teilweise persistierende Untergruppen bakterieller Gemeinschaften voneinander 
abgegrenzt werden, jeweils klar definiert durch ihre individuelle Zusammensetzung. Bei den 
Pilzen ließ sich eine unerwartet große Artenvielfalt nachweisen. Deren starke Fluktuation 
über die Zeit sowie zwischen verschiedenen Patienten deutet auf ein schwaches 
Kolonisierungspotential der Pilze hin. Für die Atemanalytik wurden verschiedener 
Mikroorganismen zunächst in vitro anhand ihrer abgesonderten VOCs unterschieden. Obwohl 
in vivo jene Verbindungen nicht detektiert wurden, ließ die individuelle Zusammensetzung 
der ausgeatmeten VOCs eine Differenzierung von Patienten und Kontrollen zu.   
In der vorliegenden Arbeit wurden zum ersten Mal die mikrobiologischen Gemeinschaften, 
einschließlich Pilzen und Bakterien, in einer größeren Kohorte analysiert. Die Ergebnisse 
unterstützen die Hypothese von polymikrobiellen Lungeninfektionen. Das Potential der 
Atemanalytik zur Unterscheidung verschiedener Krankheitserreger wurde nachgewiesen und 
könnte die Grundlage zur Entwicklung einer verbesserten Diagnostik bilden. 
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Chapter I 
General Introduction 
 
 
 
 
1.1 Microbial communities and the human microbiome 
“Owing to this struggle for life, any variation, however slight and from whatever 
cause proceeding, if it be in any degree profitable to an individual of any species, in 
its infinitely complex relations to other organic beings and to external nature, will 
tend to the preservation of that individual, and will generally be inherited by its 
offspring.”                                             (Charles Darwin, On the Origin of Species, 1859) 
With these words, Charles Darwin described the major concept of nature in its entirety. The 
relevance of it can be seen in all aspects of biology and in particular in microbial life. In their 
“struggle for life” microorganisms conquered and adapted to the most extreme and hostile 
environments. Bacterial communities are accordingly found in the Antarctica at minus 13°C 
within the brine of isolated lakes, on the sea bottom at 350°C hot water emanated from ‘black 
smokers’ or in the toxic drainage of iron ore mining (Baross & Deming 1983) (Bond et al. 
2000) (Murray et al. 2012). The evolutionary principles apply in all habitats, enable their 
colonization and establish the microbial diversity that can be observed in each individual 
environmental site. However, interactions between microorganisms are not only of 
competitive nature, in fact, synergistic interactions, like exchange of metabolites or 
mutualistic cooperation between anaerobic and aerobic bacteria, may be even more the rule 
than the exception (Schink 2002). Consequently, sophisticated social interrelations were 
elucidated within the microbial life (Velicer 2003). The complex and multifaceted outcome of 
these can particularly be observed in the formation of biofilms which can be regarded as 
integrated communities (Stoodley et al. 2002). Advanced interactions were also observed 
between bacteria and fungi to create selective conditions in their environment and provide 
growth advantages (Boer et al. 2005) (Minerdi et al. 2011). The development of defence 
mechanisms, invasion and colonization strategies or even antibiotic resistance are all 
consequences of microbial interactions including bacteria and fungi, their impact on human 
health cannot be overestimated (Berg et al. 2005).  
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Like each other environmental site, also the human body is inhabited by microorganisms. The 
discovery of this microbial universe in its entirety has just started. In 2008, the Human 
Microbiome Project was launched with the aim to elucidate the microbial diversity within 
healthy human beings (The Human Microbiome Project Consortium 2012a). The individual 
bacterial communities from different body sites, like the oral cavity and oropharynx, were 
presented and their specific metabolic function was demonstrated (The Human Microbiome 
Project Consortium 2012b). Whereas the interaction between the microbial flora and the 
healthy human host can be regarded as symbiosis, certain species within the flora are capable 
of causing damage if environmental conditions or the microbial communities are altered 
(Casadevall & Pirofski 2000). An overview about the outcome of host-microbe interactions 
are given in Figure 1.  
 
Figure 1: Outcome of infection and host-microbe interaction. In detail: A, acquisition of a microbe can be 
followed by elimination through physical defenses or immune mechanisms. B, acquisition results in damage and 
disease in the host. C, commensal microbes cause disease if the state of commensalism is disturbed by immune 
impairment or alterations of the host microbial flora. D, the state of colonization may be terminated by an 
immune response. E, the state of colonization may lead to disease if sufficient damage ensues from the 
interaction. F, the state of colonization may lead to a state of persistence. G, eradication of infection (but damage 
may be already irreversible). H, damage causes death. J, persistent infections may reactivate and cause overt 
disease. Double-headed arrows indicate conditions where there may be variable amounts of damage              
(modified from Casadevall & Pirofski 2000). 
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The trigger for opportunistic pathogens to cause diseases is not well understood and might be 
of various ecological aspects. The entire microbial community may be regarded as 
opportunistically pathogenic, considering the multitude of interactions between the different 
microbes within the flora which potentially influence each single species (Jenkinson & 
Lamont 2005) (Rogers et al. 2010). These “infinitely complex relations to other organic 
beings and to external nature” were defined the driver of evolution by Charles Darwin and it 
is becoming more and more apparent that they are similarly relevant for human health in the 
context of infectious diseases.  
 
 
1.2 Cystic fibrosis and pathogenesis 
Cystic fibrosis (CF; mucoviscidosis) is regarded as the most common genetic disorder in the 
caucasian population. CF affects the ion and water transport in and out of cells, causing thick 
mucus to build up and therefore disturb the normal function of several organs. One in 2,500 
newborns has cystic fibrosis and also in other ethnic groups it is increasingly recognized 
(Davies et al. 2007). Albeit relatively rare, CF is of substantial public interest. Patients are 
treated and ask for regular check-ups in specialized centre for adult and pediatric CF health 
care. Depending on the individual health condition, medical services of CF patients are done 
ambulant and interferences in the patient’s life are tempted to be kept at a minimum. 
Successful clinical research in the past decades led to rapid improvements in health 
management, therapy and diagnostics, resulting in a vast increase of life expectancy and 
quality for CF patients: predicted survival age, depicted in 5-year periods, revealed a median 
age of 28 years for 1987-1991 followed by a constant increase which is resulting in predicted 
survival age of 37 years for 2007-2011 (Cystic Fibrosis Foundation Patient Registry 2012). 
Consequently, soon more than 50 % of the population with CF will be adults, whereas in the 
beginning of the 1980s the number of children was still two and a half times larger than the 
respective number of adults (Cystic Fibrosis Foundation Patient Registry 2012). The trend is 
continuing and for newborns with CF in the 21
st
 century the predicted median survival 
exceeds 50 years (Dodge et al. 2007). In summary, clinical manifestations of the genetic 
disorder and their progressions are changing with age, resulting in new challenges in 
healthcare of the patients. Further research is needed to meet these challenges and to retain the 
positive trend in survival and life quality for CF patients. 
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1.2.1 Genetic background   
Cystic fibrosis is an autosomal recessive genetic disorder, which means both allels of a gene 
have to be mutated to cause the disease. Normally, it is caused by a mutation in the Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) gene. The relatively high 
prevalence for a genetic disease might be evolutionary explained by the finding that 
Salmonella typhi uses CFTR to enter intestinal epithelial cells and the decreased susceptibility 
to typhoid fever might be an advantage for heterozygous carriers (Pier et al. 1998). In 1989, 
the cystic fibrosis gene sequence was identified on the human chromosome 7 (Rommens et al. 
1989). CFTR encodes a protein with a size of 1,480 amino acids that serves as a channel for 
chloride ions and is expressed in many epithelial cell types throughout the human body 
(Riordan et al. 1989). Further analyses revealed that the CF mutant gene pool consists of 
different mutations from which the major one is responsible for over 70 % of all CF cases and 
defined as a nucleotide deletion resulting in the loss of one amino acid at position 508 
(ΔF508) (Kerem et al. 1989). Until today, more than 1,600 different mutations duplications 
were described within the 189,000 base pairs of the CFTR locus (Quemener et al. 2010). The 
outcome of these mutations are multifaceted, like channel dysfunctions, abnormal production 
or disturbed intracellular processing of the protein (Zielenski & Tsui 1995). Correlations 
between the CFTR mutation and clinical manifestation are only known for the pancreatic 
functions: Carriers of homozygotes ΔF508 generally have pancreatic insufficiency (Chen & 
Férec 2009). The phenotypic diversity of CF is best demonstrated by the definition of the 
atypical or nonclassical form which is diagnosed in about 2 % of all cases: Patients 
demonstrate a CF like phenotype in at least one organ but have normal sweat chloride values 
(Boyle 2003). In most of these cases, patients have pancreatic sufficiency and lung 
malfunction may be less severe compared to classic CF but still exhibits phenotypic 
similarities. Additionally, variant CF phenotypes can also result from mutations other than 
CFTR-associated and are clinically indistinguishable from nonclassic CF (Paranjape & Zeitlin 
2008). 
 
1.2.2 Pathogenesis of lung diseases 
In CF, the whole body is affected and a wide range of associated diseases in different organs 
are observed (Davies et al. 2007). However, respiratory infections are known to be the leading 
cause of death for the patients. The protein CFTR is crucial for a number of transport 
processes across the epithelia and may further play a role in other physiological processes 
(Jentsch et al. 2002). The impact of a dysfunctional protein on the airway epithelial cell 
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permeability is presented in Figure 2. Severe impairments in the ion transport lead to an 
increased viscosity of the mucus layer which covers human airways and serves to trap inhaled 
objects. In a permanent clearance process the mucus is normally removed from the respiratory 
tract of healthy individuals (Wanner et al. 1996). In CF patients, the disturbed ion transports 
in airway epithelia additionally lead to abnormal volumes of extracellular layers, resulting in a 
dysfunction of the complex pulmonary clearance mechanism (Matsui et al. 1998) (Boucher 
2004). Together with the high viscosity of the mucus, this provides promoting conditions for 
microbial colonization.  
 
Figure 2: Comparison of models of basic electrolyte absorption 
properties in normal and CF airway cells. Cells are shown with tight 
junctions in between, basal membrane on the left and apical membrane 
on the right. The apical Cl
- 
impermeability of the CF cell depolarizes 
the apical membrane, but does not reverse the transmembrane electrical 
gradient. A significant increase in the Na
+
 permeability more than 
compensates for the decrease in the driving force for Na
+
 entry, and as 
Cl
-
 can move across this epithelium paracellularly as well as 
transcellularly, the net result is enhanced NaCI absorption. In turn, 
when fluid secretion is stimulated, Cl
-
 permeability of the apical 
membrane is not increased and normal fluid secretion characteristically 
fails (modified from Quinton 1990). 
 
Since, the pulmonary airways are normally free of microbial colonization, the persistent 
presence of bacteria and fungi can be assumed to be wholly negative for the host (Rogers et 
al. 2010). Lung damage is further boosted by an increased adhesiveness and cohesiveness of 
mucus which is plugging small airways and lead to neutrophilic inflammation (Flume & Van 
Devanter 2012).  
 
 
1.3 Diagnostic methods for respiratory infectious diseases in clinic and research 
In a visionary article, Raoult et al. (Raoult et al. 2004) elucidated the future developments in 
clinical diagnostics and their impact on health management. Various culture-independent 
methods used in research are useful options for clinical diagnostics, like sequence-based 
microbial identification or mass spectrometry. Adaptation to clinical needs is crucial for this 
technology transfer especially the ease of operation for not highly specified users is 
substantial. Undoubtedly, a rapid and precise diagnosis of any infection will substantially 
improve the chance for patient recovery and respective individually targeted antimicrobial 
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therapies will diminish the costs of broad band antibiotic treatments in healthcare. This is 
particularly true for the complex respiratory microbial infection in CF patients. Conventional 
culture-based methods are still the basis of clinical diagnostics for bacteria and fungi. 
Although they provided the fundamentals for improvements in CF healthcare of the past 
decades, microbial isolation by culture is i) time-consuming, ii) selective due to species-
specific media, iii) allowing at best a semi-quantitative assessment of the respective pathogen 
load (Rogers et al. 2003).  
 
 
Figure 3: The different technologies used to identify bacteria in cystic fibrosis sputum samples. Conventional 
culture methods are useful for isolation of bacteria and they are the first step for identification and antibiotic 
susceptibility testing. However, especially 16S rRNA gene amplification and sequencing has revolutionized the 
current knowledge with the description of many emerging and multidrug-resistant bacteria that can be found in 
CF patients. Many other promising strategies for the identification of bacteria have been recently applied 
including chromatographic methods and mass spectrometry (modified from Bittar & Rolain 2010) 
 
Technological achievements in research have further increased the knowledge about 
microbial infections and initiated a discussion about their polymicrobial nature (Rogers et al. 
2009) (Rogers et al. 2010) (Bittar & Rolain 2010). To address these new challenges and 
further improve diagnostics of CF respiratory diseases, complementary technologies are 
needed with the potential to replace some day the conventional method of microbial isolation. 
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An overview about different technologies already used for accurate microbial identification in 
research and clinics is illustrated in Figure 3. The majority of the molecular identification 
methods are based on amplification of the rRNA genes. The bacterial 16S rRNA gene is 
known to have good taxonomic informativeness even in short sequence reads and enable 
bacterial community profiling if primers are thoroughly chosen (Soergel et al. 2012). The 
ribosomal 16S rRNA gene of bacterial species is known to contain highly variable regions 
with highly informative character for phylogenetic analysis and low variable regions to be 
used as target regions for universal primers to amplify 16S rRNA gene sequences in an 
unselective manner (Andersson et al. 2008). For fungi, the ribosomal internal transcript spacer 
regions (ITS) between the 18S rRNA and 28S rRNA genes were demonstrated to be best 
suitable for taxonomic identification (Schoch et al. 2012). Besides species-specific sequence 
variations, this region further exhibits high length heterogeneity across fungal species. 
 
Major drawbacks of amplification-based methods are sequencing artefacts and bias induced 
by the polymerase chain reaction (PCR). High coverage rates and proof-reading enzymes 
minimize errors but a need for culture and amplification independent methods is apparent and 
would substantially improve clinical diagnostics. 
 
 1.3.1 SSCP fingerprinting  
A variety of fingerprinting methods, like automated ribosomal intergenic spacer analysis 
(ARISA), terminal restriction fragment length polymorphism (T-RFLP), denaturing gradient 
gel electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE) or single strand 
conformation polymorphism (SSCP), have been used to study microbial communities based 
on ribosomal DNA analysis (Nocker et al. 2007). Of these technologies, especially SSCP 
electrophoresis became a widely applied method in environmental, clinical and diagnostic 
research (Ghozzi et al. 1999) (Kumar & Shukla 2006) (Wos-Oxley et al. 2010) (Henne et al. 
2012). First used to study polymorphisms and mutations in single genes, SSCP analysis was 
successfully applied to microbial community profiling based on the 16S rRNA gene analysis 
(Orita et al. 1989) (Lee et al. 1996). In this electrophoretic method, DNA-based SSCP 
fingerprints are achieved under non-denaturating conditions by polymorphism in the 
secondary/tertiary structure of single strand DNA (ssDNA). The spacial structure of nucleic 
acids depends on the sequence, thus DNA fragments of the same length but with different 
sequences fold differently and can be separated from each other (Figure 4). Separation of 
gene fragments is achieved in a native polyacrylamide gel by different migration behaviours 
and motilities depending on the tertiary structure. Using the 16S rRNA gene as target region, 
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the structure and composition of complex bacterial communities can be elucidated (Eichler et 
al. 2006). For fungi, the ribosomal internal transcript spacer regions (ITS) have been 
successfully applied to identify pathogenic fungi using this technology (Kumar & Shukla 
2005).  
ITS 1 ITS 2 
conserved regions
16S rRNA gene
bacteria fungi
I II III IV
ribosomal ssDNA fragments 
form secondary structures 
amplicons of ribosomal DNA 
fragments from bacteria and fungi
DNA fingerprints by SSCP 
electrophoresis elucidate 
microbial communities 
excision of DNA bands, 
reamplification and sequencing 
reveal species identity 
18S 5.8S 28S rRNA gene
 
Figure 4: Schematic representation of SSCP technique for microbial community profiling. Parts of ribosomal 
DNA from bacteria and fungi are shown. Horizontal arrows represent exemplary primer positions for 
amplification of ribosomal DNA fragments with sufficient taxonomic information. Amplicons with different 
sequences form different secondary structures. SSCP gel with four lanes (I-IV) is indicated. All amplicons of one 
sample are injected in one lane, black bars represent DNA bands. Bands at the same height represent the same 
DNA sequence.     
 
Though ribosomal DNA-based SSCP fingerprints allow rapid elucidation of microbial 
communities with minimal bioinformatic effort, the number of samples that can be analyzed 
and compared simultaneously is limited to 24 lanes of one gel. 
 
1.3.2 Illumina-based next generation sequencing   
Next generation sequencing (NGS) technologies have revolutionized molecular biology 
during the past years. Large volumes of data can be cost effectively produced within a short 
period of time and NGS has almost no limitation of application in any sort of sequence-based 
biological research. Different techniques are commercially available, like emulsion PCR-
based pyrosequencing by Roche/454, solid-phase amplification-based sequencing by 
Illumina/Solexa or real-time single molecule sequencing by Pacific Bioscience (Bennett 
2004) (Margulies et al. 2005) (Eid et al. 2009). Of these, especially the cost efficient Illumina-
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based sequencing has become a widely applied technique to study bacterial diversity by 16S 
rRNA gene analysis (Gloor et al. 2010) (Caporaso et al. 2011) (Degnan & Ochman 2012).  
 
Illumina sequencing, described by Metzker (Metzker 2010), is based on solid-phase 
amplification with cyclic reversible termination (CRT). First, DNA binds on a slide with 
covalently attached primers in high density which in turn defines the density of amplified 
template clusters. In each amplification step, the DNA polymerase incorporates only one 
modified nucleotides with a specific fluorescent dye before the reaction is terminated. The 
remaining nucleotides are washed out and fluorescent imaging is performed. In a cleavage 
step, the terminating group and fluorescent dye of the modified nucleotides are removed and 
washed out, before the cycle starts again with incorporation of the next nucleotide.  
 
In 2008, Illumina introduced a multiplexed sequencing method in which initially prepared 
samples are tagged with unique short sequences (indices). Up to 12 indices, each comprised 
of 6 base pairs, allow identification of pooled samples which are sequenced together. The 
number of samples to be analyzed at once can be further increased substantially by 
incorporation of barcodes. These barcodes consist of unique short sequences and can be part 
of the PCR primers. A combinatorial approach using indices and barcodes was applied in 
several studies investigating microbial communities based on 16S rRNA gene analysis 
(Andersson et al. 2008) (Bartram et al. 2011) (Amélia Camarinha Silva 2011). Each DNA 
library with unique indices consists of multiple samples from different sampling sites, again 
each tagged with a unique barcode. Since 2,000 sequence reads per sample are sufficient to 
recapture the microbial community, Illumina-based sequencing is suitable for large-scale 
community comparisons (Caporaso et al. 2011).    
 
 1.3.3 Exhaled breath analysis based on VOC-biomarker  
Routine clinical diagnostic procedures for the detection of infectious agents in the respiratory 
tract are based on sputum analysis. However, recent studies suggest an uneven spatial 
distribution for certain bacteria in sputum and a spatial heterogeneity of microbial 
communities in the CF lung itself (Willner et al. 2012) (Goddard et al. 2012). These regional 
differences may bias the diagnoses and consequently comprise a potential risk of an 
ineffective antibiotic treatment. In this regard, exhaled breath may be an alternative clinical 
specimen to be used for the detection of microbial pathogens in the lower respiratory tract. 
During breathing, air enters the lungs and flows through all compartments before it finally 
exits the lungs again. This exhaled air comprises a broad spectrum of molecules from 
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different origins, such as gases like oxygen, nitrogen, carbon dioxide and water but also 
volatile compounds produced in or outside the human body, which includes the lungs itself or 
other organs from where these compounds are transported via the blood stream to the alveolae 
(Buszewski et al. 2007) (Tisch & Haick 2010). Of particular interest for exhaled breath 
analysis in diagnostics of respiratory infections are volatile organic compounds (VOCs) 
produced and emitted by microorganisms colonizing the lower human airways. Bacteria and 
fungi are known to produce a broad spectrum of VOCs, like aromatic hydrocarbons, esters, 
alcohols or mono-, sesqui- and diterpenes (Schulz & Dickschat 2007) (Brakhage & Schroeckh 
2011). Some of these VOCs have essential ecological functions for the organisms, including 
important roles in defence and quorum sensing (Kai et al. 2009) (O’Brien & Wright 2011) 
(Kramer & Abraham 2012). Therefore, these compounds may be used as specific biomarker. 
The diagnostic potential of these emitted VOC-biomarkers in exhaled air is attracting growing 
attention and different approaches were tested in recent years (Miekisch et al. 2004) (Boots et 
al. 2012). In the current study, a combined approach including different commercially 
available devices was developed in order to facilitate the crucial step of adaptation to clinical 
needs (Figure 5).  
 
 
 
Figure 5*: Breath sampling procedure developed in the current study. VOCs are emitted by microorganisms 
colonizing the lower respiratory tracts. These VOCs are exhaled together with several other molecules, including 
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endogenous VOCs of the human body. VOCs are collected in a breath sampler, extracted by a sorbent trap 
(solid-phase micro-extraction) and subsequently analyzed and characterized with a GC-MS.  
* Figure was designed by modifying Miekisch et al. (Miekisch et al. 2004) as well as commercial booklets of Markes International Ltd, 
Supelco Bellefonte and iBuySteroids.com)    
 
By breathing through a breath sampler (BIO-VOC
®
 sampler, Markes International Ltd, 
Rhonda Cynon Taff, UK), the last portion of the exhaled breath is collected. This air derived 
mostly from the alveolar spaces, excluding contaminants from upper airways. This sampling 
procedure was applied in different studies analyzing exhaled compounds (Henderson & 
Matthews 2002) (van den Velde et al. 2007) (Poli et al. 2010). Subsequently, a sorbent trap is 
exposed to the sampler and unspecifically binds the exhaled volatile organic compounds. The 
extraction methods is called solid phase micro-extraction (SPME), continuously developed 
since 1990, and applied in different breath analytical approaches as well as in vitro VOC 
emissions analysis (Arthur & Pawliszyn 1990) (Ligor et al. 2009) (Preti et al. 2009). The 
sorbent trap consists of a fiber coated with the polymers carboxen and polydimethylsiloxan 
(PDMS) and a protective needle to secure the adsorbents and the adsorbate compounds 
(Portable Field Sampler, Supelco Bellefonte, PA, USA). Finally, VOCs are released again by 
thermal desorbtion, separated and analyzed with gas chromatography coupled with mass 
spectrometry to characterize the different compounds.  
 
Despite the great potential of such a fast accurate and non-invasive diagnostic method, the 
technical issues are demanding. The discriminative potential of VOCs as well as their origin 
and the influence of metabolic processes have to be elucidated. These challenges are become 
more apparent considering that 1,099 VOCs were recently extracted from exhaled breath of 
pediatric CF patients (Robroeks et al. 2010). However, different approaches are in research 
phase but standards in breath sampling and in VOCs extractions will have to be developed 
before a routine exhaled breath diagnostics for lower respiratory infections can be 
successfully implemented in the clinic.   
  
 
1.4 Studies of microbial infections in CF respiratory tracts 
In CF clinical research, microbial studies with adult patients focus mainly on the presence of 
single pathogens in respiratory specimen, in particular on Pseudomonas aeruginosa and 
Staphylococcus aureus. Certainly, P. aeruginosa is the most important pathogen associated 
with CF and several studies revealed their sophisticated adaptation to the human host (Rau et 
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al. 2012) (Folkesson et al. 2012). Isolated strains from CF patients exhibit remarkable 
phenotypic diversity, even within one individual, and evidence is growing for evolutionary 
progressions of single strains resulting in highly successful lineages for survival in the human 
environment (Mowat et al. 2011) (Folkesson et al. 2012). Interestingly, the prevalence of P. 
aeruginosa correlates with the age and is detected more often in adults, in contrast to 
Haemophilus influenza which is more prevalent in paediatric patients (Cystic Fibrosis 
Foundation Patient Registry 2012). Besides P. aeruginosa, also S. aureus and Burkholderia 
cepacia are extensively studied species, whereas the role of other pathogens in pulmonary 
infections, like Stenotrophomonas maltophilia or Achromobacter xylosoxidans, still need to 
be elucidated in more detail (LiPuma 2010) (Hauser et al. 2011). A number of bacteria are 
recognized as emerging pathogens, like species from the genera Bordetella and 
Mycobacterium, however, their pathogenic potential in CF remains to be shown (Olivier et al. 
2003) (Spilker et al. 2008). Species from the oral cavities are commonly found in CF sputum 
and are suggested to immigrate into the CF lung from the upper airways which may act as a 
reservoir and ‘stepping stone’ for infectious agents (Rogers et al. 2006). Evidence for such 
immigrations have been particularly demonstrated for distinct clones of P. aeruginosa 
migrating from the paranasal sinuses into lower airways (Hansen et al. 2012). 
 
With the increasing interest in anaerobic bacterial species, microbial studies shifted from 
single pathogen detection to microbial community profiling. With methods providing 
advanced resolution, a complex picture of community compositions is emerging (Bittar et al. 
2008) (Guss et al. 2011). Anaerobes are observed in high numbers and their contribution to 
CF lung diseases is under discussion (Tunney et al. 2008) (Worlitzsch et al. 2009) (Jones 
2011). As a consequence, the concept of polymicrobial consortia to be seen as one pathogenic 
entity was announced (Jenkinson & Lamont 2005) (Rogers et al. 2010). Such polymicrobial 
infections resulting in an enhanced pathogenicity are best investigated with B. cepacia and P. 
aeruginosa: Quorum sensing-mediated mixed biofilm formation with increased inflammatory 
response of the host was demonstrated (Riedel et al. 2001) (Eberl & Tümmler 2004) 
(Bragonzi et al. 2012). Similarly, co-infections of P. aeruginosa with obligate anaerobic 
species from the Streptococcus milleri group were suggested to cause severe lung diseases by 
enhanced virulence (Parkins et al. 2008). Determination of such polymicrobial pathogenic 
entities is challenging but persistence might be regarded as one key parameter for their 
identification. To make it more aggravating, the number of species associated with CF is 
increasing but long-term studies revealed relatively stable communities over time with 
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differences in the community structure depending on the individual (Zhao et al. 2012) 
(Stressmann et al. 2012). This would suggest that many species are rather persistent than 
transient and therefore potentially involved in the pathogenic consortia. 
 
 
 
Figure 6: Filamentous fungi 
associated with CF according to 
their frequency in this clinical 
context and to their capacity to 
chronically colonize the 
airways (modified from Pihet et 
al. 2009). 
 
 
 
 
Considering the whole microbial community to be one pathogenic entity also the fungal 
species have to be included and consequently first attempts to elucidate the complete 
microbiome including bacteria and fungi were made (Delhaes et al. 2012). Like bacteria, also 
fungal species, especially Candida yeasts, are commonly found in CF sputum and known to 
be part of the oral microbiome (Doern & Brogden-Torres 1992) (Ghannoum et al. 2010) 
(Müller & Seidler 2010). Likewise, they also might migrate to the lower airways. Adaptation 
of fungi to the CF host might be observed in Candida dubliniensis. This fungus has the ability 
to take advantage of the dehydrated respiratory secretion of CF patients and is rarely found in 
non-CF individuals (Hazen et al. 2001) (Peltroche-Llacsahuanga et al. 2002). The potential of 
Candida yeasts to cause primary pneumonia even in non-CF individuals is known but their 
incidences are low (Pasqualotto 2009). Therefore, the prevalence of Candida or any other 
fungal infections in CF patients still remains to be elucidated (Pihet et al. 2009). Few 
pathogenic fungal species are known, mostly filamentous fungi like Aspergillus fumigatus, 
Scedosporium apiospermum (teleomorph: Pseudallescheria boydii) and Exophiala 
dermatitidis (Müller & Seidler 2010) (LiPuma 2010). An overview about these species with 
known or assumed pathogenic potential is shown in Figure 6. Further studies are needed to 
analyse the fungal microbiome in CF and to elucidate the virulence of single fungal species.  
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1.5 Studies of exhaled breath diagnostics for lung diseases 
Experimental techniques in exhaled breath analysis for clinical diagnosis and therapeutic 
monitoring are continuously evolving (Amann et al. 2007). The potential of exhaled breath 
diagnostics, is best demonstrated by the 13C-urea breath test (UBT) for the diagnoses of 
Helicobacter pylori infections, which is well established in the clinic and also considered to 
be sufficient to initiate treatment if results are positive (Malfertheiner et al. 2007). For lung 
diseases, several diagnostic approaches are currently in the research phase. In particular the 
detection of volatile tumor markers for the diagnosis of lung cancer is investigated. A unique 
chemical signature of exhaled VOCs in the breath of lung cancer patients was observed and in 
a recent study even dogs were trained to scent volatile markers to evaluate the diagnostic 
potential (Horváth et al. 2009) (Ehmann et al. 2012). Thus, a broad range of VOCs, 
synthesized or catabolised by cancer tissue in detectable amounts, were used in clinical trials 
to identify patients with different stages of lung cancer (Phillips et al. 2003) (Ligor et al. 
2009) (Poli et al. 2010). Likewise, VOCs were used to distinguish between asthmatic and 
healthy children with high accuracy, interestingly, compounds were mainly linked with 
oxidative stress in these cases (Dallinga et al. 2010) (Caldeira et al. 2011). Oxidative stress 
and reactive oxygen species (ROS) are tightly linked with inflammation and volatile 
compounds generated in associated processes have the potential to be used for diagnostics 
(Boots et al. 2012). Likewise, the breath of CF patients was monitored for such inflammatory 
marker and revealed elevated levels of ethane and carbon monoxide (Paredi et al. 1999) 
(Paredi et al. 2000).  
 
Despite those indirect detections of microbial infections, several studies focussed on the 
characterization of compounds emitted by the microorganisms itself. Great potential for 
microbial VOCs to be used in pathogen-directed breath testing is currently seen for 
Mycobacterium tuberculosis, P. aeruginosa and the fungus A. fumigatus (Chambers et al. 
2012). A large number of patients with tuberculosis were tested for respective marker 
compounds and potential candidates were observed, however, technical challenges complicate 
a broader application (Syhre et al. 2009) (Phillips et al. 2010). P. aeruginosa is known for its 
characteristic odour, the respective compound was identified as 2-aminoacetophenone and 
elevated levels of it were found in the exhaled breath of infected patients (Cox & Parker 
1979) (Scott-Thomas et al. 2010). Since 2-aminoacetophenone was repeatedly detected in 
healthy and non-infected individuals, doubts on its reliability remain. A potential marker 
compound was also observed for A. fumigatus, which causes fungal infections of the lower 
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respiratory tract (Chambers et al. 2011). However, the origin of that compound still has to be 
elucidated before a diagnostic routine can be developed.  
 
In particular VOCs can be of various origins, being produced endogenously in the human 
body, they can be metabolites of food products and pharmaceuticals or inhaled from outside 
the body and gradually released again. Therefore, the profile of exhaled VOCs rather than 
single molecules might be more reliable and informative for clinical diagnostic purposes 
(Kharitonov & Barnes 2001). 
 
 
1.6 Statistical analysis 
New generations of bio- and chemo-analytical technologies are characterized by low detection 
limits and precise data recording. Large data sets are produced and require advanced 
mathematical tools, like multivariant analyses, to be explored thoroughly. Bio-statistical 
procedures are becoming more important and are often essential to find patterns between 
samples or variables in large data sets or to draw the right conclusions. In the current studies, 
technologies like Illumina-based sequencing for microbial community profiling and 
SPME/GC-MS for analytical screening of exhaled breath were applied to clinical samples. 
The resulting data sets were analyzed and interpreted by the use of PRIMER 6 (Version.6.1.6, 
PRIMER-E, Plymouth Marine Laboratory, UK). Important statistical routines being used are 
introduced below and additionally described in the respective chapters.  
 
• Multi-dimensional scaling (MDS) plots: Multivariante statistical techniques use clustering or 
ordination to explore patterns within the data sets. In the current studies, MDS plots were 
mostly used to display the similarity between a set of samples. Similarity or distances between 
every pair of samples were calculated by the use of coefficients, like Euclidean distance or 
Bray-Curtis similarity. The resultant resemblance or (rank) similarity matrices express the 
respective scores for each pair (K. R. Clarke & M. Ainsworth 1993). The ideal display of the 
similarities or distances according to these scores would be in n-dimensional space, but was 
reduced in two dimensional space for an intuitively accessible manner. The 2D stress value, 
given for every MDS plot, basically measures these differences between ideal distances in 
higher dimensional space and the actual distances in two dimensional space. Therefore, the 
more similar the samples are according to the pairwise similarity calculations, the more close 
together the samples are displayed in the MDS plot. Single variables can be superimposed on 
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the plots for demonstration purposes, however, for the construction of the MDS plots all 
variables are always taken into account.   
 
• RELATE:  RELATE is a comparative (Mantel-type) test, which measures the similarity 
between two resemblance matrices (Clarke & Warwick 2001). In the current study, similarity 
was measured by the Spearman's rank correlation coefficient Rho and data sets were 
permuted to test for null hypothesis. Histograms were displayed to show distribution of Rho 
values for permutations as well as Rho value for the actual data sets.    
   
• Similarity profile routine (SIMPROF): SIMPROF is analysing an a priori unstructured data 
set in order to test for the presence of sample groups (Clarke et al. 2008). In the current study, 
it was used to interpret a dendrogram from hierarchical cluster analysis of a resemblance 
matrix. SIMPROF is a permutation procedure and avoids over-interpretation of cluster 
analysis.   
 
 
1.7 Research approach  
Cystic fibrosis is becoming a more complex disease in adults. Recent developments in health 
care increased the life expectancy dramatically and new challenges for clinical research have 
to be addressed in order to facilitate further improvements in diagnostics as well as treatment 
for CF patients. Ecological studies of microbial communities and respective correlation 
analysis with clinical factors are crucial for the understanding of adult CF lung diseases and 
similarly crucial for future developments in diagnostics.  
 
On the one hand, the pathogenic potential of emerging species has to be elucidated which 
includes the identification of polymicrobial pathogenic consortia as well as elucidation of the 
general prevalence of fungi in the respiratory tract. On the other hand, healthcare of CF 
patients will further benefit from advanced diagnostic methods suitable for clinical use that 
avoid bias due to sputum preparation. Both challenges were addressed in the current study 
(Figure 7). Bacterial and fungal communities were elucidated with culture-independent 
methods and analyzed with regard to host factors as well as clinical features of the patients. 
Additionally, a breath analytical diagnostic approach was developed and its feasibility for 
clinical use investigated in order to detect volatile microbial biomarker in vivo in the exhaled 
breath of CF patients. 
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Figure 7: Project scheme of the current study. Diagnostics of respiratory communities associated with cystic 
fibrosis was addressed in two ways: Elucidation of fungal prevalence as well as bacterial community 
compositions in sputum samples and monitoring of microbial VOCs in exhaled breath of CF patients. Microbial 
VOCs of prominent microorganism in CF sputum were first characterized in vitro, including bacteria and fungi. 
Detection of microbial VOCs in exhaled breath entails potential for a non-invasive and rapid diagnosis of 
respiratory infections.  
 
 
 
 1.7.1 Objectives of thesis 
Three objectives were defined in order to address the main goal of the current thesis, which is 
to further improve the technology and comprehension in diagnostics of lower respiratory tract 
infections on the basis of a more profound understanding of the microbial communities in the 
airways of CF patients. Therefore, the following aims were approached: 
 
• Chapter II – To elucidate the structure and composition of bacterial communities in
 sputum samples, including the validation of different diagnostic methods for
 microbial profiling and assessment of the individual pathogenic potential of
 certain bacterial species for CF patients. 
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• Chapter III – To identify and analyse the fungal microbiome present in sputum
 samples, consequentially compare with bacterial taxa and estimate the
 prevalence and role of fungal pathogens in respiratory tract infections of CF
 patients.    
 
• Chapter IV – To develop a rapid, non-invasive diagnostic method based on the
 detection of exhaled VOCs in the human breath, determine VOC-biomarker
 emitted by pulmonary pathogens in-vitro and test the feasibility of the method 
 in the CF outpatient clinic in-vivo.      
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2.1 Abstract 
Lung disease due to microbial infections is the leading cause of death in cystic fibrosis (CF) 
patients. Although routine clinical diagnostics is focusing on only a modest number of 
species, recent studies suggest that infections are polymicrobial. In the current study, sputum 
samples of 56 adult CF patients were analyzed and different diagnostic methods compared, 
including cultivation, 16S rRNA gene analysis based on Illumina sequencing and single-
strand conformation polymorphism (SSCP) fingerprinting. Occurrence frequencies of known 
pathogens observed with cultivation and culture-independent methods were highly similar; 
however, only molecular approaches revealed the broad spectrum of bacteria associated with 
CF. Furthermore, no strong correlation was observed between relative abundances of single 
bacterial species and lung functions of the infected patients. A polymicrobial perspective was 
utilized and multivariant statistical analysis revealed distinct subgroups of bacterial 
communities in the cohort defined by their individual compositions. Persistence of distinct 
communities was then demonstrated by a longitudinal analysis of 13 CF patients. 
Characterization of such polymicrobial consortia involved in respiratory infections may 
further improve diagnostics of lung diseases and health care for CF patients. 
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2.2 Introduction 
Lower respiratory infections are among the five most common causes of death worldwide and 
are the leading cause for patients with cystic fibrosis. In the Caucasian population, one out of 
2,500 newborns has cystic fibrosis (CF) and in other ethnic groups its importance is 
increasing, what makes the disease a substantial public health issue (Davies et al. 2007). CF is 
an autosomal recessive genetic disorder, caused by mutations in the gene for a chloride ion 
channel (CFTR) which result in a dysfunction of the mucociliary clearance mechanisms and 
in conditions that promote microbial growth in the human lungs (Matsui et al. 1998) (Boucher 
2004). In particular bacteria cause lower respiratory infections in CF with recurrent 
exacerbations and entail immune responses which in turn are thought to be responsible for the 
majority of irreversible lung damages (Sibley et al. 2008).  
 
On the one hand for CF patients improved diagnostics and health management have lead to a 
constantly increasing life expectancy and quality of patients, on the other hand it is becoming 
apparent that disease manifestations and infections are changing with age (Davies et al. 2007) 
(Cystic Fibrosis Foundation Patient Registry 2012). These new challenges have to be 
addressed and alternatives to conventional microbial culture-based diagnostics were 
developed, including molecular fingerprinting methods and, more recently, next generation 
sequencing technologies (Ghozzi et al. 1999) (Bittar & Rolain 2010). Hereby, bacterial 
communities are elucidated via 16S rRNA gene analysis and revealed a broad spectrum of 
microbial species associated with CF, many of which were previously under-diagnosed or 
even not undetected (Rogers et al. 2004) (Guss et al. 2011). A complex picture of bacterial 
communities in the CF respiratory tracts is developing with emerging pathogens, anaerobic 
species and polymicrobial interactions (Bittar et al. 2008) (Tunney et al. 2008) (Sibley et al. 
2008) (Worlitzsch et al. 2009). However, their potential to cause lower respiratory infections 
in CF remains to be unclear for most species. In this regard, multiple factor analyses were 
performed with distinct environmental or physiological parameter associated with the host 
and the airway microbiota in order to reveal any relation (Cox et al. 2010) (Klepac-Ceraj et al. 
2010). As a consequence, improved understanding of the complex bacterial community rather 
than the identification of single pathogenic species may positively influence treatment and 
health management of patients (Flanagan et al. 2007). In this context, Rogers et al. (2009) 
suggested to consider the bacterial community in CF airways as one pathogenic entity where 
the virulence of single species may be triggered by co-colonization and interactions with other 
bacteria in a polymicrobial consortium. Persistence of bacteria over time may give insights in 
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their contribution to the respiratory communities that infect the CF airways. Recent respective 
investigations revealed stable communities over time within patients including species not 
classically considered to be pathogenic in CF (Stressmann et al. 2012). The same study 
observed a higher diversity among patients rather than within the same individual which 
demonstrates that each CF airway infection has a unique character and treatment strategies 
have to be individually adjusted.   
 
However, introduction of molecular diagnostic methods like pyrosequencing in routine 
clinical diagnostics remain to be challenging. Until then, elucidation of emerging pathogens 
and associated polymicrobial consortia by molecular methods will facilitate clinical attention 
for them and facilitate their incorporation in routine diagnostics. In the current study, such 
diagnostic methods for community profiling were compared to reveal their reliability and 
their relation to classical clinical microbial diagnostics. Multiple factor analyses were 
performed to compare the different bacterial communities in a cohort of 56 adult CF patients 
and distinct polymicrobial consortia could be statistically identified and their persistence 
evaluated.      
 
 
2.3 Material and Methods 
 
2.3.1 Patient cohort and sample collection 
Sputum samples were collected in sterile containers from 56 CF patients recruited in the CF 
outpatient clinic of the Hannover Medical School (MHH; Hannover, Germany), including a 
subgroup of 13 patients who provided sputum twice (n=10) or three times (n=3) within the 
sampling period of 2 years. In total, 72 separate sputum samples were collected after ethical 
approval for the current study was granted by the local health authority ethics committee. 
Sputum collection was done during the routine medical examination. The patients were 
between 18 - 51 years old and a median age of 31 was calculated for the cohort. Both genders 
were equally represented (48.2 % female and 51.8 % male). Signs of acute infections were 
observed for some patients, but most of them were in a stable phase of their disease and had 
no pulmonary exacerbation by the time of sputum collection. Sputum samples were collected 
in duplicates. Containers with sputum for DNA extraction were stored at -20°C. Sputum 
samples for clinical microbial diagnostics were immediately processed in the local 
microbiological laboratory of the MHH. Methods were applied according to the German 
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Quality Standards in Clinical Microbiology and Infectious Diseases (Hogardt 2006). 
Pulmonary functions were measured as forced expiratory volume in 1 second (FEV1) with 
Ganshorn Body Scope version LF8.5E (Ganshorn Medizin Electronic; Niederlauer, Germany) 
and assessed according to the predicted normal values for adults defined by E.G.K.S. 1993 
(The European Respiratory Society 1993). FEV1 ≥ 90 % is considered to be normal, however, 
some lung disease may be present. FEV1 70 - 89 % shows mild lung malfunction, 40 - 69 % 
indicates moderate lung malfunction and less than 40 % is a sign of severe lung malfunction 
(Cystic Fibrosis Foundation Patient Registry 2012). 
 
2.3.2 Sputum preparation and DNA extraction 
An optimized protocol for the extraction of fungal and bacterial DNA was developed by 
modifying the manufacture’s instructions of the kit and by adaptation of guidelines for the 
preparation of sputum samples recommended for detection of Mycobacterium tuberculosis in 
sputum (ifp Institut für Produktqualität 2008). Briefly, sputum samples were aliquoted and 
boiled for 15 minutes. To decrease the viscosity, a cysteine buffer (2 % NaOH, 1.45 % 
sodium citrate and 0.5 % N-acetylcysteine) was added in the same volume and the solution 
was mixed for 40 minutes. Milli-Q water was added to a final volume of 15 ml and 
centrifuged for 30 minutes at 4000 g. Supernatant was discarded and the pellet resuspended in 
300 µl lysis buffer (20 mM Tris-Cl with pH 8.0, 2 mM sodium EDTA, 1.2 % Triton® X-100). 
6 mg of Lysozyme (SERVA; Heidelberg, Germany) was added and incubated for 30 min at 
37°C. To the total volume of the solution 0.5 % of β-mercaptoethanol was given together with 
50 U of Lyticase (Sigma-Aldrich; Germany). The solution was incubated for another 45 min 
at 37°C before centrifugation at 12.000 rpm for 10 min. The pellet was resuspended in 300 µl 
Lyse T buffer from GeneMATRIX Tissue & Bacteria DNA purification kit (EurX Roboklon; 
Berlin, Germany) and 20 µl of Proteinase K (Qiagen; Hilden, Germany) was added. After 
incubation of 2 hours at 56°C, the DNA was extracted by following the instructions of the 
manufactures. DNA extracts were kept frozen at -20°C for further analysis.              
 
2.3.3 Fingerprints by SSCP electrophoresis and sequencing of individual bands 
PCR amplification of parts of the rRNA gene from bacteria was performed, using the 
following primers 27F (5´-AGAGTTTGATCMTGGCTCAG-3’) and 521R (5’-
ACCGTGGCTGCTGGCAC-3’). Amplicons of the 16S rRNA gene included the variable 
regions V1-V3 of the small subunit of the ribosome (SSU) with a amplicon size between 459 
bp for Nocardia sp. and 505 bp for Veillonella sp. (Wos-Oxley et al. 2010). PCR was carried 
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out using 50 ng DNA of sputum extractions in a final volume of 50 μl, starting with an initial 
denaturation for 15 min at 95°C. A total of 30 cycles (1 min at 95°C, 40 sec at 56°C, and 1 
min at 72°C) was followed by a final elongation for 10 min at 72°C. 1.5 U of HotStarTaq 
DNA polymerase was used for all amplifications (Qiagen). For single-strand DNA (ssDNA) 
preparation, reverse primer 521R was 5´-biotin labeled and magnetic streptavidin coated 
beads (Promega, Madison, Wis.) were applied to obtain ssDNA from the PCR amplicons 
according to Eichler et al. (Eichler et al. 2006). Dried pellets of ssDNA were resuspended in 7 
µl of gel loading buffer (95 % formamide, 10 mM NaOH, 0.25 % bromphenol blue, 0.25 % 
xylene cyanol). After incubation for 10 min at 95°C, the ssDNA samples were shortly stored 
on ice and loaded onto a non-denaturing polyacrylamide-like gel (0.6x MDE gel solution; 
Cambrex BioScience, Rockland, Maine) for SSCP electrophoresis. Molecular fingerprints of 
bacterial DNA were obtained at 20°C and 400 Volt for 21 hours. More details on the SSCP 
fingerprints are given in Eichler et al. (Eichler et al. 2006). The gel was silver stained 
according to the method described by Bassam et al. (Bassam et al. 1991). SSCP gels were 
digitized using a HP Scanjet G4050 scanner. Bands with intensities of ≥5% of the total lane 
were considered for further statistical analysis. Intensities were determined by using the 
GelCompare II software (Applied Maths, Kortrijk, Belgium). Bands were excised from the 
SSCP gel, boiled in Tris buffer (10 mM Tris-HCl, 5 mM MgCl2, 5 mM KCl, 0.1 % Triton X-
100, pH 9.0) and reamplified according to the conditions described above. Purified amplicons 
were sequenced by cycle sequencing (ABI PRISM BigDye Terminator Cycle Sequencing 
Ready Reaction kit; Applied Biosystems, Foster City, Calif.), products were purified again 
with the BigDye Terminator purification kit (Qiagen) and analyzed using capillary 
electrophoresis with fluorescence detection (ABI Prism 3100 Genetic Analyzer). 
 
2.3.4 Preparation of Illumina high-throughput sequencing 
PCR amplification of parts of the 16S rRNA gene, including the variable region V3, was 
performed by using the following primers 341F (5´-ATTACCGCGGCTGCTGG-3’) and 
518R (5’-CCTACGGGAGGCAGCAG-3’) (Bartram et al. 2011). Amplicon library 
preparation was performed according to Camarinha-Silva et al. (Amélia Camarinha Silva 
2011). Briefly, the 16S rRNA primers were designed with integrated complementary 
sequences to the Illumina specific adaptors to the 5’ends (Table S1). Further, a 6 nucleotide 
error correcting barcode (BC) was integrated in the forward primer, together with a 2 
nucleotide CA linker to avoid amplification bias (Hamady et al. 2008) (Meyer & Kircher 
2010). PCR was carried out using 50 ng DNA of sputum extracts in a final volume of 50 μl, 
starting with an initial denaturation for 15 min at 95°C. A total of 20 cycles (10 sec at 98°C, 
Chapter II 
 33 
10 sec at 53°C, and 45 sec at 72°C) was followed by a final elongation for 2 min at 72°C. 
Specific Illumina multiplexing sequencing primers as well as index primers were integrated 
with accordingly designed primers in a second subsequently performed PCR reaction.  The 
second PCR was carried out using 1 µl of the reaction mixture as template. Additionally, 5µl 
of Q solution (Qiagen) were added to the final volume of 50 µl. Initial denaturation for 15 min 
at 95°C was followed by a total of 20 cycles (10 sec at 98°C, 10 sec at 62°C, and 45 sec at 
72°C) and a final elongation for 2 min at 72°C. PCR products were separated on a 2% agarose 
gel and bands of correct size (around
 
330 bp) extracted and recovered using the QIAquick Gel 
Extraction kit (Qiagen). For each index, equimolar ratios of amplicons (50 ng) were pooled, 
all tagged with unique barcodes. Quality of these libraries as well as the DNA concentration 
was measured by an Agilent Bioanalyzer. Libraries were sent for paired-end multiplex 
sequencing on a GAIIx Genome Analyzer. Image analysis and base calling were done by 
using the Illumina Pipeline (version 1.7).  
 
2.3.5 Data processing and phylogenetic analysis 
Phylogenetic analysis of sequences was performed with the NCBI Tool BLAST/blastn and 
Ribosomal Data Base Project (RDP) Seqmatch Tool (Cole et al. 2009). Closest taxonomical 
groups were determined by sequence similarity and height of ssDNA bands in the molecular 
fingerprints. For sequences obtained from SSCP fingerptints, species identification was 
defined for sequence similarity of ≥ 98 %, ssDNA bands of same heights were considered to 
be same species. Further, phylogenetic distance analyses were performed to confirm the 
identification of the individual operational taxonomic unit (OTU) (data not shown). For 
sequences obtained by Illumina sequencing, only the forward end sequence reads were 
processed.  A quality filter was applied and determination of representative reads were both 
done according to Camarinha-Silva et al. (Amélia Camarinha Silva 2011). Only 90 bp of the 
forward 5’ end of all reads were used for further analysis, due to decreasing sequence quality. 
Representative reads were defined as i) present in at least one sample in a relative abundance 
> 1 % of the total sequences of that sample, ii) present in at least 2 % of samples at a relative 
abundance > 0.1 % or iii) present in at least 5 % of samples. Median number of total reads per 
sample was 10,933 sequences. For individual samples which were prepared and analyzed 
more than once, only the one with the most total sequence-reads was taken into account for 
the comparison of all 72 sputum samples. Species identification was defined for sequence 
similarity of ≥ 98%. However, sequences with ambiguous results were defined according to 
the closest shared taxonomical level. Sequences affiliated to human DNA were removed 
Chapter II 
 34 
before calculation of relative abundances of bacterial OTUs. Results from different Illumina 
runs were pooled and a cut-off level of 0.5 % relative abundance was chosen for each sample, 
in order to analyse only OTUs with a minimum relevance for the community. In total 65 
OTUs from 72 sputum samples were further processed (Table S2).   
 
2.3.6 Statistical analysis 
Multivariant statistical analyses were performed using PRIMER 6 (Version.6.1.6, PRIMER-
E, Plymouth Marine Laboratory, UK). Resemblance matrices were calculated using the Bray-
Curtis similarity coefficient (Bray & Curtis 1957). According to the similarities the samples 
were ordinated in non-metric multidimensional scaling (MDS) plots (with 50 random 
restarts), distances between samples in these plots reflect similarities of associated OTU 
compositions. The reliability of MDS plots is indicated by the 2D stress value, which 
basically measures the differences between ideal distances in higher dimensional space and 
the actual distances in two dimensional space. Hierarchical agglomerative clustering was 
performed for the resemblance matrices using the group-average mode and SIMPROF 
(similarity profile permutation test), which tests for significant groups in an a priori 
unstructured data set (permutations for mean profile: 1000; simulation permutations: 999). To 
compare two resemblance matrices, the RELATE routine analysis was applied. This 
comparative (Mantel-type) test measures the similarity and calculates the Spearman's rank 
correlation coefficient Rho.   
 
 
2.4 Results 
2.4.1 Comparisons of methods for microbial composition profiling 
 
The bacterial community composition of 72 sputum samples was analyzed using Illumina 
sequencing (NGS) and molecular fingerprinting by SSCP electrophoresis (fingerprinting). In 
order to validate the reproducibility and accuracy of the results, all samples were analyzed 
separately with both methods. Parts of the 16S rRNA gene were amplified, comprising the 
V1-V3 region for fingerprinting and only the V3 region for NGS. Accordingly, OTUs were 
defined and identified for both methods individually and their frequency of occurrence within 
the 72 sputum samples compared (Figure 1). For this direct comparison of fingerprinting and 
NGS, abundant OTUs were defined as ≥ 5 % relative abundance. Overall, a high degree of 
agreement for the frequency of occurrence of individual OTU for both methods was observed. 
High occurrence rates in both methods of at least 10 % positive samples were detected for the 
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dominant genera Pseudomonas, Staphylococcus, Streptococcus, Rothia and Prevotella. For 
both methods, a similar diversity of OTUs with lower occurrence rates was observed likewise. 
Discrepancies between NGS and fingerprinting were detected in the genus Streptococcus. 
Four additional OTUs within the genus Streptococcus were defined only by fingerprinting and 
therefore biased the comparability of detected occurrence rates for both methods. The higher 
taxonomic resolution in fingerprinting was achieved due to longer fragments of the 16S rRNA 
gene, comprising three variable regions. Nevertheless, most OTUs defined by NGS could 
unambiguously be affiliated to the respective OTUs defined by fingerprinting.  
 
Besides the occurrences, also the relative abundances of all OTUs were analyzed and the 
community compositions of all 72 samples compared. The community compositions were 
assessed by the relative abundance of each individual OTU within one sample. The relative 
abundance of individual OTUs in NGS was defined equal to the relative frequency of the 
associated bacterial sequences. Results from fingerprinting and NGS correlated strongly, 
though partly different OTUs were defined due to different taxonomical resolutions (Figure 
S1). Thus, comparison of both compositional data sets revealed a rank correlation value (Rho) 
of 0.816 (P-value= 0.01), which indicates highly similar community compositions in the 
sputum samples revealed by both methods (Table 1). A histogram of this similarity analysis 
is shown in Figure S2a. In Figure 2, the high degree of agreement is illustrated by 
comparisons of the relative abundance of the most dominant OTU in each individual sample, 
in disregard of the taxonomy. 
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Figure 1: Occurrence of OTUs observed in 72 sputum samples with Illumina (white bars) and SSCP 
fingerprinting (black bars). OTUs are listed on the left according their occurrence observed with Illumina. OTUs 
defined only in SSCP fingerprinting are marked with * and those defined only in Illumina are marked with **. 
Only OTUs with  ≥ 5 % relative abundance were taken into account.    
 
Although a higher taxonomic resolution could be achieved by fingerprinting, NGS assured 
identification of OTUs at lower relative abundances. Whereas OTUs with ≥ 5 % relative 
abundance were considered for the comparisons of the different methods, microbial 
composition profiling based on NGS took OTUs into account with a relative frequency of             
≥ 0.5 % if a minimum of 2,000 sequence-reads per sample was achieved. An overview of all 
OTUs observed by NGS with relative abundances of ≥ 0.5 % as well as their minimum and 
maximum relative abundance in individual samples is given in Table S2. 
 
 
 
 
Figure 2 (below): Comparisons of the relative abundance of the most dominant OTU in each individual sample 
assessed with Illumina (white bars) and SSCP fingerprinting (black bars). Numbers indicate patients and letters 
are according order of sputum collection. Samples are listed according their order in the more detailed 
compositional comparisons shown in Figure S1. 
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Subsets of sputum samples were chosen to be analyzed repeatedly to estimate the extraction 
and amplification bias. From a subset of eight sputum samples, DNA extractions were 
performed twice from different aliquots. Sputum samples from this subset exhibited different 
viscosity and visual appearance as well as considerable differences to each other concerning 
the bacterial community composition. Comparison of the compositional data assessed by 
NGS from the first and second DNA extraction of each sample revealed a high degree of 
agreement (Figure 3). The same OTUs were detected in both extractions. Discrepancies were 
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observed in relative abundance of sequences but mostly moderate. The highest discrepancy 
was observed for the abundances of Pseudomonas -1 in the sample e/e*, followed by 
Pseudomonas -1 of the sample b/b*. Comparing all OTUs of corresponding DNA extractions 
in the subset, a mean discrepancy of 2.9 % relative abundance was calculated. 
  
 
Figure 3: Comparisons of community composition of sputum samples (a – h). Two different DNA extractions 
per sample were analyzed. Left: Comparisons of relative abundances of bacteria. Colour code is given beneath 
the diagram. Right: Corresponding MDS plot to the diagram. Dissimilarity matrix was calculated with Bray-
Curtis algorithm taken all bacterial abundances into account and displayed in the MDS plot. Exemplarily, 
relative abundances of Streptococcus -1 were indicated by bubbles, sizes are according the abundances (max. 
40%). .2D Stress value of 0.13 indicated moderate stress on the plot.    
 
A resemblance matrix was calculated including the first and second DNA extraction and 
samples were accordingly ordinated in a MDS plot (Figure 3). To further assess the 
extraction bias for the community composition of each sample. The more similar the 
community compositions of each sample, the more close they ordinated together in the MDS 
plot. To illustrate the coherence of the individual relative abundance of each OTU and the 
ordination of the samples in the MDS plot, the abundances of Streptococcus -1 were 
exemplarily highlighted for each sample in the figure. It is important to note here, that for the 
distances between samples the abundances of all bacteria were taken into account. The MDS 
plot revealed high similarity of community compositions in each corresponding DNA 
extraction. Again, the highest discrepancies were observed for sample e/e* and b/b*. 
Individually calculated resemblance matrices for the first and second DNA extraction were 
compared and revealed a rank correlation value (Rho) of 0.911 (P-value= 0.01), indicating 
strong agreement of the results (Table 1). The histogram of this similarity analysis is shown 
in Figure S2b. 
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Figure 4: Comparisons 
of the community 
composition of sputum 
samples (i – r). Two 
different preparations of 
each sample were 
performed and separately 
analyzed with NGS.           
Samples are individually 
labelled, those with * 
were analyzed in the 
second run. 
 
 
The amplification bias for NGS-based assessment of the community composition was 
estimated likewise. A subset of ten samples was analyzed twice. PCR amplicons and libraries 
were prepared separately and NGS performed in different runs. Compositional data are shown 
in Figure 4. Comparisons revealed a high degree of agreement, indicated by a rank 
correlation value (Rho) of 0.976 (P-value= 0.01). Comparing all OTUs of corresponding 
amplifications in the subset, a mean discrepancy of 3.5 % relative abundance was calculated 
(Table 1). The histogram of this similarity analysis is shown in Figure S2c. 
 
Data sets compared Spearman rho Major discrepancies 
Illumina;                            
different extractions 
0.911 
mean of 2.9 %                                                               
differences in OTU abundances 
Illumina;                            
different sequencing reactions 
0.976 
mean of 3.5 %                                                    
differences in OTU abundances 
Illumina and SSCP fingerprinting;                     
all samples (≥ 5%) 
0.816 
different taxonomic resolution for the 
genus Streptococcus   
 
Table 1: Comparison of data sets from bacterial community elucidation. Resemblance matrices were calculated 
for each dataset and compared using spearman rank correlation (rho). Major discrepancies observed for each pair 
of data sets are mentioned. For the comparison of SSCP fingerprinting and Illumina, only OTUs with a relative 
abundance of ≥ 5 % were considered.        
 
The occurrence rates of these OTUs were additionally compared with the results of the 
clinical diagnostics: Simultaneously collected sputum samples from each patient were 
analyzed with conventional culturing methods in the microbiology department of the clinic. 
Results were reported and compared with the results of the NGS analyses (Figure 5a). High 
degree of agreement was achieved for the known pathogens, like P. aeruginosa, S. aureus,       
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B. cepacia, A. xylosoxidans, S. maltophilia. Most other species detected by NGS were not 
observed with culturing, including all strict anaerobic bacteria, like Streptococcus millerii or 
Fusobacterium nucleatum. Furthermore NGS revealed a considerably higher detection 
frequency of alpha-hemolytic Streptococci than culture-based diagnostics. Very few species 
were detected only once or twice by cultivation and not observed in NGS.   
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Figure 5a (above): Occurrence of OTUs observed in sputum samples analyzed with Illumina (white bars) and 
culturing for diagnostics (black bars). OTUs are listed on the left according their occurrence observed with 
Illumina. Only 71 sputum samples were taken into account (no reported data from culturing for sample #20B).                                
* Streptococcus-1 was compared with alpha-hemolytic Streptococci.   
 
 
Figure 5b (below): Phylogeny of detected Streptococcus species in sputum samples. High sequence variation 
was observed with SSCP fingerprinting. Closest described representatives from databases are given in the 
taxonomic tree. Associated OTUs defined in NGS are indicated with brackets. Aerobic alpha-hemolytic 
Streptococci are further marked with bold branch lines. Staphylococcus aureus was included for rooting of the 
tree. Scale bar represents base substitution per site.     
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Since the greatest differences between NGS and clinical diagnostics were observed for the 
genus Streptoccus, phylogeny of respective species in sputum samples was further elucidated 
(Figure 5b). Sequences from SSCP fingerprinting revealed several aerobic alpha-hemolytic 
Streptococci. The individual relative abundances of these species in sputum samples varied 
strongly, but S. parasanguinis and S. salivarius were the dominant bacteria in several samples 
(Figure S1). Additionally two distinct species of the strict anaerobic S. millerii group were 
identified.  
 
2.4.2 Community composition and dominant bacterial species 
Although some differences between compositional analyses with SSCP fingerprinting and 
NGS were observed, the overall similarity was shown to be high and with a good resolution of 
the community composition by NGS. Therefore, results from NGS were taken for further 
microbial community profiling. Higher taxonomic resolution for individual OTUs in NGS 
could be achieved by comparisons with the strongly correlating results obtained by 
fingerprinting. Although sequence similarity of NGS alone would not assure the species 
identification, if OTUs defined in NGS were unambiguously and equally assigned with both 
methods they could be affiliated to the species level according to the fingerprinting results 
(Table S2). Accordingly, all 72 sputum samples were analyzed, the compositional similarities 
determined and samples ordinated in one MDS plot (Figure 6a). Although individual 
bacterial community compositions of each sample were partially highly divers, all of them 
exhibited at least one of the previously identified dominant OTUs Pseudomonas -1, 
Staphylococcus -1, R. mucilaginosa and Streptococcus -1 (Figure 6b). A distinct distribution 
of sputum samples according the abundances of these OTUs was shown and four categories 
were observed: The major CF pathogens P. aeruginosa and S. aureus, represented by the 
accordingly affiliated OTUs Pseudomonas -1 and Staphylococcus -1, characterized the first 
two categories, whereas category three and four was characterized by the abundances of R. 
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mucilaginosa and Streptococcus -1 respectively. The OTU Streptococcus -1 could not be 
affiliated to one distinct species but exhibited high sequence similarity to S. salivarius and S. 
parasangunis. Together with R. mucilaginosa, both are not considered to be classical 
pulmonary pathogens in CF. However, no explicit borders between those categories could be 
defined. Samples with high relative abundances of these dominant OTUs were ordinated in 
the individual periphery of each category. For P. aeruginosa and S. aureus communities with 
respective individual relative abundances of ≥ 80% were observed, whereas the maximum 
relative abundance of R. mucilaginosa and Streptococcus -1 was 52% and 50% respectively. 
Samples with moderate abundances of the individual dominant OTU were more likely 
ordinated in the centre of the plot. Overlaps were observed for all four categories. 
Furthermore, the plot revealed some outlier. Especially samples #5, #20B, #20C, #34A, #35A, 
#2 and #16 were ordinated differently in comparison to the other samples, demonstrating 
rather different community compositions observed in these samples.  
       
    
Figure 6a, b: MDS plots from 
bacterial community composition 
observed in 72 sputum samples. 
Bubbles indicate relative 
abundances of dominant OTUs in 
the cohort: P. aeruginosa in green, 
S. aureus in orange, Streptococcus -
1 in yellow, R. mucilaginosa in blue. 
2D Stress values are given in each 
plot and reveal moderate stress. 6a: 
Merged bubble plots from all four 
dominat OTUs. Coloured bubbles 
indicating the individual 
abundances.  P. aeruginosa as well 
as S. aureus have priority. 
Abundances for R. mucilaginosa 
and Streptococcus -1 are in 
background. 6b: Individual MDS 
plots for each dominant OTU. 
Numbers indicate individual 
patients. Letters are according order 
of sputum collection. 
 
Fig. 6a 
Fig. 6b 
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2.4.3 Comparison of host factors and the bacterial community composition  
The relationships between bacterial communities, host factors and clinical aspects were 
analyzed. Comparisons of factors and aspects between samples from all four categories were 
of particular interest. In order to examine any correlation between the overall community 
composition and the patient’s age, the cohort was divided into four age classes according to 
the corresponding statistical quartils. Symbols for each age class were superimposed in the 
previous MDS plot calculated for the community composition of all 72 sputum samples 
(Figure 7a). No correlation was observed between age of the patient and the four previously 
defined categories of bacterial communities. Patients with a community composition 
dominated by the major CF pathogens P. aeruginosa and S. aureus were distributed equally in 
all age classes as well as patients with high relative abundances of R. mucilaginosa and 
Streptococcus -1. In more detail, the relationship of P. aeruginosa and age is demonstrated 
(Figure S4). Samples were ordered by the age of patients at the time point of sputum 
collection and compared with the individual relative abundances of Pseudomonas -1. Again, 
no correlation was observed. Although most samples without presence or with low relative 
abundances (≤ 5 %) of P. aeruginosa were observed for patients with ≤ 25 years, similarly 
low abundances were also detected in several samples of other age classes. Likewise samples 
from patients of all ages exhibit communities dominated by P. aeruginosa. In summary, a 
tendency for young adult CF patients to exhibit less frequently communities with highly 
abundant P. aeruginosa could be shown but exceptions in individual cases were observed.  
 
In order to examine any correlation between the overall community composition and the lung 
function of the patients, the cohort was divided into four classes according to the statistical 
quartils of the FEV1 values of all patients. Symbols for each class were superimposed in the 
previous MDS plot calculated for the community composition of all 72 sputum samples 
(Figure 7b). A median predicted FEV1 of 35 % was calculated for the cohort and patients 
with strongly reduced lung functions (≤ 25 %) were observed in all four previously defined 
categories of bacterial communities. Likewise, relatively high FEV1 values of ≥ 51 % were 
observed for patients with communities dominated by the major CF pathogens P. aeruginosa 
and S. aureus. Further demonstrated were the relationship between P. aeruginosa and the lung 
function: Samples were ordered by relative abundances of Pseudomonas -1 and compared 
with the predicted FEV1 values (Figure 8). No clear correlation was observed between the 
lung function and the relative abundance of P. aeruginosa. Like described above, although all 
patients with FEV1 values of ≤ 60 % exhibited none or low relative abundance of P. 
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aeruginosa in sputum samples, relatively good lung functions (≤ 51 %) were also measured 
for some patients with P. aeruginosa-dominated bacterial communities. Likewise, strongly 
reduced lung functions of ≤ 25 % and no or low relative abundance of P. aeruginosa was 
observed for the same patients.  
 
Figure 7a, b: MDS plots 
from bacterial community 
composition observed in 72 
sputum samples with 
superimposed host and 
clinical factors. For a better 
orientation in the plot, 
relative abundances of S. 
aureus are indicated like 
previously shown. 7a: Age of 
patients superimposed on the 
previous MDS plot calculated 
for the community 
compositions of 72 sputum 
samples. Four age classes 
were determined for the 
cohort according to the 
statistical quartils. Symbols 
indicate the age of the patient 
at the time point of sputum 
collection. 7b: Lung function 
of patients superimposed on 
the previous MDS plot 
calculated for the community 
compositions of 72 sputum 
samples. Four classes of lung 
functions were calculated according to the statistical quartils of FEV1 values measured for the patients on the day 
of sputum collection. Symbols indicate the four classes and samples without associated FEV1 values.  
 
Correlation analyses were further performed between the genotype of the CFTR gene of each 
patient and the corresponding community composition in the sputum samples (Figure S5). 
Patients were classified according the genotypes: 41 % were homozygous-ΔF508, 16 % 
heterozygous-ΔF508, 16 % had a non-ΔF508 mutation and for 27 % of the patients the 
precise genotype was not or only partly determined. Neither of the genotypes correlated 
Fig.  7b 
Fig.  7a 
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significantly with communities dominated by P. aeruginosa, S. aureus, R. mucilaginosa or 
Streptoccocus -1. However, the class of patients with non-ΔF508 mutations was composed of 
diverse genotypes. In only three samples from patients out of this class, the community was 
dominated by P. aerugionsa with relative abundances ≥ 50 % and in seven samples the 
communities exhibited only low abundance of P. aeruginosa (≤ 5 %).  
 
Figure 8: Comparison between relative abundance of P. aeruginosa (grey bars) and lung function of the patient 
(black bars). Samples are ordered by relative abundance of P. aeruginosa. Lung functions of the patients at the 
individual time point of sputum collection is measured by the predicted FEV1 value. Both, relative abundance of 
P. aeruginosa and lung function are given in % on y-axis. For each patient, both parameters are indicated. 
Missing bars for P. aeruginosa indicate its absence in the sample and missing bars for FEV1 indicates no 
measurement for the patient at time point of sputum collection. A median FEV1 of 35 % was calculated for the 
cohort.  
 
Overall, the high relative abundances of P. aeruginosa, S. aureus, R. mucilaginosa and 
Streptoccocus -1 in sputum samples could not be clearly correlated with any clinical 
parameter or host factor of the CF patients. 
 
2.4.4 Community composition and polymicrobial consortia 
To determine microbial subgroups within the four previously defined categories of bacterial 
communities, cluster analyses were performed with the community compositions from all 72 
sputum samples. Further statistical determination of discrete clusters was performed by 
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SIMPROF. A low significance level of 1 % was applied and revealed 14 subgroups of sputum 
samples with distinct bacterial community compositions (Figure 9). These SIMPROF groups 
(A-N) were superimposed on the MDS plot previously calculated for all 72 sputum samples 
(Figure 10).  
 
 
 
Figure 9 (left): Cluster analysis with SIMPROF 
test on bacterial communities observed in 72 
sputum samples.  Clustering was performed on 
the resemblance matrix based on Bray-Curtis 
similarities and in group average mode. A 
significance level of 1 % was applied for 
statistical determination of discrete clusters by 
SIMPROF. Numbers represent patients and 
letters represent the order of sputum collection 
(e.g. 20A, 20B, 20C). Hyphenated letters 
indicate SIMPROF groups (A-N). Discrete 
clusters in the dendogram are additionally 
highlighted with bold dashed lines. 
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Figure 10: SIMPROF groups superimposed on the previous MDS plot calculated for the community 
compositions of 72 sputum samples. Distinct microbial communities determined by cluster analysis and 
SIMPROF test, are indicated by the individual groups A-N with associated symbols. All three samples 
associated with group M are marked with bold dashed circles and also samples of groups B, C, E and F are 
circled additionally for orientation 
 
The plot demonstrated several distinct microbial communities within samples dominated by 
the major CF pathogens P. aeruginosa and S. aureus. Furthermore, previously observed 
outliers with distinct bacterial communities were accordingly determined as distinct groups: 
#5 in -A, #20B and #20C in -B, #34A in E, #35A and #2 were grouped together with #35B in 
-F, #16 was grouped with #47 and #56 in group -M. Whereas samples of most SIMPROF 
groups are ordinated closely together in the MDS plot, group M was more unequally 
distributed though all three samples of this group could still be considered within the 
previously defined categories of R. mucilaginosa and Streptococcus -1. 
 
For each SIMPROF group, the characteristic abundances of bacterial species were observed 
and number of positive samples and patients were mentioned (Table 2). Characteristic 
bacteria were defined as those present in all associated samples. One exception was group N 
which consisted of more diverse samples in terms of microbial community composition. In 
group N, R. mucilaginosa was abundant in all samples and detected together with several 
anaerobic bacteria at high relative abundances in individual samples. Numbers of positive 
samples are mentioned for each species in table 2. Notably, SIMPROF group N was almost 
completely represented by samples dominated by R. mucilaginosa and Streptoccocus -1. For 
Chapter II 
 48 
all SIMPROF groups, ranges of relative abundances of each OTU were given. P. aeruginosa 
was defined characteristic for most of the groups (particularly in D-L). Groups I and J were 
differentiated only by different relative abundances, though both communities were strongly 
dominated by P. aeruginosa. All other SIMPROF groups were characterized by the consistent 
abundance of more than one bacterial species. Relative abundances of more than 50 % were 
only observed for the major CF pathogens P. aeruginosa and S. aureus as well as for S. 
millerii, Fusobacterium nucleatum, Bordetella petrii  and Nocardia sp..  
 
 Table 2 A B C D E F G H I J K L M N 
P. aeruginosa  3-4  17-43 12 17-43 67 86 89-93 74-76 43-66 24-36   
Streptococcus -1   2-14        4-19 18-38 19-20  
R. mucilaginosa            4-9  4-48 
(n=21) 
S. millerii  72-76             
S. aureus   69-88 37-44           
A. xylosoxidans             36-48  
Granulicatella -1            1-3  0-6          
(n=15) 
S. maltophilia       10 3       
Prevotella - 2  6-12             
Nocardia -1     62          
Prevotella -1      1-38        0-23 
(n=15) 
A. graevenitzii              0-15 
(n=10) 
Veillonella atypica              0-14         
(n=9) 
G. haemolysans 31             0-2            
(n=7) 
Gemella -2            1-4  0-2             
(n=9) 
F. nucleatum      16-54         
Bordetella petrii 56              
Actinomyces -1              0-14        
(n=9) 
pos. samples 1 2 7 3 1 3 1 1 7 3 12 7 3 21 
pos. patients 1 1 6 3 1 2 1 1 7 3 10 6 3 20 
range % FEV1  
22 
38         
- 48 
25            
- 96 
22        
- 56 38 
19         
- 26 28 21 
19           
- 59 
26        
- 58 
14         
- 58 
19          
- 64 
21           
- 37 
21            
- 114 
 
Table 2: Groups of bacterial communities according cluster analysis and SIMPROF test. Fourteen SIMPROF 
groups A-N are determined, numbers of positive samples and patients are shown. Groups are characterized by 
OTUs with consistent presence. Ranges of individual abundances of these characteristic OTUs are given in % for 
each associated group. Group N contains more diverse samples and characteristic bacteria are not consistently 
present in all samples, therefore the number of positive samples for each identified characteristic OTU in this 
group are given in brackets 
 
Comparison between SIMPROF groups and lung function values, revealed consistently 
strongly reduced values for patients of group F which were characterised by highly abundant 
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Fusobacteria. Other groups comprised of the previously observed outlier in the MDS plot 
were also associated with strongly reduced lung functions, like group A characterized by co-
occurring high abundant G. haemolysans and B. petrii and group M characterized by high 
abundant Achromobacter xylosoxidans. Further, associated with low lung functions were 
groups H-J with communities strongly dominated by P. aeruginosa, though exceptions of 
patients with moderate lung function were also observed (FEV1 ≥ 51 %). For the other groups, 
including group C and D both characterized by the highly abundant pathogen S. aureus, no 
such association was observed.  
 
2.4.5 Community dynamics 
Cluster analysis and SIMPROF revealed rather distinct bacterial communities partly 
characterized by infrequent bacterial species within the 72 analyzed sputum samples. To 
further examine the clinical relevance of the communities and of associated infrequent 
bacterial species, dynamics of the community composition were observed in a subcohort of 13 
CF patients (Table 3). Sputum samples were collected within 4 month, 8 month or with more 
than 12 month to the previous sample from the same patient. Dynamics of bacterial 
communities were indicated by the SIMPROF group mentioned for each sample. Constant 
and changing community compositions were observed for sputum samples taken in all three 
time ranges. Strong changes within a short time were detected for patient #41, whereas 
constant communities were observed for patients #6 and #1 in a long time range of more than 
12 month, both were constantly clustered into group K.  
 
To examine the persistence of infrequent bacteria, the dynamics of communities characterized 
by these species were of particular interest. The communities over time were demonstrated for 
the patients #20, #34 and #35 (Figure 11). For patient #20, after a complete change of the 
community composition within the initial 12 month the community stayed constant with 
strong dominance by S. millerii in both samples (group B). Group F was associated with 
strongly reduced lung functions and characterized by highly abundant Fusobacterium 
nucleatum. In two associated samples of patient #35, communities stayed relatively constant 
over a period of 8 month. Nocardia -1 was detected with high relative abundance in patient 
#34. Though Nocardia -1 was still detectable in low relative abundance, a change of the 
community composition was observed within 8 month from SIMPROF group E to the S. 
aureus-dominated group C.  
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Table 3 (left): Table shows subgroup of 13 patients giving sputum 
samples twice or three times. Time indicates the temporal distance to 
the previous sample. SIMPROF groups from cluster analysis of 
community compositions are mentioned. Constant communities in 
sequent samples of one patient indicated by constant SIMPROF 
groups are bold. Patients with constant microbial communities are in 
the lower part of the table. Dynamics of community composition. CF 
patients are given by numbers and sputum sample in chronological 
order by capital letters (A-C). Labels are according to the previous 
MDS plot with all 72 samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 : Column plot shows 
dynamics of community composition 
in 3 individuals from subgroup of 
patients that gave samples twice or 
three times. Patients were further 
characterized by infrequent sputum 
communities revealed by cluster and 
MDS analysis. SIMPROF groups are 
mentioned with the according 
hyphenated letters. Each OTU is 
indicated by a specific colour and 
further defined in the legend. 
Dynamics of community composition. CF patients are given by numbers and sputum sample in chronological 
order by capital letters (A-C). Labels are according to the previous MDS plot with all 72 samples. 
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2.5 Discussion 
 
2.5.1 Validation of methods for microbial community profiling 
 
Elucidation of microbial communities with culture-independent methods has become a widely 
used approach in the past years and different methods were compared in order to validate their 
accuracy (Hori et al. 2006) (Caporaso et al. 2012) (Cleary et al. 2012). In the current study, 
conventional SSCP fingerprinting was compared with sequencing of barcoded amplicons 
using an Illumina short read genome analyzer. Good reproducibility of the results was 
observed: Community structures and compositions revealed by both methods are highly 
similar. However, some differences were detected but mainly due to different taxonomic 
resolutions. Using three variable regions in SSCP fingerprinting for affiliation of the different 
OTUs provided confident identification of the species, whereas the short reads used for 
Illumina provide reliable classification to the genus level in most cases. However, even short 
reads of the 16S rRNA gene are known to have good taxonomic information and enable 
microbial community profiling if primers are thoroughly chosen (Soergel et al. 2012). 
Likewise, a minimum read count of 2,000 sequences per sample chosen in the current study 
was also shown to be sufficient to recapture the bacterial community (Caporaso et al. 2011). 
Considering the low costs and rapid availability of results, SSCP fingerprinting can be used as 
an alternative to examine the compositional variation of microbial communities. 
 
DNA extraction and amplification are crucial steps in sample preparation for culture-
independent methods. Uneven spatial distribution for certain bacteria in biofilms are known 
and may also be found in sputum (Stewart et al. 1997) (Goddard et al. 2012). Therefore, 
especially DNA extraction from different aliquots of the sputum sample may bias the 
community profile. Respective comparisons of subsets with separately prepared samples 
revealed high conformity of the community compositions for both crucial steps. These 
comparisons suggest that bias due to DNA extraction and amplification only had minor 
influence and did not significantly alter the profiling of the bacterial communities in the CF 
cohort. Furthermore, these comparisons revealed that MDS plots represent a robust statistical 
analysis to display the similarity between samples that reflect minor changes in the individual 
compositions without overly affecting the total display of all the samples.   
 
Clinical diagnostic of respiratory infections in adult CF patients is based on the detection of 
single pathogenic species by conventional culturing. Respective comparisons with NGS 
revealed high degree of agreement for well known CF pathogens like S. aureus, P. aeruginosa 
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and other Proteobacteria. However, great discrepancies were observed for the detection of 
species from the genus Streptococcus. Clinically relevant alpha-hemolytic Streptocci were 
under-diagnosed in comparisons to culture-independent methods. Correct identification of 
these bacteria by phenotypic methods, in particular the S. mitis and S. sanguinis group,  is 
known to be difficult whereas sequencing methods allow at least identification of the correct 
streptococcal group (Haanperä et al. 2007). Anaerobic species, including the S. millerii group 
or Fusobacteria, were not detected at all by culturing but occurrence frequencies over 15 % in 
this cohort indicate a significant prevalence of these bacteria in CF patients. There clinical 
relevance is discussed below. Overall, culturing did not reflect the complex bacterial 
communities revealed by NGS.  
 
Considering the growing interest in community analysis for CF, culture-independent methods 
are becoming more important (Rogers et al. 2009) (VanDevanter & LiPuma 2012). 
Fingerprinting methods allow confident elucidation of abundant bacteria, whereas the 
detection limit of NGS includes also rare species but might have less taxonomic resolution 
depending on the technique (Pedrós-Alió 2012). Whereas, occurrence frequencies of known 
CF pathogens, including S. maltophilia or A. xylosoxidans, were similar to the reported 
numbers for adult CF patients, in particular the detection of emerging pathogens will 
undoubtedly benefit from these methods (Bittar et al. 2008) (Hauser et al. 2011). Intuitively 
accessible statistical methods, like MDS plots, are essential to display compositional datasets 
and will further increase the knowledge about respiratory bacteria as integrated communities.   
 
2.5.2 Single bacterial species versus polymicrobial consortia  
Understanding the microbial flora is of considerable importance for treatment strategies of CF 
patients and inter-species interactions have to be considered to elucidate the precise 
contribution of different bacteria to patient morbidity (Harrison 2007). In the current study, a 
direct comparison of the microbial communities observed throughout the cohort was 
approached to understand their individual impact on health of the patients. Therefore, two 
strategies were tested and correlation with clinical parameter drawn, i) categorization of 
communities by single pathogens and ii) elucidation of communities by polymicrobial 
consortia.  
 
In regard of the routine clinical diagnostics, the categorization of communities by single 
pathogens can be considered to be more conventional. Noticeable, the four most frequently 
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found OTUs also exhibited high relative abundances within individual samples and therefore 
defined the four categories of microbial communities. Such a correlation between frequency 
and relative abundance of bacteria within CF sputum samples was also observed in recent 
studies (Gast et al. 2011) (Zhao et al. 2012). This dominance occurred within the cohort and 
within individual samples. It was not observed for any other bacteria in the study and 
indicates the strong growth advantage of these major pathogens in the CF airways. In 
particular, relative abundances of more than 80 %, only observed for P. aeruginosa and         
S. aureus, are indicating the clinical relevance of these species. Besides these major 
pathogens, communities in sputum samples were further categorized by Streptococcus -1 and 
R. mucilaginosa which similarly not only exhibited high frequency of occurrence but also 
high relative abundances in individual samples. The OTU Streptococcus -1 could not be 
affiliated to a single species but comparisons with SSCP fingerprints suggest that it may 
primarily represent S. salivarius and S. parasanguinis among other alpha-hemolytic 
Streptococci. Together with R. mucilaginosa, both species are known to be highly abundant in 
the healthy human oral microbiome (The Human Microbiome Project Consortium 2012). 
These species are commonly detected in CF sputum samples but their clinical relevance 
remains to be elucidated (Guss et al. 2011) (Gast et al. 2011). These four OTUs of the 
respective categories comprised the major proportion of most communities revealed in the 
cohort and characterize the associated samples in this regard. However, samples in the overlap 
between categories could not unequivocal be characterized and several outliers with distinct 
bacterial communities could not confidently associated with any category.  
 
Elucidation of communities by polymicrobial consortia rather than single species is another 
approach with growing interest in the past years (Sibley et al. 2008) (Stressmann et al. 2012). 
Interactions between species in CF airways are well known and mixed biofilms have been 
studied especially between P. aeruginosa and B. cepacia (Eberl & Tümmler 2004). In respect 
to the complexity of communities found in the samples, different microbial subgroups were 
revealed by cluster analysis in the current study. Although a low significance level was 
applied, 14 distinct bacterial communities were determined in 72 samples which indicated the 
complexity of respiratory tract communities in CF patients. Previously observed outliers with 
more distinct bacterial communities and not well ordinated within the four previous 
categories, were comprised within these subgroups or defined their own group. Examples of 
such rather unique communities with great distance to other samples are the one with high 
abundant Nocardia sp. or B. petrii/G. haemolysin. The impact of individual species beyond 
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the well known pathogens can be elucidated much more detailed by the determination of such 
microbial groups. To further elucidate the persistence of polymicrobial consortia, sputum 
samples from a subcohort of patients were collected repeatedly and revealed certain 
unfrequently detected communities to be stable over a long period of time. In particular, the 
persistence in high proportions of distinct consortia including the strict anaerobic bacteria S. 
millerii and F. nucleatum was demonstrated and their pathogenic potential will be discussed 
below.  
 
2.5.3 Clinical relevance of bacterial species is depending on consortia 
Cystic fibrosis used to be a lung disease of young children but more recently has become a 
complex disease in adults (Davies et al. 2007). Improved diagnostics and treatment increased 
life expectancy and quality of patients but causative agents of respiratory infections are also 
known to change with age (Cystic Fibrosis Foundation Patient Registry 2012). Certainly, P. 
aeruginosa is the most important pathogen in CF and its pronounced adaptation to the airway 
of its host has been subject of many studies (Rau et al. 2012) (Folkesson et al. 2012). 
Together with S. aureus it is responsible for the majority of infections (LiPuma 2010). In 
contrast, R. mucilaginosa and S. salivarius/S. parasanguinis which were commonly detected 
together and were both not reported to be explicit causative agents of respiratory infections in 
CF. However, correlations between the microbial categories and clinical or host factors 
apparently fail to give unambiguous results for adult patients. Considering the pathogenicity 
of the respective species, patients with high abundant S. aureus and P. aeruginosa in their 
sputum were expected to show lower lung function values than patients from the third 
category. However, this was not generally the case. Furthermore, P. aeruginosa is known to 
be more prevalent in adults than in infant CF patients (Cystic Fibrosis Foundation Patient 
Registry 2012). A strong correlation of its abundance and the age of adult CF patients was not 
observed either. A recent study with pediatric and adult patients reported a strong relationship 
between the CFTR mutation and the microbial community (Cox et al. 2010). However, such a 
strong correlation was not observed for the cohort of adult patients. Neither of the factors like 
age, lung function or mutation allowed a prediction of the category of microbial community to 
be found within the sputum sample of the patient. These findings demonstrate the complexity 
of adult CF lung disease manifestations and illustrate that infections will not be understood by 
considering single pathogens only. Respiratory communities in CF are influenced by a 
number of physiological or environmental factors and suggest a more comprehensive view on 
the respiratory infections for adult patients. 
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Such a more comprehensive view was introduced by Rogers et al. (Rogers et al. 2009), who 
discussed the concept of bacterial communities as one pathogenic entity in the context of CF. 
The idea of pathogenic bacterial communities to cause infections rather than single species 
was introduced previously (Jenkinson & Lamont 2005). The current study, albeit small, 
demonstrates bacterial consortia from which some may act as pathogenic entities. For each 
subgroup, characteristic species were determined. Some communities were strongly 
dominated (relative abundance ≥ 50 %) by bacterial species with an unclear pathogenic 
potential as single infectious agents in CF, like Nocardia -1, S. millerii and Fusobacterium 
nucleatum (Bolstad et al. 1996) (LiPuma 2010) (Hauser et al. 2011). These species were 
infrequently found in the cohort suggesting specific conditions promoting their growth in 
individual communities. Particularly, species from the anaerobic S. millerii group are thought 
to be underestimated infectious agents and observed co-colonization with P. aeruginosa 
leading to speculation of polymicrobial interactions resulting in enhanced virulence in CF 
(Parkins et al. 2008). Communities with highly abundant S. millerii were observed to be 
persistent and the defined respective microbial subgroup accordingly comprised both bacteria 
as characteristic species. Also, communities characterized by high abundances of the strict 
anaerobic F. nucleatum (subgroup F) were associated with decreased lung functions. Sequent 
sputum samples of one patient revealed a stable community over eight months and suggesting 
persistence of F. nucleatum with high abundances in the communities. Although, it is 
regularly isolated from healthy oral body sites, this species is known to be involved in serious 
infections with a strong ability to form co-aggregates with other species (Bolstad et al. 1996). 
Strongly decreased lung functions were also associated with the unique community dominated 
by B. petrii and G. haemolysins. Regarding their clinical relevance, B. petrii was found to be 
persistent in one patient with a chronic pulmonary disease but previously described to lack 
pathogenic potential and G. haemolysins, known to be part of the normal oral flora but with 
pathogenic potential, was associated with CF before (Blitman et al. 2007) (Bittar et al. 2008) 
(Gross et al. 2008) (Le Coustumier et al. 2011). 
 
Overall, distinct microbial communities were observed in the CF cohort, from which some 
polymicrobial entities may have pathogenic potential. Besides the limited number of species 
considered to be major CF pathogens, more recent studies revealed a wide range of bacteria in 
clinical samples from CF patients  (Bittar & Rolain 2010) (Stressmann et al. 2011). 
Correlations between certain microbial subgroups and strongly decreased lung functions were 
found suggesting that these bacterial consortia have an influence on patient health and results 
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of the current study support the idea of enhanced pathogenicity due to interactions between 
species. Likewise, these findings indicate under-diagnosed species, like the strict anaerobic 
bacteria S. millerii and F. nucleatum, to be of clinical relevance and associated with infection 
manifestation and decline of health in CF patients. 
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forward primers sequence (5'->3') 
V3_1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGCCTCAATTACCGCGGCTGCTGG 
V3_2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTAAGTTACAATTACCGCGGCTGCTGG 
V3_3 ACACTCTTTCCCTACACGACGCTCTTCCGATCTAATACGCAATTACCGCGGCTGCTGG 
V3_4 ACACTCTTTCCCTACACGACGCTCTTCCGATCTAATCGACAATTACCGCGGCTGCTGG 
V3_5 ACACTCTTTCCCTACACGACGCTCTTCCGATCTAATGATCAATTACCGCGGCTGCTGG 
V3_6 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACCAATCAATTACCGCGGCTGCTGG 
V3_7 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACCGTCCAATTACCGCGGCTGCTGG 
V3_8 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACCTCGCAATTACCGCGGCTGCTGG 
V3_9 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACGAGGCAATTACCGCGGCTGCTGG 
V3_10 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACTATACAATTACCGCGGCTGCTGG 
V3_11 ACACTCTTTCCCTACACGACGCTCTTCCGATCTACTTACCAATTACCGCGGCTGCTGG 
reverse primer   
IlluRevAdap_V3 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCCTACGGGAGGCAGCAG 
 
Table S1: Primers used for library preparation in Illumina-based sequencing. Underlined letters denote 
complementary sequences for the variable region V3 of the 16S rRNA gene. Eleven different barcodes were 
used, each indicated with bold letters within the primer sequence. In a second PCR, amplicons for libraries were 
accomplished by adding Illumina-specific indices.  
 
 
Table S2:  
OTU Illumina 
Identity 
in % 
closest representative species by SSCP 
pos. 
samples 
(total no.) 
min. 
abund. 
in % 
max. 
abund.  
in % 
Streptococcus -1 100 
KC632197.1 Streptococcus 
parasanguinis    63 0.86 51.67 
Rothia 
mucilaginosa 100 
KC632201.1Rothia 
mucilaginosa  
99% R. mucilaginosa 
DQ409140.1 60 0.54 50.06 
Pseudomonas -1 100 
HF572851.1 Pseudomonas 
aeruginosa  
100% P. aeruginosa  
CP003149.1 57 0.63 93.31 
Rothia -2 100 
KC632226.1 Rothia 
dentocariosa    36 0.72 25.77 
Granulicatella -1 100 
JF803551.1 Granulicatella 
para-adiacens   33 0.53 5.87 
Prevotella -1 100 
JN867317.1 Prevotella 
melaninogenica   30 0.55 38.32 
Staphylococcus -
1* 100 
KC465401.1 Staphylococcus 
aureus  
99% S. aureus 
AB680391.1 27 0.60 87.81 
Gemella 
haemolysans 100 
HE974940.1 Gemella 
haemolysans  
100% G.haemolysans 
NR025903.1 22 0.57 31.49 
Gemella -2 100 AY757357.1 Gemella sanguinis    22 0.51 4.28 
Atopobium -1 100 GU425926.1 Atopobium rimae    18 0.55 3.23 
Streptococcus -3 100 
KC632205.1 Streptococcus 
sanguinis    18 0.54 8.77 
Streptococcus 
millerii 100 
KC632214.1 Streptococcus 
anginosus    17 0.54 75.53 
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Streptococcus -2 99 
KC632193.1 Streptococcus 
salivarius   16 0.60 10.10 
Actinomyces 
graevenitzii  97 
AY866429.1 Actinomyces 
graevenitzii   16 0.58 14.51 
Actinomyces -1 100 
HQ850579.1 Actinomyces 
turicensis   15 0.57 14.16 
Actinomyces -2 97/100 
HQ616392.1 Actinomyces sp. / 
JQ031125.1 Actinomyces 
funkei   13 0.54 5.53 
Veillonella atypica 100 KC632238.1 Veillonella dispar   13 0.52 13.83 
Veillonella -2 100 HM596287.1 Veillonella sp.   11 0.70 5.98 
Fusobacterium 100 
NR_074412.1 Fusobacterium 
nucleatum 
98% F.nucleatum 
AB588016.1 11 0.55 53.52 
Achromobacter -1 100 
KC010531.1 Achromobacter 
xylosoxidans 
99% A. xylosoxidans 
EU266588.1 6 0.77 46.35 
Stenotrophomon
as maltophilia 100 
KC683776.1 
Stenotrophomonas maltophilia 
99% S.maltophilia 
JX848739.1  6 0.62 15.41 
Mogibacterium -1 100 
KC632200.1 Mogibacterium 
diversum   5 0.51 1.31 
Actinomyces -3 97/100 
HQ616392.1 Actinomyces sp. / 
JQ031122.1 Actinomyces 
funkei   5 0.66 1.74 
TM7 100 
GQ422738.1 TM7 phylum sp. 
oral   5 0.52 1.93 
Porphyromonas -
1 100 
GU409265.1 Porphyromonas 
sp.   4 0.76 1.58 
Bifidobacterium 
longum 100 
HE974928.1 Bifidobacterium 
longum   4 0.54 3.55 
Stomatobaculum 
longum 100 
HM120209.1 Stomatobaculum 
longum   4 0.51 4.36 
Clostridiaceae -1 100 
NR_074652.1 Clostridium 
phytofermentans    4 0.50 1.11 
Prevotella pallens 100 KC632223.1 Prevotella pallens   4 0.55 0.90 
Nocardia -1 100 KC478309.1 Nocardia farcinica   3 1.10 61.87 
Solobacterium 
moorei 100 JX104033.1 Solobacterium sp.   3 0.57 0.70 
Actinomyces -4 96/95 
EF473992.1 Actinomyces sp. / 
JF803550.1 Actinomyces 
graevenitzii   3 3.36 13.04 
Prevotella salivae 100 JN867237.1 Prevotella salivae   3 0.52 1.58 
Granulicatella 
elegans 100 
JN801174.1 Granulicatella 
elegans   3 0.60 0.81 
Streptococcus 
mitis  100 
GU326246.1 Streptococcus 
pneumoniae   3 0.74 1.17 
Actinomyces -5 100 JX524818.1 Actinomyces oris   3 0.53 0.75 
Lactobacillus -2 100 
KC456368.1 Lactobacillus 
fermentum   3 0.60 1.40 
Prevotella - 2 100 JN867292.1 Prevotella oris   2 5.64 12.27 
Rothia-3 100 GQ900845.1 Rothia sp.   2 0.51 1.10 
Haemophilus -2 100 
JF506651.1 Haemophilus 
parainfluenzae   2 1.21 1.21 
Streptoccocus -4 99 
KC632199.1 Streptococcus 
australis   2 0.51 0.67 
Veillonella -2 100 
AB679112.1 Veillonella 
tobetsuensis   2 1.52 2.04 
Megasphaera 
micronuciformis 98.59 
JF803576.1 Megasphaera 
micronuciformis   2 0.50 0.83 
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Porphyromonas -
2 100 JF803575.1 Porphyromonas sp.    2 1.05 2.49 
Atopobium -2 100 
KC297229.1 Atopobium 
parvulum   2 0.54 1.29 
Prevotella 
tannerae 100 
GU561345.1 Prevotella 
tannerae   2 0.52 1.26 
Burkholderia -1 100 
HF678361.1 Burkholderia 
cepacia 
100% B. cepacia 
AB680641.1 1 8.60 8.60 
Micrococcineae -
1 100 
KC346300.1 Streptomyces 
violaceorectus   1 1.12 1.12 
Neisseria -2 100 KC178474.1 Neisseria mucosa   1 2.43 2.43 
Acinetobacter -1 100 
KC337241.1| Acinetobacter 
tjernbergiae   1 1.09 1.09 
Neisseria 
flavescens 100 
KC178511.1 Neisseria 
flavescens   1 1.61 1.61 
Bordetella petrii  100 HE672085.1 Bordetella petrii   1 55.88 55.88 
Prevotella -3 100 GU409603.1 Prevotella sp.   1 2.92 2.92 
Veillonella -3 93 KC632234.1 Veillonella sp.   1 1.94 1.94 
Scardovia 
wiggsiae 100 
HM596282.1 Scardovia 
wiggsiae   1 0.54 0.54 
Prevotella 
nanceiensis  100 
JN867319.1 Prevotella 
nanceiensis   1 0.68 0.68 
Capnocytophaga 
gingivalis 100 
GU561334.1 Capnocytophaga 
gingivalis   1 1.81 1.81 
Leptotrichia 
wadei 100 AB588021.1 Leptotrichia wadei   1 0.53 0.53 
Lactobacillus 
kalixensis 100 
FR683096.1 Lactobacillus 
kalixensis   1 1.39 1.39 
Prevotella -4 98 GU413291.1 Prevotella sp.   1 2.28 2.28 
Alloscardovia -1 100/97 
AB425070.1 Alloscardovia sp. / 
AB437351.1 Bifidobacterium 
psychraerophilum   1 1.90 1.90 
Propionibacteriu
m acidifaciens 100 
JF803561.1 Propionibacterium 
acidifaciens   1 0.60 0.60 
Haemophilus 
influenzae 100 
CP000057.2 Haemophilus 
influenzae   1 1.11 1.11 
Leptotrichia -2 100 
NR_074440.1 Leptotrichia 
buccalis    1 0.74 0.74 
Propionibacteriu
m acnes* 100 
JQ435685.1 Propionibacterium 
acnes    1 3.59 3.59 
   
99% S. parasanguinis 
AY281078    
   
100% S. salivarius 
FR873482.1    
   
99% S. mitis 
FN568063.1    
   
99% S. gordonii 
AY281088.1    
   
100% S. sanguinis 
AB596946.1    
   
99% S. peroris 
GU425263.1    
   
99% S. oralis 
AF003932    
   
99% S. anginosus 
AF306838.1    
   
100% S. intermedius 
AF104671.1    
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Table S2: OTUs observed with Illumina exhibiting a minimum relative abundance of 0.5 %. Sequence similarity 
revealed by BLAST is given as well as the closest representative (acquisition number and name) for each OTU. 
Comparison with SSCP fingerprinting allowed phylogenetic affiliation of some previously ambiguous OTUs to 
species level. Streptococcus species identified by SSCP are mentioned with sequence identity scores in percent 
as well as accession numbers of closest representatives in the end of the table. For Illumina-based data, number 
of positive samples for each OTU is given as well as minimum and maximum relative abundances in individual 
samples. *V1 instead of the V3 region was amplified in rare events for the OTUs Propionibacterium acnes as 
well as for Staphylococcus -1 in some samples. However, comparisons of the relative abundances assessed by 
repeatedly analyzed samples did not reveal any significant difference in the affected samples. 
 
Figure S1 (below): Comparison of individual relative abundances for all samples assessed by NGS (^) and 
SSCP fingerprinting (°).  Only OTUs with relative abundance of ≥ 5 % were considered for these comparisons. 
Each diagram shows 24 samples in total which means 12 distinct samples each one analyzed with both methods. 
Each colour represents one bacterial OTU according to the legend. OTU only defined in NGS are respectively 
labelled (^) as well as OTUs only defined in SSCP fingerprinting (°). OTUs unambiguously and equally assigned 
with both methods are accordingly marked with both labels (^°). Numbers indicate individual patients. Letters 
are according order of sputum collection. 
Pseudomonas aeruginosa^° Streptococcus -1^
Streptococcus parasanguis° Streptococcus salivarius°
Streptococcus mitis group° Rothia mucilaginosa^°
Staphylococcus aureus^° Fusobacterium nucleatum^°
Achromobacter xylosoxidans^° Burkholderia cepacia^°
Stenotrophomonas maltophilia^° Gemella haemolysans^°
Nocardia -1^° Bordetella petrii^°
Granulicatella -1^° Rothia -2^°
Streptococcus millerii^ Streptococcus anginosus°
Streptococcus intermedius° Veillonella atypica^
Veillonella° Veillonella -2^
Actinomyces graevenitzii^ Actinomyces graevenitzii°
Actinomyces -2^ Actinomyces -1^
Actinomyces -4^ Prevotella -1^
Prevotella° Prevotella - 2^
Streptococcus -2^ Streptococcus -3^
Streptococcus gordonii° Streptococcus peroris°
Streptococcus oralis° Gemella sanguinis°
Atopobium parvulum° TM7°
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Figure S1 (continuing): 
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Figure S1 (continuing): 
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Figure S2: Histograms of RELATE analysis: Testing matched resemblance matrices based on separately 
analyzed compositional data sets. Similarity is measured by Spearman’s Rho and data sets were permuted. 
Distribution of Rho values for permutations are shown in the histograms. The according frequencies of 
permutations are given on y-axes. Rho values of the actual sample are additionally shown in each histogram. For 
all analysis the number of permuted statistics greater than or equal to Rho value of the actual sample was zero. 
 
 
Figure S2a: Testing 
similarity of compositional 
data sets for 72 sputum 
samples assessed by NGS 
and by SSCP. Significance 
level of sample statistic: 
0.01 %. Number of 
permutations: 9999. 
 
 
 
 
Figure S2b: Testing similarity 
of compositional data sets for 
different extractions of 8 
sputum samples assessed by 
NGS. Significance level of 
sample statistic: 0.01 %. 
Number of permutations: 9999. 
 
 
 
 
 
 
Figure S2c: Testing similarity 
of compositional data sets for 
different amplifications and 
preparations of 10 sputum 
samples assessed by NGS. 
Significance level of sample 
statistic: 0.001 %. Number of 
permutations: 99999. 
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Figure S4: 
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Figure S4: Comparison between age of patients (white bars) and relative abundance of P. aeruginosa (black 
bars). Samples are ordered by age of the patient at the individual time point of sputum collection. Age of patient 
is given in years and relative abundance of P. aeruginosa is given in % on y-axis. For each patient, both 
parameters are indicated. Missing bars for P. aeruginosa indicate its absence in the sample. A median relative 
abundance of 24.8 % was calculated for the bacteria. Median age at time point of sputum collection was 31 
years. 
 
 
 
 
Figure S5: CFTR mutations 
of patients superimposed on 
the previous MDS plot 
calculated for the 
community compositions of 
72 sputum samples. Three 
classes of identified 
genotypes were determined 
for the cohort. Partly or 
completely unknown 
genotypes are accordingly 
labelled.  
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3.1 Abstract 
The current study presents major bacterial and fungal species associated with cystic fibrosis 
(CF). Molecular fingerprinting based on single-strand conformation polymorphism (SSCP) 
analysis revealed a rather different picture for bacteria and fungi detected in 72 sputum 
samples. Microorganisms were further taxonomically classified and the individual detection 
frequencies are presented. In contrast to bacteria, a large number of fungi were observed 
together with high fluctuation rates over time and between different patients, suggesting low 
colonization abilities of fungi in CF airways. Major bacterial pathogens were frequently 
observed, whereas fungal species with demonstrated pathogenicity in CF were detected at a 
low frequency. Overall, the current study provides for the first time an overview of the major 
bacterial and fungal species of an entire microbiome in a broader CF cohort. 
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3.2 Introduction 
Cystic fibrosis (CF) is the most common inherited disease in the western human population 
and respiratory tract infections are the leading cause of death for these patients. Human 
airways are covered with a mucus layer that serves to trap inhaled objects and in a permanent 
clearance process the mucus is removed from the respiratory tract. In CF patients, disturbed 
ion transports in airway epithelia lead to a dysfunction of  this clearance mechanism, resulting 
in conditions that promote microbial colonization (Matsui et al. 1998) (Boucher 2004). 
Improved treatments and diagnostic methods have led to a constantly increasing life 
expectancy during the past two decades and it is predicted that within the next years more 
than 50% of the population with CF will be adults (Cystic Fibrosis Foundation Patient 
Registry 2012). In turn, the occurrence and frequencies of pathogens are changing with age, 
resulting in new challenges in the healthcare of these patients. Major bacterial CF pathogens 
belong to the phylum Proteobacteria and include Pseudomonas aeruginosa, Burkholderia 
cepacia and Stenotrophomonas maltophilia. Together with Staphylococcus aureus from the 
phylum Firmicutes they are considered to be responsible for the majority of respiratory tract 
infections in adult CF patients (LiPuma 2010) (Hauser et al. 2011). Besides bacteria, fungi 
also exhibit the potential to cause lung diseases, like the allergic bronchopulmonary 
aspergillosis (ABPA). Already in the 1970s, culturable fungi were observed in over 80% of 
sputum and human lung samples which were taken randomly from necropsies (reason of 
death not specified) (Mullins & Seaton 1978). Despite the high exposure, the number of 
reported fungal lung infections is remarkably low but the real prevalence and role of fungal 
pathogens in CF patients still remains to be elucidated (Pihet et al. 2009).  
Additionally, the clinical relevance of several bacterial species associated with CF sputum is 
yet to be defined. Culture-independent methods revealed a broad spectrum of bacteria that are 
frequently detected in sputum and a polymicrobial concept for the development of respiratory 
diseases in the context of CF was suggested (Rogers et al. 2009). In such a polymicrobial 
concept, the pathogenicity of certain species depends on the interaction with others and, as a 
consequence, the community as a whole has to be considered pathogenic rather than single 
species (Jenkinson & Lamont 2005) (Delhaes et al. 2012). Ecological and physiological 
factors related to one microorganism may promote the growth and colonization ability of 
others. In this regard, fungal species also present in the human respiratory tract have to be 
considered in microbiological studies. In contrast to the bacterial community, a 
comprehensive view of fungal species being part of the human respiratory microflora was 
hardly approached. Only in a recent study a fungal microbiome of healthy individuals was 
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proposed for the oral cavity (Ghannoum et al. 2010). Interactions between fungi and bacteria 
have been reported and shown in more detail for the yeast Candida albicans and P. 
aeruginosa (Cugini et al. 2007) (McAlester et al. 2008) (De Sordi & Mühlschlegel 2009). A 
negative correlation between the Candida spp. load and the bacterial species diversity of the 
salivary microbiome in elderly healthy individuals was observed (Kraneveld et al. 2012). In 
the context of cystic fibrosis, fungal and bacterial species out of the same sputum samples 
were recently analyzed from four patients and correlations drawn with the clinical data 
(Delhaes et al. 2012). Overall, knowledge about fungal communities associated with the 
human respiratory tract is poor. Occurrence as well as exposure rates for the fungi first have 
to be determined before conclusions about their impact on respiratory microbial communities 
or on the health of infected patients can be made. 
 
The aim of the current study was to provide an overview about the fungal and bacterial taxa 
present in CF sputum using a culture-independent approach. This taxonomic survey was 
further compared with clinical abnormalities observed in the patients. In total, 72 sputum 
samples from 56 adult CF patients were analyzed. Species richness from the CF cohort was 
estimated and detection frequencies given for all fungal and bacterial taxa which were further 
taxonomically classified. The current study is the first to present the major taxa of an entire 
microbiome in a broader CF cohort, including fungi and bacteria.   
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3.3 Material and Methods 
 
3.3.1 Sample collection 
Sputum samples were collected in sterile containers from 56 CF patients recruited in the 
cystic fibrosis ambulance centre of the Hannover Medical School (MHH; Hannover, 
Germany), including a subgroup of 13 patients who provided sputum twice (n=10) or three 
times (n=3) within the sampling period of 2 years. In total, 72 separate sputum samples were 
collected. Ethical approval for the current study was granted by the local health authority 
ethics committee. Sputum collection was done during the routine medical examination. All 
patients were between 18-51 years old and a median age of 31 was calculated for the cohort. 
Both genders were equally represented (48.2% female and 51.8% male). Signs of acute 
infections were observed for some patients, none of them were in a critical health condition at 
the time of sputum collection. Containers with sputum were stored at -20°C before DNA 
extraction. 
 
3.3.2 Sputum preparation and DNA extraction 
An optimized protocol for the extraction of fungal and bacterial DNA was developed by 
modifying the manufacturer’s instructions of the kit and by adaptation of guidelines for the 
preparation of sputum samples recommended for detection of Mycobacterium tuberculosis in 
sputum (ifp Institut für Produktqualität 2008). Briefly, sputum samples were aliquoted and 
boiled for 15 minutes. To decrease the viscosity, a cysteine buffer (2% NaOH, 1.45% sodium 
citrate and 0.5% N-acetylcysteine) was added in the same volume and the solution was mixed 
for 40 minutes. Milli-Q water was added to a final volume of 15 ml and centrifuged for 30 
minutes at 4000 g. The supernatant was discarded and the pellet was resuspended in 300 µl of 
lysis buffer (20 mM Tris-Cl with pH 8.0, 2 mM sodium EDTA, 1.2% Triton® X-100). 6 mg 
of lysozyme (SERVA; Heidelberg, Germany) was added and incubated for 30 min at 37°C. 
To the total volume of the solution 0.5% of β-mercaptoethanol was given together with 50 U 
of lyticase (Sigma-Aldrich; Germany). The solution was incubated for another 45 min at 37°C 
before centrifugation at 12.000 rpm for 10 min. The pellet was resuspended in 300 µl Lyse T 
buffer from GeneMATRIX Tissue & Bacteria DNA purification kit (EurX Roboklon; Berlin, 
Germany) and 20 µl of proteinase K (Qiagen; Hilden, Germany) were added. After incubation 
of 2 hours at 56°C, the DNA was extracted by following the instructions of the manufactures. 
DNA extracts were kept frozen at -20°C for further analysis.              
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3.3.3 PCR amplification and preparation of ssDNA 
PCR amplification of parts of the rRNA gene from bacteria and fungi was performed. For 
bacteria, the primers 27F (5´-AGAGTTTGATCMTGGCTCAG-3’) and 521R (5’-
ACCGTGGCTGCTGGCAC-3’) were used to amplify parts of the 16S rRNA gene, including 
the variable regions V1-V3 of the small subunit of the ribosome (SSU) with an amplicon size 
between 459 bp for Nocardia sp. and 505 bp for Veillonella sp. (Wos-Oxley et al. 2010). PCR 
was carried out using 50 ng DNA of sputum extractions in a final volume of 50 μl, starting 
with an initial denaturation for 15 min at 95°C. A total of 30 cycles (1 min at 95°C, 40 sec at 
56°C, and 1 min at 72°C) was followed by a final elongation for 10 min at 72°C. For fungi, a 
semi-nested PCR strategy was chosen, using the forward primers ITS1 (5´-
TCCGTAGGTGAACCTTGCGG-3’), ITS4 (5´-TCCTCCGCTTATTGATATGC-3´) and 
ITS2 (5’-GCTGCGTTCTTCATCGATGC-3’) for reverse primers respectively (Schoch et al. 
2012). High length heterogeneity for the internal transcript spacer (ITS) regions are known, 
amplicon sizes in the current study varied from 134 bp for Yarrowia lipolytica to 475 bp for 
Candida glabrata (Chen et al. 2001). The first PCR was carried out using 50 ng DNA from 
sputum extracts in a final volume of 50 μl. By adding 3µl of MgCl2 (25 mM), PCR efficiency 
was substantially improved. Starting with an initial denaturation for 15 min at 95°C, 20 cycles 
(1 min at 95°C, 1 min at 58°C, and 1 min at 72°C) were followed by a final elongation for 10 
min at 72°C. Amplification of the final target region, ITS between the 18S and 5.8S, was 
achieved by using 1 µl of the previous PCR in a final volume of 50 μl. Initial denaturation for 
15 min at 95°C was followed by a total of 30 cycles (30 sec at 95°C, 20 sec at 62°C, and 30 
sec at 72°C) and a final elongation for 10 min at 72°C. 1.5 U of HotStarTaq DNA polymerase 
was used for all amplifications (Qiagen). For single-strand DNA (ssDNA) preparation, 
reverse primer 521R and ITS2 were 5´-biotin labeled and magnetic streptavidin coated beads 
(Promega, Madison, Wis.) were applied to obtain ssDNA from the PCR amplicons according 
to Eichler et al. (Eichler et al. 2006).    
 
3.3.4 SSCP fingerprints and sequencing of individual ssDNA bands  
Dried pellets of ssDNA were resuspended in 7 µl of gel loading buffer (95% formamide, 10 
mM NaOH, 0.25% bromphenol blue, 0.25% xylene cyanol). After incubation for 10 min at 
95°C, the ssDNA samples were stored on ice and loaded onto a non-denaturing 
polyacrylamide-like gel (0.6x MDE gel solution; Cambrex BioScience, Rockland, Maine) for 
SSCP electrophoresis. SSCP fingerprints of bacterial DNA were obtained at 20°C and 400 
Volt for 21 hours on 20 cm glass plates and at 20°C and 700 Volt for 20 hours for fungal 
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DNA on 55 cm glass plates respectively. More details on the SSCP fingerprints are given in 
Eichler et al. (Eichler et al. 2006). The gel was silver stained according to the method 
described by Bassam et al. (Bassam et al. 1991). SSCP fingerprints were digitized using a HP 
Scanjet G4050 scanner. Bands with an intensity ≥1% of the total lane were considered for 
further analysis and excised from the SSCP gel, boiled in Tris buffer (10 mM Tris-HCl, 5 mM 
MgCl2, 5 mM KCl, 0.1% Triton X-100, pH 9.0) and re-amplified according to the conditions 
described above. Purified amplicons were sequenced by cycle sequencing (ABI PRISM 
BigDye Terminator Cycle Sequencing Ready Reaction kit; Applied Biosystems, Foster City, 
Calif.), products were purified again with the BigDye Terminator purification kit (Qiagen) 
and analyzed using capillary electrophoresis with fluorescence detection (ABI Prism 3100 
Genetic Analyzer). 
 
3.3.5 Data processing and phylogenetic analysis 
Phylogenetic analysis of sequences was performed with the NCBI Tool BLAST/blastn and 
Ribosomal Data Base Project (RDP) Seqmatch Tool (only for bacteria) (Cole et al. 2009). The 
closest taxonomic groups were determined by sequence similarity and height of ssDNA bands 
in the molecular fingerprints. For fungi, species identification was defined for sequences with 
a similarity of at least 97%. Operational taxonomic units (OTUs) with ambiguous BLAST 
results were defined according to the closest shared taxonomic level. Taxonomic 
classification of fungi followed the outline published by Hibbett at al. (Hibbett et al. 2007). 
Classification of fungi is originally based on morphological features and developed further by 
genetic and physiological analysis. Therefore, molecular analysis of parts of the ribosomal 
RNA operon does allow identification of fungi but associated phylogenetic trees may not 
always display closely related species in the same clade. For bacteria, species identification 
was defined for sequences with a similarity of >97% and ssDNA bands of the same heights 
were considered to be the same species. Further, phylogenetic distance analysis was 
performed to confirm OTU determination (data not shown). Phylogenetic distances of 
sequences were calculated with Jukes-Cantor algorithm and displayed in Neighbour-joining 
trees using MEGA version 5 (Tamura et al. 2011). Species accumulation curves were 
calculated using AccuCurve 1.0 (Drozd & Novotny 2010). Incidence-based datasets were 
applied, permutated 250 times and the resultant curves were averaged.  
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3.4 Results  
 
3.4.1 Comparison of fungal and bacterial species richness in CF cohort 
The incidence of bacterial and fungal species was assessed in 72 separate sputum samples, 
collected over a period of 2 years. Molecular fingerprints of the microbial communities from 
sputum were generated using SSCP electrophoresis, followed by sequencing of all major 
bands (Figure 1).  
Figure 1: Molecular fingerprints by SSCP 
electrophoresis from bacteria (left) and fungi 
(right). Each lane (A-H; I-P) represents one 
sputum sample. Each band represents ssDNA 
from one microbial species. Bands at the 
same height were the same species. Numbers 
indicate some species identified by 
sequencing of the respective bands: For 
bacteria 1= Bordetella petrii, 2= 
Staphylococcus aureus, 3= Streptococcus 
salivarius, 4= Pseudomonas aeruginosa; for 
fungi 5= Saccharomyces cerevisiae, 6= 
Candida glabrata, 7= Exophiala dermatitidis, 8= Candida albicans and 9= Candida dubliniensis. Discrimination 
between C. albicans and C. dubliniensis was only achieved by sequencing. 
  
The resultant sequences were aligned and the OTUs defined. In total, 60 fungi and 38 bacteria 
were considered as OTUs and species affiliation identified by comparative sequence analysis 
(Table S1, S2). Individual species counts per sample showed a median of 4 bacterial and 2 
fungal OTUs per sputum sample (Figure 2). In most of the 72 sputum samples between 3-6 
bacterial species and 1-3 fungal species were observed. For bacteria and fungi, a maximum 
number of 11 species in one sample was detected.  At least one bacterial OTU was detected in 
each sample, whereas few sputum samples exhibit no fungal species count.  
 
 
Figure 2: Boxplots of species counts per sample for bacteria 
and fungi. Bars within boxes indicate the median number of 
OTUs. End of whiskers represent the minimum and maximum 
of species counts found in one sample.  
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In order to estimate richness for both types of microbes in the cohort, species accumulation 
curves were calculated using observed species counts (S) and counts for species only 
occurring in one sample (Q1; unique species) (Figure 3). Comparison of both curves for S 
showed a rather different picture for fungi and bacteria. For bacteria, the curve strongly rises 
in the beginning, indicating a high number of bacterial species in a relatively small number of 
samples. With increasing sample number the curve flattens and indicates in the end only a 
small incremental increase in species number if more samples would be analyzed. For fungi, 
no flattening of the curve was observed. A small number of samples showed a low incidence 
of species but a continuous rise of the curve indicates a steady increase in fungal OTUs. 
Considering that in a comprehensive sampling the number of unique species should be as low 
as possible, the trends for the curves of Q1 are more informative for the estimation of species 
richness. For bacteria, a flat curve similarly shows only a small increase of unique species 
when taking more samples into account and indicates in the end no substantial increase of 
new unique species with further sampling. In 72 sputum samples, 15 bacterial species were 
only occurring in one sample (unique species). Again, a rather different picture was observed 
for fungi: the curve for Q1 indicates a continuous rise of unique species with increasing 
sample numbers. After 72 analyzed sputum samples, 42 out of 60 fungal OTUs were 
occurring only once.    
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Figure 3: Species accumulation curves are shown for bacterial and fungal OTUs detected in 72 sputum samples. 
Averaged curves show the number of detected species versus number of samples. Curves for bacteria are shown 
in grey and curves for fungi are shown in black. Full lines show observed species counts (S; Mao Tao) and 
dashed lines show unique species counts (Q1; species which occur in only one sample).    
 
Overall, contrary trends were observed for fungal and bacterial species detected in the CF 
cohort. Whereas, the number of bacterial counts seemed to stabilize beyond 72 samples, new 
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fungal species have to be continuously considered with increasing sample numbers. Species 
accumulation curves for 56 sputum samples (only the first collected sample from each patient) 
were likewise calculated and confirmed these results (Figure S3). Therefore, a high richness 
of fungal species in contrast to a relatively small number of bacteria was determined in this 
CF cohort study.  
 
From a subgroup of 13 CF patients, sputum samples were collected twice or three times over 
a period of 2 years. Comparing the individual species richness, this subgroup also showed a 
different picture for fungi and bacteria (Figure 4). For fungi, the star-like appearances of the 
curves indicate major differences in numbers of observed OTUs. Individual numbers are 
rather diverse throughout the 13 patients as well as between the different time points of the 
same patient. In contrast, the comparatively circular-like appearances of the curves for 
bacteria indicate a relatively stable number of OTUs throughout the patients as well as 
between the different time points of the same patient. One exception was patient #7: samples 
showed at the first time point of collection only 2 bacterial OTUs whereas in the second 
sputum sample 10 OTUs were detected. Further correlations between the individual numbers 
of fungal and bacterial OTUs for one patient could not be observed.   
 
 
 
 
Figure 4: Differences in individual bacterial and fungal OTU counts for a subgroup of 13 CF patients with 
repeated sputum collection. Radar charts are showing patient #1 to #13 on angular axes. Numbers of detected 
species are given in radial axes. Blank and grey symbols indicate values for first and second sputum samples, 
respectively. Symbols are accordingly combined with black and grey lines to locate the correct values for each 
patient. Three sputum samples were analyzed for patients #11*-13* and values are represented by black triangles 
only. Fungal OTU counts are shown in the left and bacterial counts in the right plot.   
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3.4.2 Species diversity and occurrence frequency of bacteria in CF cohort 
Bacterial species from nine major taxonomic groups at the class level were observed in the 
sputum samples of the CF cohort (Figure 5). The highest number of positive samples 
(occurrence) was observed for the 14 OTUs of the class Bacilli, including Streptococcus 
salivarius and Streptococcus parasanguinis which were both detected in 56.9% of the 
samples (Table S1). Considering the individual occurrences of all OTUs, all other taxonomic 
classes, with the exception of Bacteroidia, were dominated by a single OTU. In 70.8% of the 
samples Gammaproteobacteria were observed and P. aeruginosa was detected in 69.4%. 
Actinobacteria with 6 detected species were dominated by Rothia mucilaginosa which was 
found in 43% of the samples. Three species of Betaproteobacteria were considered, 
Achromobacter xylosoxidans was the most frequent with 8.3% positive samples. Four 
taxonomic classes with a single OTU each were observed, Fusobacterium nucleatum 
(Fusobacteria) was detected in 6.9% of the samples and Veillonella -1 (Negativicutes) in 
5.5%. Unique classes were found in just one sample and were represented by 
Capnocytophaga gingivalis (Flavobacteria) and an oral TM7 candidate taxon. Further details 
on individual occurrences are given in Table S1. 
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Figure 5: Frequency of taxonomic classes of bacteria detected in 72 CF sputum samples. Black bars give 
number of OTUs observed for each class. Grey bars indicate percentage of positive samples of respective OTUs. 
Precise values for each bar are given in the figure. 
*formerly member of the class Clostridia 
 
In the class Bacteroidia, 9 OTUs of the genus Prevotella were observed. P. histicola and P. 
melaninogenica were the most frequently detected with 6.9% positive samples each. The 
phylogenetic diversity of all observed bacterial species was depicted in Figure 6. Likewise, 
the genus Streptococcus was represented by 9 OTUs in the CF cohort. Most of them are 
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considered to be members of the Streptococci mitis group with the exception of S. salivarius 
and two species of the S. millerii group, S. anginosus and S. intermedius which were detected 
in 8.3% and 6.9% of the samples, respectively. For the OTU affiliated to S. mitis itself an 
occurrence rate of 43% was observed.  
 
Figure 6: Phylogenetic tree for all bacterial OTUs observed in the 72 sputum samples based on 16S rRNA gene 
sequence analysis. Bacteria from 8 taxonomic classes were observed, representative sequences from closest 
described bacterial species for each OTU were used to construct the tree. Dominant species of each class are 
additionally labelled with black circles. Scale bar represents base substitution per site. 
 
From the class Bacilli, three Staphylococcaceae species were found, including S. aureus, with 
25% positive samples the most frequent non-Streptococci, and two Gemella species. G. 
sanguinis was found in 20.8% and G. haemolysans in 11.1% samples. From Actinobacteria, 
two OTUs each in the genus Rothia and the genus Actinomyces were detected. For 
Actinomyces, A. graevenitzii was the most frequent with 13.8% positive samples. Overall, five 
species from the phylum Proteobacteria were observed, including S. maltophilia 
(Gammaproteobacteria) detected in 4.1% of the samples and B. cepacia as well as Bordetella 
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petrii (both Betaproteobacteria) were detected in 1.3%. All OTUs not particularly mentioned 
in the text were found in less than 5 samples (detailed individual occurrences are mentioned in 
Table S1). Absolute number of incidences for each bacterial class and an overview of the 
occurrences of the bacterial species are given in Table 1.a.  
 
3.4.3 Species diversity and occurrence frequency of fungi in CF cohort 
Ten taxonomic classes could be identified from the two fungal divisions Ascomycota and 
Basidiomycota. One OTU could not be taxonomically assigned, but partial 18S and 5.8S 
sequences of the amplicon exhibit typical fungal structures and was therefore considered. 
Additionally, one OTU in each division did not exhibit sufficient similarity to be further 
assigned to a specific class. In total, members of 13 fungal classes were observed (Figure 7). 
While for bacteria a single dominant species was found in most taxonomic classes, no such 
observation was made for fungi.  
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Figure 7: Frequency of taxonomic classes of fungi detected in 72 CF sputum samples. Black bars give number 
of OTUs considered for each class. Grey bars indicate incidence of associated OTUs. Values for each bar are 
given in the graphic. 
 
Saccharomycetes were the most frequently found fungi and this class comprised the five most 
frequently found species. 88.8% of samples were positive for the 19 OTUs observed. The 
polymorphic yeasts C. albicans and C. dubliniensis were the dominant fungal species in the 
CF cohort with 44.4% and 23.6% positive samples respectively, followed by S. cerevisiae 
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with 19.4% and Candida parapsilosis with 13.8% positive samples. C. glabrata was detected 
in 12.5%.  From Dothideomycetes, 10 species in 25% of the samples were observed. Two 
OTUs were dominant in this class: the Cladosporium cladoporoides complex with 11.1% and 
the Cladosporium herbarum complex with 9.7%. The basidiomycete class Pucciniomycetes 
showed only two species, the yeasts Sporobolomyces roseus and Sporobolomyces ruberrimus 
which were found in 11.1% and 5.5% of sputum samples, respectively. These two species 
were repeatedly detected together in the same samples (n=3). Within the other taxonomic 
classes, individual incidences of the associated OTUs were more equally distributed. An 
overview about the occurrences of major fungal species is given in Table 1.b and detailed 
individual occurrences of fungal OTUs are mentioned in Table S2 
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Figure 8: Phylogentic trees for fungal OTUs observed from the division Ascomycota based on ITS region 
sequence comparisons. On the left: Saccharomycetes species found in the CF cohort. C. albicans and C. 
dubliniensis were the most frequently found fungi in the CF cohort. On the right: non-Saccharomycetes OTUs 
including filamentous fungi considered as major CF pathogens like Aspergillus spp., Exophiala dermatitidis and 
Scedosporium apiospermum (teleomorph: Pseudoallescheria  boydii). Scale bar represents base substitution per 
site. 
 
From the total of 60 fungal OTUs observed, 41 could be assigned to the division Ascomycota 
and 18 to the division Basidiomycota. Due to their high diversity, ascomycetes OTUs were 
further split into Saccharomycetes species and non-Saccharomycetes (Figure 8). Likewise, all 
OTUs considered Basidiomycota were depicted in a third phylogenetic tree (Figure 9). 
Several filamentous mould species from the classes Dothiomycetes and Eurotiomycetes, 
including four Aspergillus-like species (A. fumigatus, A. conicus, A. versicolor and 
Neosartorya pseudofischeri), were observed in the CF cohort and represent most of the OTUs 
in the associated phylogenetic tree. From the basidiocarp-forming Agaricomycetes, eight 
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mushroom-producing fungi were observed, like Plicaturopsis crispa, Megacollybia 
platyphylla, Piptoporus betulinus, Polyporus gayanus, Strobilurus sp., Baeospora sp. and 
Hyphodontia sp..  
 
 
 
Figure 9: Phylogentic tree for fungal OTUs observed 
from the division Basidiomycota based on ITS region 
sequence comparisons. Species from several 
basidiomycetes classes were detected. Scale bar 
represents base substitution per site. 
 
 
 
 
Overall, a high species diversity of fungi was observed in sputum samples from the CF 
cohort. Both major fungal divisions were represented by several classes and species. Yeast-
like fungi were found in all three groups and showed the highest diversity. Poly- and 
dimorphic fungal species were found as well as species limited to a single type of growth.    
 
3.4.4 Dynamics of fungal OTUs and clinical abnormalities in individual CF patients 
In Figure 4 differences of individual fungal OTU counts for a subgroup of 13 CF patients are 
presented. In addition to the total number of fungi, the individual incidences of single OTUs 
over time were analyzed in this subgroup and revealed rare OTUs that were repeatedly 
associated with the same patients. These rare OTUs were further characterized by overall low 
occurrence rates. The emerging CF pathogen Exophiala dermatitidis from the class 
Eurotiomycetes was found in two samples collected within a three-month period from patient 
#3. With a total of two and three fungal OTU counts, a relatively constant number of species 
was observed for this patient. The major CF pathogen Scedosporium apiospermum 
(Sordariomycetes) was detected in two sputa samples collected within a three-month period 
from patient #5. In total, six fungal species were observed in the first and nine OTUs in the 
second sputum sample. In the second, several filamentous fungi were found like Penicillium 
sp. (Eurotiomycetes), Fusarium oxysporum (Sordariomycetes) and both Cladosporium OTUs 
mentioned above, whereas Aspergillus fumigatus (Eurotiomycetes) was only detected in the 
first sample of that patient. Two Rhodotorula OTUs, from the class Microbotryomycetes, 
were observed in the CF cohort. Both of these basidiomycetes yeast-like species were found 
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in patient #13* showing an advanced number of 6 fungal species counts in the sputum. A 
second sample from this patient collected 15 months later still exhibited 6 fungal OTUs, 
though comprising mostly yeast and not Rhodoturola species OTUs. Five months later, a third 
sample from patient #13* showed a reduced number of species but the major CF pathogen 
Scedosporium apiospermum was found.  
 
Clear correlations between single fungal OTUs and clinical features of CF patients could not 
be observed. However, from five CF patients exhibiting an unusually high number of 
individual fungal OTU counts (>4) three showed conspicuous clinical abnormalities. As 
mentioned above, in two sputum samples from patient #5 six and nine fungal OTUs were 
observed. ABPA was diagnosed for this patient. From the same subgroup, patient #13* 
exhibited 6 fungal OTUs in the first two sputum samples and lung function tests revealed low 
FEV1 values (predicted forced expiratory volume in one second), not exceeding 30% at any 
time of sputum collection. In total three Cryptococcus OTUs (Tremellomycetes) were 
observed in the CF cohort, two of these yeasts were detected in a sample of an additional 
patient who exhibited an unusually high number of 7 fungal OTUs in the sputum. This patient 
was suffering from an acute infection with advanced levels of inflammatory markers in the 
blood (C-reactive protein: 129 mg/l).  
 
Four fungi from the class Agaricomycetes, which comprises typical mushrooms, were found 
in one sample, together with the maximum number of eleven fungal OTU counts. Although 
no conspicuous clinical abnormalities were mentioned, this patient was characterized by an 
untypical CF caused by a mutation in the sodium channel. Besides the four cases described 
above, one additional patient exhibited an unusually high number of fungal OTUs in the 
sputum. No conspicuous clinical abnormalities were observed. Six fungi in total were 
detected of which four belong to the class Saccharomycetes, all OTUs were repeatedly 
observed throughout the CF cohort with an occurrence rate of at least 4.1%.   
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1.a phylum class (total no. of incidences) major species % pos. samples 
Bacteria 
Firmicutes 
Bacilli (185) 
Streptococcus salivarius 56.9 
Streptococcus parasanguis  56.9 
Streptococcus mitis 43.0 
Staphylococcus aureus  25.0 
Gemella sanguinis  20.8 
Granulicatella -2 19.4 
Gemella haemolysans  11.1 
Streptococcus anginosus 8.3 
Streptococcus intermedius 6.9 
Negativicutes (4) Veillonella -1 5.5 
Proteobacteria 
Gammaproteobacteria (53) 
Pseudomonas aeruginosa  69.4 
Stenotrophomonas maltophilia  4.1 
Betaproteobacteria (8) 
Achromobacter xylosoxidans 8.3 
Bordetella petrii  1.3 
Burkholderia cepacia 1.3 
Actinobacteria Actinobacteria (50) 
Rothia mucilaginosa 43.0 
Actinomyces graevenitzii 13.8 
Bacteroidetes 
Bacteroidia (21) 
Prevotella histicola 6.9 
Prevotella melaninogenica 6.9 
Flavobacteria (1) Capnocytophaga gingivalis 1.3 
Fusobacteria Fusobacteria (5) Fusobacterium nucleatum 6.9 
TM7 candidate phylum TM7 candidate class (1) TM7  1.3 
1.b division class (total no. of incidences) major species % pos. samples 
Fungi 
Ascomycota 
  Saccharomycetes (101) 
Candida albicans 44.4 
Candida dubliniensis 23.6 
Saccharomyces cerevisiae 19.4 
Candida parapsilosis 13.8 
Candida glabrata 12.5 
Candida tropicalis 4.1 
Cyberlindnera jadinii  4.1 
Candida sake 2.7 
Dothideomycetes (24) 
Cladosporium cladosporioides 11.1 
Cladosporium herbarum 9.7 
Lewia infectoria 2.7 
Eurotiomycetes (9) 
Exophiala dermatitidis 4.1 
Aspergillus fumigatus 2.7 
Sordariomycetes (5) Scedosporium apiospermum 4.1 
 Leotiomycetes (3) Blumeria graminis  2.7 
Basidiomycota 
Pucciniomycetes (12) 
Sporobolomyces roseus 11.1 
Sporobolomyces ruberrimus 5.5 
Microbotryomycetes (3) Rhodotorula glutinis  2.7 
 
Table 1.a, b: Occurrence of major OTUs detected in 72 CF sputum samples. Table 1.a comprises bacterial 
OTUs described in the text. Table 1.b shows fungal OTUs detected more than once. Bacterial and fungal OTUs 
are grouped according to taxonomic classification and ranked according to number of positive samples (in %). 
Additionally, the absolute number of detected incidences for each class is given in brackets (considering all 
detected OTUs including unique species). The following basidiomycetes classes are represented by unique 
OTUs only and are therefore not considered in the table: Agaricomycetes, Tremellomycetes, Exobasidiomycetes.  
Chapter III 
 85 
3.5 Discussion  
 
3.5.1 Microbial species identification  
The analysis of microbial species from the sputum samples was performed using ribosomal 
RNA gene fragments and sequences: For bacteria the V1-V3 region of the 16S rRNA gene 
was used and for fungi the internal transcribed spacer (ITS) between the 18S rRNA and 5.8S 
rRNA gene. Elucidation of bacterial communities in CF sputa by different techniques of 16S 
rRNA gene analysis is the most commonly used culture-independent strategy and shown to 
reveal more species associated with the respiratory tracts than cultivation of bacteria (Rogers 
et al. 2003) (Guss et al. 2011). Next generation sequencing methods are capable of detecting 
species down to lower relative abundances than classical molecular fingerprints. However, the 
clinical relevance of very low abundant bacteria within a community is disputable. In the best 
case, SSCP electrophoresis is considered to have a detection limit down to a relative 
abundance of 0.1% (Eichler et al. 2006). In the current study, a detection limit of about 1% 
was assumed. Furthermore, the variable regions targeted were shown to be appropriate for the 
differentiation of bacterial pathogens in diagnostics (Chakravorty et al. 2007).  
 
Besides the bacterial microflora, fungal communities were also detected with the same 
strategy. The fungal target region is further known to exhibit high length heterogeneity across 
fungal species. The species-specific length polymorphism was used in previous studies to 
characterize fungal communities and to identify medically important fungi (Chen et al. 2001) 
(Ranjard et al. 2001). SSCP electrophoresis was successfully applied for the diagnosis of 
fungal infections in other body sites (Kumar & Shukla 2005). Furthermore, the target region 
chosen in the current study was shown to be appropriate for community representation and 
species resolution (Schoch et al. 2012). Overall, the identification and detection methods 
chosen for the current study seemed to be appropriate to obtain a comparable level of 
taxonomic resolution, i.e. species of bacteria and fungi. High taxonomic informativeness and 
sequence similarity allowed confident identification of the species for most OTUs. It is 
important to note here, that the methods are DNA-based and therefore no distinction is made 
between respiratory tract microbial colonisers, DNA originating from dead bacteria, inhaled 
fungal spores or tissue fragments. 
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3.5.2 Bacterial species present in CF sputum 
The species diversity of bacteria in the CF cohort was described here to be comparatively low. 
Individual communities were partly highly diverse and rather different from each other but the 
more sputum samples that were analyzed, the more known (previously observed) bacterial 
species were detected. Similarly, individual OTU counts showed a comparatively constant 
number of species throughout different patients and between different sputum samples of the 
same patients. Higher bacterial richness found in other CF cohort studies resulted from 
detection sensitivities down to 0.012% of the total volume and less than 1% volume for the 
majority of observed OTUs (Rogers et al. 2004). Taking only higher abundant species into 
account, the current study presents the major bacterial taxa of a broad CF cohort. The concept 
of defining core taxa in bacterial communities of CF airways was approached previously by 
Gast et al. (Gast et al. 2011). This study divided bacterial taxa from 14 clinically stable CF 
patients into a core and a satellite group, the core comprised only 15 taxa and the satellite 
group included major CF pathogens. The current study suggests a core group consisting of a 
broader number of bacterial taxa: 23 bacteria from 7 taxonomic classes were detected more 
than once. These bacteria comprised the major CF pathogens P. aeruginosa, S. aureus, S. 
maltophilia and candidate CF pathogen A. xylosoxidans (LiPuma 2010) (Hauser et al. 2011). 
However, the important pathogen B. cepacia was only detected in one sample. Together with 
several other rarely reported candidate CF pathogen in the literature, like Nocardia sp., the 
number of CF relevant taxa is beyond the 23 described in the current study. 
 
Concerning the origin of bacteria present in CF sputum, the communities in the human oral 
cavity has to be considered. Most of the observed bacterial species in the current study are 
part of the common oral micoflora (Zaura et al. 2009). However, some of the most abundant 
oral genera were not detected at all in the current study, suggesting a different composition of 
the bacterial communities detected in the sputum. The oral cavities are assumed to potentially 
act as a reservoir and ‘stepping stone’ for bacterial immigration into the CF lung (Rogers et al. 
2006). As a consequence, oral bacteria might substantially influence the microbial community 
compositions in the lower airway and their presence in sputum should not only be seen as 
contamination from oral cavities. The healthy oral microflora recently presented by the human 
microbiome project, revealed the genera Streptococcus, Haemophilus, Actinomyces and 
Prevotella to be the most dominant taxa. Abundances of species in the genus Streptococcus 
were further elucidated: S. parasanguinis and S. salivarius were the most dominant species, 
whereas S. mitis was only ranked as the sixth most abundant one and was comparable to S. 
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peroris (The Human Microbiome Project Consortium 2012). Both dominant species were also 
observed to be the most prevalent ones in the CF cohort. But S. mitis was detected in 43% of 
the samples and therefore the third most common Streptococcus species, whereas S. peroris 
was detected in less than 5 sputa. Overall, the similarities and main differences in 
communities present in oral cavities and CF sputum samples suggests that the upper and 
deeper respiratory tract microflora are closely related but selective conditions promote growth 
of different species resulting in bacterial communities with altered frequencies and 
abundances in CF sputum. 
 
A high similarity was observed between the dominant OTUs in the current study and highly 
abundant OTUs observed in two recent studies, one investigating the bacterial community 
dynamics over one decade in six CF patients and the other analyzing the phylogenetic 
diversity of the human respiratory microbial ecosystem in 4 children with CF (Guss et al. 
2010) (Zhao et al. 2012). These similarities support the recent observation of a correlation 
between the occurrence frequency of OTUs and their relative abundances (Gast et al. 2011) 
(Zhao et al. 2012). The frequent detection of the same dominant bacterial species throughout 
different studies suggests growth advantages for these species in the CF respiratory tract and 
therefore the communities in CF airways are presumably highly influenced by the dominant 
species, like P. aeruginosa, S. aureus, Rothia mucilaginosa and Streptococcus spp. 
 
The clinical relevance of the bacterial species present in sputum is a key issue in 
microbiological studies of CF patients. End-stage lungs are shown to harbour relatively low 
numbers of species and 16S rRNA gene analysis of explanted lung tissue samples revealed 
the same four phyla of the five bacterial classes with more than one OTU found in the current 
study: Proteobacteria, Bacteroidia, Firmicutes, Actinobacteria (Rudkjøbing et al. 2011). 
Rudkjøbing et al. (Rudkjøbing et al. 2011), further reported the same bacterial species to be 
found in sputum taken prior to the lung explantation. A notably high species diversity for the 
families Prevotellaceae and Streptococcaceae was recently described similar to the current 
study and particularly the pathogenicity of the S. millerii group is under discussion (Sibley et 
al. 2008) (Sibley et al. 2011). S. millerii species, frequently found in the current study, is 
suggested to be associated with a decline in health. A consistent correlation of these 
Streptococci and co-colonisation with P. aeruginosa was observed and a resultant enhanced 
virulence of the bacteria suggested (Parkins et al. 2008). Several particularly anaerobic 
bacterial species were found, that may potentially be CF pathogens, like Prevotella spp. and 
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Actinomyces spp. (LiPuma 2010). More studies are needed to compare their occurrence and 
relative abundances with a decline in the health condition of CF patients. 
 
3.5.3 Fungal species present in CF sputum  
The richness of fungal species in the CF cohort was shown to be high. The large number of 
unique fungal OTUs observed only once implies that the actual species richness of fungi is 
presumably even larger than detected. Individual fungal OTU counts showed a rather diverse 
picture throughout patients and between different sputum samples of the same patient. 
Therefore, a high fluctuation of fungi present in CF airways has to be assumed. 
 
The question about the origin of fungal DNA arises. Aerial dispersal is considered to be a 
major distribution factor of many fungal species and the high richness of fungal species was 
recently analyzed in particulate matter of air from the outskirts of a major city in Germany 
(Fröhlich-Nowoisky et al. 2009). Similarly, a high number of unique species observed only 
once was also found in air and more importantly all fungal classes identified in the current 
study were also observed by Fröhlich-Nowoisky et al. (Fröhlich-Nowoisky et al. 2009) with a 
relative proportion of at least 1% in the air. Furthermore, some classes of a major proportion 
of the detectable fungi in air like Dothideomycetes, Eurotiomycetes, showed similar 
occurrence frequency in the clinical samples, suggesting that the fungal species diversity in 
air is mirrored in sputum. Interestingly, the dominant fungi in air and in sputum showed a 
contrary picture. The most frequently detected and most diverse fungal class in CF sputum 
was Saccharomycetes, which represents only a small minority in the air. In contrast, 
Agaricomycetes were shown to be the dominant class in air but only 6.9% of sputum samples 
were positive (Fröhlich-Nowoisky et al. 2009). These comparisons between fungal 
occurrences in the major exposure medium (air) and sputum samples suggest that fungi 
present in CF airways are not only a reflection of the species in the ambient air. Once they are 
inhaled, selective conditions presumably promote rapid removal or persistence of fungal 
species. Mushroom-forming fungi and several plant pathogens are more likely to be removed 
quickly, as seen for Agaricomycetes or Leotiomycetes species, like Blumeria graminis 
(powdery mildew). In contrast, yeast species are more likely to find conditions to temporally 
colonize the human respiratory tract in CF patients. Accordingly, the most frequently detected 
fungi from both fungal divisions are yeast-like species: Pucciniomycetes, represented by two 
Sporobolomyces species, and Saccharomycetes, dominated by Candida species. 
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Several fungi from the observed classes are yeast-like species. Their ability to persist in the 
respiratory tract can be elucidated by comparisons of the dynamics of fungal OTUs in sputum. 
Unlike Candida species, Sporobolomyces species are among the most abundant fungi of 
indoor air (Fairs et al. 2010). Half of all incidences were detected in only three sputum 
samples from two patients. Together with S. roseus, also Cryptococcus and Rhodotorula 
species are considered to be the most important viable yeasts in outdoor air, though generally 
only about 2% of all viable spore counts are yeast species (Rantio-Lehtimäki 1985). Again, 
species from these genera were rarely found but repeatedly detected in the same samples, 
suggesting certain conditions in the airways of those patients which are promoting persistence 
of these yeast species, whereas they are removed quickly from the airways of other 
individuals.   
 
Though, the genus Candida is almost not present in air, these fungi are known to represent the 
most frequent species in the oral fungal microbiome (Ghannoum et al. 2010). Several studies 
confirmed C. albicans to be the most isolated fungi from CF patients (Bakare et al. 2003) 
(Valenza et al. 2008) (Muthig et al. 2010). The second most commonly isolated fungus in the 
current study was C. dubliniensis with 23.6% positive samples. This yeast is of particular 
interest: not much is known about its prevalence in other body sites or the environment but 
colonization rates over 10% where also observed in other CF studies (Peltroche-Llacsahuanga 
et al. 2002) (Muthig et al. 2010). In terms of morphology and genetics, this fungus is closely 
related to C. albicans though several important virulence genes are missing (Moran et al. 
2012). C. dubliniensis is rarely found in non-CF individuals, which might be explained by its 
ability to display cell surface hydrophobicity-associated adherence at 37°C that enables the 
fungus to take advantage of the dehydrated respiratory secretion of CF patients (Hazen et al. 
2001) (Peltroche-Llacsahuanga et al. 2002). The other important Candida species, namely C. 
parapsilosis, C. glabrata and C. tropicalis are observed with lower occurrence rates but 
different CF studies showed a surprisingly similar ranking of occurrence (Doern & Brogden-
Torres 1992) (Müller & Seidler 2010). Therefore, Candida species are presumably a common 
colonizer of airways in CF patients. This high conformity suggests a similar picture observed 
for the dominant bacterial taxa. Conditions in the CF airways might differentially promote 
growth of these species according to their rank of occurrence, resulting in this prevalently 
observed pattern for the genus Candida. In this context, corresponding individual relative 
abundances of species in the fungal communities would be expected and therefore the 
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communities in CF airways are presumably highly influenced by these dominant Candida 
species.  
 
3.5.4 Clinical relevance of fungal species 
Despite the high isolation rates in the sputum, the virulence of Candida spp. in the context of 
CF respiratory tract infections is under debate (LiPuma 2010). Mainly considered to be 
clinically relevant causative fungal agents of respiratory tract infections in CF patients are 
filamentous fungi from classes Sordariomycetes and Eurotiomycetes, namely A. fumigatus, S. 
apiospermum (teleomorph: Pseudallescheria boydii) and E. dermatitidis (in Germany) 
(Müller & Seidler 2010) (LiPuma 2010). The occurrence rates of these fungi vary strongly in 
different studies and the current cohort showed comparatively low rates, especially with 2,7% 
for A. fumigatus (Pihet et al. 2009). Nevertheless, positive samples exhibited strong 
distinctions of clinical relevance: A. fumigatus was detected in the only patient with a 
diagnosted ABPA, likewise S. apiospermum was repeatedly detected in the same patient. The 
latter one was accordingly recently described to be associated with A. fumigatus, usually 
following its colonization of the CF airways (Pihet et al. 2009). The emerging pathogen E. 
dermatitidis was repeatedly found in sputum from the same patient within 3 months, 
suggesting persistence of this fungus in the patient. The virulence of a few other filamentous 
fungi is further under debate, including the highly prevalent Cladosporium spp. which are 
similarly found at high frequency in air and in healthy oral cavities (Fröhlich-Nowoisky et al. 
2009) (Ghannoum et al. 2010). However, confirmed reports about colonization of human 
airways by these species are missing.  
 
In consideration of the high abundances of fungal spores in indoor and outdoor air and the 
high phylogenetic diversity of fungal species in CF sputum, the number of reported and 
confirmed cases of fungal respiratory infections is relatively low. Just a very few species from 
these highly diverse airborne contaminants are considered to be the causative agents of 
infections in CF, and even these fungi are often considered to be commonly found in the 
environment, suggesting a high exposure of CF patients to these fungal spores. Therefore, the 
current study suggests that virulence of fungal species in the context of human respiratory 
infections should be considered to be generally low and probably depending on further 
circumstances which remain to be elucidated.  
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An advanced number of fungal species in the respiratory tract, however, may act as an 
indicator for changing conditions associated with bad health. Patients with advanced fungal 
species numbers often showed conspicuous clinical abnormalities. For example, the sputum 
from the patient with the ABPA exhibited advanced numbers of filamentous fungal species in 
both sputum samples. The highest C-reactive protein level in the CF cohort was measured in 
one patient with seven fungal species in the sputum. In a third patient, high species counts 
were further measured in two sputa over a long time period (15 month) which showed 
constantly low FEV1 values and subsequently the same patient exhibited the fungal CF 
pathogen S. apiospermum another 5 months later.  
 
 
3.6 Conclusion & Outlook 
Comparing the fungal and bacterial richness associated with CF sputum, bacterial 
communities consist of a relatively small number of species. Respiratory tract communities 
are closely related to the oral microbiome but significant differences were observed. A core 
group of major bacterial taxa associated with CF is presented. A high conformity of these 
species with other CF studies was observed, suggesting advanced colonization abilities for 
these bacteria. Although the clinical relevance for most of the species is unclear, a major 
influence on the pulmonary microbial community for the dominant bacteria is assumed. A 
potential influence of these species on the pathogenicity of the entire community remains to 
be elucidated as well as their role as single pathogenic species.   
 
A high richness for fungal species was determined for the cohort and high fluctuations of 
different species were observed. The frequencies of occurrence of fungi in the air as a major 
exposure medium showed similarities, but major differences were observed for the dominant 
classes. Indications for individual persistence of yeast-like fungi in respiratory tracts were 
shown and high colonization abilities for given Candida species assumed. Although major 
fungal pathogens were repeatedly observed in sputum samples, the overall virulence of fungal 
species was considered to be low. However, advanced numbers of fungi in the respiratory 
tract may act as an early indicator for a progression towards infection-related illness. High 
exposure rates in contrast to low occurrence rates imply that colonization and persistence of 
filamentous fungi is presumably related to certain ecological factors and depending on 
circumstances which promote these rare events. Therefore, fungal infections may 
substantially be reduced if these ecological interactions are better understood. 
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Microbial growth and persistence promoting conditions have to be elucidated and further 
studies on the ecology of pulmonary communities are necessary, combining the bacterial and 
fungal microbiota. Hereby, interactions of the dominant bacteria and yeasts presented in the 
current study may have a major impact on the respiratory microbial communities. A deeper 
understanding of ecological factors that promote the colonization by fungi and increase the 
pathogenicity of bacterial communities may substantially improve the diagnostics and 
prediction in the progression of respiratory diseases.   
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3.8 Supplementary Material 
 
S1: Bacteria 
OTU 
designation 
taxonomic 
class 
sputa          
no. pos.       
(%)  
patients 
no. pos.           
(%) 
RDP 
score 
closest described bacterial species                                                
(% similarity, accession no.) 
representative sequence         
(accession no., name) 
Pseudomonas 
aeruginosa  
Gammaproteo 
bacteria 
50            
(69.4 %) 
38         
(67.8 %) 1.000 
100%_CP003149.1_Pseudomonas 
aeruginosa DK2 
AB626118_Pseudomonas_aeruginosa 
strain__JCM_14847 
Streptococcus 
parasanguis  Bacilli 
41          
(56.9 %) 
36           
(64.2 %) 0,990 
99%_AY281078_Streptococcus           
mitis ATCC 903* 
AF003933_Streptococcus_parasanguinis
ATCC_15912 
Streptococcus 
salivarius Bacilli 
41         
(56.9 %) 
35         
(62.5 %) 1.000 
100%_FR873482.1_Streptococcus 
salivarius JIM8777  
AY188352_Streptococcus_salivarius 
strain_ATCC_7073 
Streptococcus 
mitis Bacilli 
31         
(43.0 % 
29        
(51.7 %) 0,988 
99%_FN568063.1_Streptococcus               
mitis B6 
DQ303188 Streptococcus mitis                
strain ATCC 49456 
Rothia 
mucilaginosa Actinobacteria 
31         
(43.0 %) 
28            
(50.0 %) 0,969 
99%_DQ409140.1_Rothia            
mucilaginosa strain C90  
X87758_Rothia_mucilaginosa 
DSM_20746 
Staphylococcus 
aureus  Bacilli 
18        
(25.0 %) 
15        
(26.7 %) 1.000 
99%_AB680391.1_Staphylococcus 
aureus subsp. aureus strain NBRC 13276 
X68417_Staphylococcus_aureus 
ATCC_12600 
Gemella 
sanguinis  Bacilli 
16        
(22.2 %) 
14      
(25.0 %) 1.000 
100%_NR_026419.1_Gemella            
sanguinis strain 2045-94 
Y13364_Gemella_sanguinis          
strain_2045-94 
Granulicatella -2 Bacilli 
14        
(19.4 %) 
13        
(23.2 %) 1.000 
100%_FR822389.1_Granulicatella 
adiacens strain CCUG 60768 
D50540_Granulicatella_adiacens 
ATCC_49175 
Actinomyces 
graevenitzii Actinobacteria 
12        
(16.6 %) 
11         
(19.6 %) 0,964 
99%_  NR_042167.1_Actinomyces 
graevenitzii strain CCUG 27294  
AJ540309_Actinomyces_graevenitzii 
strain_CCUG_27294T 
Gemella 
haemolysans  Bacilli 
7               
(9.7 %) 
7          
(12.5 %) 1.000 
100%_NR_025903.1_Gemella 
haemolysans strain ATCC 10379  
L14326_Gemella_haemolysans 
ATCC_10379 
Streptococcus 
anginosus Bacilli 
6              
(8.3 %) 
5               
(8.9 %) 0,986 
99%_AF306838.1_Streptococcus 
anginosus genotype VA8466 
AF169355 Streptococcus anginosus 
strain VAMC5219 
Achromobacter 
xylosoxidans 
Betaproteo 
bacteria 
6               
(8.3 %) 
5              
(8.9 %) 1.000 
99%_EU266588.1_Achromobacter 
xylosoxidans strain CS5  
Y14908_Achromobacter_xylosoxidans 
DSM_10346 
Prevotella 
histicola Bacteroidia 
5              
(6.9 %) 
5               
(8.9 %) 1.000 
100%_AB547685.1_Prevotella             
histicola strain JCM 15637 
AB547685_Prevotella_histicola           
strain_JCM_15637 
Prevotella 
melaninogenica Bacteroidia 
5               
(6.9 %) 
5               
(8.9 %) 0,985 
99%_JN867309.1_Prevotella 
melaninogenica strain SEQ236  
L16469_Prevotella_melaninogenica 
ATCC_25845 
Fusobacterium 
nucleatum Fusobacteria 
5               
(6.9 %) 
4               
(7.1 %) 0,951 
98%_AB588016.1_Fusobacterium 
nucleatum subsp. nucleatum JCM 6328 
AB573068_Fusobacterium_nucleatum 
subsp._nucleatum_strain__JCM_8532 
Streptococcus 
intermedius Bacilli 
5               
(6.9 %) 
4               
(7.1 %) 1.000 
100%_AF104671.1_Streptococcus 
intermedius strain ATCC 27335 
AF104671_Streptococcus_intermedius 
strain_ATCC27335 
Veillonella -1 Negativicutes 
4               
(5.5 %) 
4               
(7.1 %) 0,985 
99%_HM596287.1_Veillonella sp.            
oral taxon 158 strain F0412 X84007_Veillonella_sp. DSM_20739 
Rothia -2 Actinobacteria 
4               
(5.5 %) 
4               
(7.1 %) 1.000 
100%_AY594189.1_Rothia           
dentocariosa strain Inje L1 
M59055_Rothia_dentocariosa 
ATCC_17931 
Stenotrophomon
as maltophilia  
Gammaproteo 
bacteria 
3               
(4.1 %) 
3               
(5.3 %) 1.000 
99%_JX848739.1_Stenotrophomonas 
maltophilia strain Sal10  
AB294553_Stenotrophomonas 
maltophilia_strain_IAM_12423 
Prevotella 
pallens Bacteroidia 
3               
(4.1 %) 
3               
(5.3 %) 0,945 
99%_AB547703.1_Prevotella                
pallens strain JCM 11140  
Y13105_Prevotella_pallens 
strain__10371 
Streptococcus 
gordonii Bacilli 
2               
(2.7 %) 
2               
(3.5 %) 0,973 
99%_AY281088.1_Streptococcus 
gordonii ATCC 12396 
AF003931_Streptococcus_gordonii 
strain_ATCC_10558 
Prevotella 
nanceiensis Bacteroidia 
2               
(2.7 %) 
2               
(3.5 %) 0,976 
99%_JN867319.1_Prevotella            
nanceiensis strain SEQ246 
AB547695_Prevotella_nanceiensis 
JCM_15639 
Prevotella oris Bacteroidia 
2               
(2.7 %) 
1               
(1.7 %) 0,924 
99%_AB547700.1_Prevotella              
oris strain JCM 12252 L16474_Prevotella_oris_ATCC_33573 
Bordetella petrii  
Betaproteo 
bacteria 1 1 1.000 
100%_AJ870969.1_Bordetella petrii 
strain GDH030510 
AJ249861_Bordetella_petrii 
strain_DSM_12804 
Streptococcus 
sanguinis Bacilli 1 1 1.000 
100%_ AB596946.1_Streptococcus 
sanguinis JCM 5708 
AF003928_Streptococcus_sanguinis 
ATCC_10556 
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Granulicatella 
elegans Bacilli 1 1 1.000 
100%_Y15413.1_Granulicatella           
elegans strain 4067-96 
AF016390 Granulicatella elegans           
DSM 11693 
Capnocytophaga 
gingivalis Flavobacteria 1 1 0,942 
99%_AB638448.1_Capnocytophaga 
gingivalis strain JCM 12953 
AB638448_Capnocytophaga_gingivalis 
JCM_12953 
Streptococcus 
australis Bacilli 1 1 0,929 
98%_NR_036936.1_Streptococcus 
australis strain ATCC 700641 
AY485604 Streptococcus australis      
strain ATCC 700641 
Actinomyces 
odontolyticus Actinobacteria 1 1 1.000 
100%_GQ131411.1_Actinomyces 
odontolyticus strain F0309  
AJ234040_Actinomyces_odontolyticus 
CCUG_20536T 
Burkholderia 
cepacia 
Betaproteo 
bacteria 1 1 1.000 
100%_AB680641.1_Burkholderia  
cepacia NBRC 14595 
AF097530_Burkholderia_cepacia 
ATCC_25416 
Prevotella 
pleuritidis Bacteroidia 1 1 0,937 
99%_ AB278593.1_Prevotella           
pleuritidis strain JCM 14110 
AB278593_Prevotella_pleuritidis 
JCM_14110 
Prevotella -8 Bacteroidia 1 1 0,741 
90%_GU409582.1_Prevotella sp.                
oral taxon 306 clone DO004 
GU409582_Prevotella_sp. 
oral_taxon_306 
Prevotella 
tannerae Bacteroidia 1 1 0,973 
99%_AF183406.1_Prevotella               
tannerae strain 93-1-2 
AJ005634_Prevotella_tannerae 
ATCC_51259 
Nocardia sp. Actinobacteria 1 1 1.000 100%_GU992878.1_Nocardia sp. W9912  GU992877_Nocardia_sp._W8474 
Atopobium 
parvulum Actinobacteria 1 1 0,985 
99%_CP001721.1_Atopobium             
parvulum DSM 20469 
AF292372_Atopobium_parvulum 
ATCC_22793 
Streptococcus 
peroris Bacilli 1 1 0,943 
99%_GU425263.1_Streptococcus           
peroris clone GD031 
AB008314_Streptococcus_peroris 
GTC_848 
TM7  
TM7 candidate 
class 1 1 0,766 
99%_GU410609.1_TM7 phylum sp.            
oral taxon 352 clone DR034  
AF385520_TM7_phylum_sp. 
oral_clone_DR034 
Prevotella -9 Bacteroidia 1 1 0,670 
99%_GU409603.1_Prevotella sp.                
oral taxon 308 clone GD054 
GU409605 Prevotella sp.                            
oral taxon 308 clone OCU043 
 
 
Table S1: OTU designation for bacterial sequences that were found in sputa. For each OTU, accession numbers 
of closest described bacterial sequence are given, matching one representative sequence of ssDNA bands from 
corresponding clade in phylognetic distance tree (data not shown). Total number of positive (no. pos.) sputum 
samples and patients are shown and respective occurrence frequencies (%) for repeatedly detected OTUs are 
given in brackets. OTUs with ambiguous results in databases were defined according to the closest shared 
taxonomic level. Highest RDP scores for described species are shown. In representative sequence, accession 
numbers of sequences and species name used for phylogenetic trees in Figure 6 are given.  
*strain reclassified into Streptococcus parasanguinis 
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S2.a: Ascomycota, Saccharomycetes 
OTU 
designation taxonomic class 
sputa  
no. pos.       
(%) 
patients 
no. pos.       
(%) 
closest described fungal species                                                          
(% similarity, accession no., name) 
representative 
sequence 
Candida albicans Saccharomycetes 
32      
(44.4 %) 
27         
(48.2 %) 
(26x) 100%_JX094781_Candida albicans                       
strain ATCC 96901 JX094781 
Candida 
dubliniensis Saccharomycetes 
17      
(23.6 %) 
14        
(25.0 %) 
(16x) 100%_DQ105856_ Candida dubliniensis                
strain DSM 13628 DQ105856 
Saccharomyces 
cerevisiae Saccharomycetes 
14       
(19.4 %) 
13       
(23.2 %) 
(3x) 100%_AM900403_Saccharomyces cerevisiae 
strain MUCL28071 FN393997 
Candida 
parapsilosis Saccharomycetes 
10        
(13.8 %) 
7           
(12.5 %) 
(9x) 100%_FJ872015_Candida parapsilosis                   
strain ATCC 22019 FJ872015 
Candida glabrata Saccharomycetes 
9          
(12.5 %) 
6            
(10.7 %) 100%_AF336836_Candida glabrata strain ATCC 2001 AF336836 
Candida 
tropicalis Saccharomycetes 
3            
(4.1 %) 
3               
(5.3 %) 100%_AY939810_Candida tropicalis strain ATCC 750 AY939810 
Cyberlindnera 
jadinii (synonyms: 
Candida utilis, Pichia 
jadnii)  Saccharomycetes 
3             
(4.1 %) 
3           
(5.3 %) (2x) 100%_FJ865435_Pichia jadinii isolate M9 
99%_DQ249199_
Cyberlindnera 
jadinii strain WM 
45 
Candida sake Saccharomycetes 
2             
(2.7 %) 
2             
(3.5 %) 98%_AJ549822_Candida sake strain CBS 159 AJ549822 
Galactomyces 
geotrichum  Saccharomycetes 1 1 
100%_EU789402_Galactomyces geotrichum               
strain M0163 EU789402 
Meyerozyma 
guilliermondii 
(synonyms: Pichia 
guilliermondii)  Saccharomycetes 1 1 
100%_JQ425356_Meyerozyma guilliermondii                
strain AUMC 7771  JQ425356 
Kazachstania 
unispora (synonym: 
Saccharomyces 
unisporus) Saccharomycetes 1 1 
100%_EU789404_Kazachstania unispora                    
strain M01621 EU789404 
Candida humilis Saccharomycetes 1 1 100%_AY188851_Candida humilis strain CBS 6897 AY188851 
Debaryomyces 
hansenii  Saccharomycetes 1 1 100%_HE967326_Debaryomyces hansenii strain MRL2 HE967326 
Clavispora 
lusitaniae Saccharomycetes 1 1 
100%_JN391310_Clavispora lusitaniae                       
isolate PUMY044 
100%_EF568023_
Clavispora 
lusitaniae strain 
WM 1138 
Yarrowia 
lipolytica Saccharomycetes 1 1 100%_ EU252546_Yarrowia lipolytica ATCC 9773   EU252546 
Kluyveromyces 
marxianus  Saccharomycetes 1 1 
100%_HQ014731_Kluyveromyces marxianus              
strain WM10.112 HQ014731 
Candida 
deformans Saccharomycetes 1 1 100%_FJ515168_Candida deformans strain SM21 FJ515168 
Candida cellae  Saccharomycetes 1 1 100%_GQ149495_Candida cellae strain UAF-93  GQ149495 
Hanseniaspora 
uvarum Saccharomycetes 1 1 
100%_AJ512432_Hanseniaspora uvarum                      
strain CBS 314 AJ512432 
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S2.b: Ascomycota, non-Saccharomycetes 
OTU designation 
taxonomic 
class 
sputa  
no. pos.       
(%) 
patients 
no. pos.       
(%) 
closest described fungal species                                                            
(% similarity, accession no., name) 
representative 
sequence 
Cladosporium 
cladosporioides 
(teleomorph: Davidiella 
sp.) 
Dothideo 
mycetes 
8             
(11.1 %) 
7             
(12.5 %) 
(5x) 100%_JQ768323_Cladosporium cladosporioides 
strain CFP14  JQ768323 
Cladosporium 
herbarum 
(teleomorph: Davidiella 
tassiana) 
Dothideo 
mycetes 
7             
(9.7 %) 
6             
(10.7 %) 
(5x) 100%_HQ263359_Davidiella tassiana                 
strain ATCC MYA-4682 HQ263359 
Scedosporium 
apiospermum 
(teleomorph: 
Pseudallescheria boydii) 
Sordario 
mycetes 
3             
(4.1 %) 
2             
(3.5 %) 
(2x) 100%_AY213682_Pseudallescheria boydii              
strain UWFP 806 AY213682 
Exophiala 
dermatitidis 
Eurotio 
mycetes 
3             
(4.1 %) 
2             
(3.5 %) 
100%_JX473286_Exophiala dermatitidis                         
strain PW2643 JX473286 
Aspergillus 
fumigatus 
Eurotio 
mycetes 
2             
(2.7 %) 
2             
(3.5 %) 
99%_HQ026746_Aspergillus fumigatus                        
strain ATCC 1022 HQ026746 
Blumeria 
graminis  
Leotio  
mycetes 
2             
(2.7 %) 
2             
(3.5 %) 
100%_AB273556_Blumeria graminis                        
isolate MUMH2335 AB273556 
Lewia infectoria 
(anamorph: Alternaria 
infectoria) 
Dothideo 
mycetes 
2             
(2.7 %) 
2             
(3.5 %) 100%_FJ214897_Lewia infectoria strain CBS 112250 FJ214897 
Coniothyrium 
fuckelii (teleomorph: 
Leptosphaeria 
coniothyrium) 
Dothideo 
mycetes 1 1 98%_FJ228185_Coniothyrium fuckelii isolate 7a-1 
98%_FJ861383_ 
Coniothyrium 
fuckelii              
strain 3T16A 
Aureobasidium 
pullulans 
Dothideo 
mycetes 1 1 
100%_AF121281_Aureobasidium pullulans                  
strain ATCC11942 AF121281 
Phaeosphaeria sp. 
Dothideo 
mycetes 1 1 
98%_AF439488_Phaeosphaeria juncophila                         
isolate CBS 575.86 HM172819 
 Leotiomycetes -2 
Leotio  
mycetes 1 1 97%_JN995647_Phialocephala sp. AU_BD20 JX317257 
Ascomycota -22 unknown 1 1 89%_FJ487945_Pichia norvegensis strain ZH2Aea  
87%_EU343827_ 
Candida ernobii 
strain MUCL 29961 
Aspergillus 
conicus 
Eurotio 
mycetes 1 1 99%_EF652039_Aspergillus conicus isolate  NRRL 149  EF652039 
Neosartorya 
pseudofischeri 
(anamorph: Aspergillus 
thermomutatus) 
Eurotio 
mycetes 1 1 
100%_AF459729_Neosartorya pseudofischeri            
NRRL 180 AF459729 
Leptosphaeria sp. 
Dothideo 
mycetes 1 1 99%_EU852362_Uncultured Leptosphaeria clone 21a EU852362 
Didymella 
exitialis  
Dothideo 
mycetes 1 1 
100%_EU167564_Didymella exitialis                              
strain CBS 446.82 EU167564 
Phoma exigua 
Dothideo 
mycetes 1 1 100%_EU770244_Phoma exigua strain ICMP 16989 EU770244 
Aspergillus 
versicolor 
Eurotio 
mycetes 1 1 
100%_EF652449_Aspergillus versicolor                   
isolate NRRL 239 EF652449 
Septoria sp. 
Dothideo 
mycetes 1 1 
100%_JX480493_Septoria erigerontis                       
voucher KUS-F25759 JX480493 
Penicillium sp. 
Eurotio 
mycetes 1 1 100%_JN983439_Penicillium sp. mcp2728 JN983439 
Fusarium 
oxysporum 
Sordario 
mycetes 1 1 100%_HQ829111_Fusarium oxysporum strain CID 207  HQ829111 
Colletotrichum 
circinans 
Sordario 
mycetes 1 1 
99%_EU400140_Colletotrichum circinans                     
strain DAOM151616  EU400140 
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S2.c: Basidiomycota 
OTU 
designation 
taxonomic 
class 
sputa  
no. pos.       
(%) 
patients 
no. pos.       
(%) 
closest described fungal species                                                           
(% similarity, accession no., name)  representative sequence 
Sporobolomyces 
roseus 
 
Puccinio 
mycetes 
8         
(11.1 %) 
7         
(12.5 %) 
(7x) 100%_AY069997_Sporobolomyces roseus   
strain CBS 993 AY069997 
Sporobolomyces 
ruberrimus 
 
Puccinio 
mycetes 
4         
(5.5 %) 
3         
(5.3 %) 
(3x) 100%_JN246564_Sporobolomyces ruberrimus 
strain CRUB 1041 JN246564 
Rhodotorula 
glutinis 
 
Microbotryo
mycetes 
2         
(2.7 %) 
2         
(3.5 %) 
100%_AF335948_Rhodotorula glutinis                      
strain ATCC 32765 AF335948 
Udeniomyces 
pannonicus 
Tremello 
mycetes 1 1 
100%_AB072231_Udeniomyces pannonicus             
strain JCM 11148 AB072231 
Plicaturopsis 
crispa  
Agarico 
mycetes 1 1 
100%_DQ534576_Plicaturopsis crispa                  
strain FP-101310-SP 
100%_HQ871872_ 
Plicaturopsis crispa 
voucher TENN53066 
Rhodotorula -2 
 
Microbotryo
mycetes 1 1 100%_AM160641_Rhodotorula sp. HB 1211 
99%_AB026015_ 
Rhodotorula aurantiaca 
strain JCM 3771 
Basidiomycota -
18 unknown 1 1 
77%_DQ411529_Trechispora alnicola                     
isolate AFTOL-ID 665 
80%_FR682413_ 
Uncultured Basidiomycota 
clone BF-OTU670 
Megacollybia 
platyphylla  
Agarico 
mycetes 1 1 
100%_EU623713_Megacollybia platyphylla         
voucher LE 256-2004 EU623713 
Cryptococcus -3 
Tremello 
mycetes 1 1 96%_JN400817_Cryptococcus tephrensis 
99%_AM160648_ 
Cryptococcus sp. HB 1222 
Cryptococcus 
victoriae 
Tremello 
mycetes 1 1 
100%_AM160647_Cryptococcus victoriae            
strain HB 1221 AM160647 
 Agaricomycetes 
-8 
Agarico 
mycetes 1 1 
99%_GQ221186_Undifferentiated Agaricomycetes 
strain FSU6258 GQ221186 
Malassezia 
restricta  
Exobasidio 
mycetes 1 1 100%_JQ088240_Malassezia restricta isolate HIV+92 JQ088240 
Piptoporus 
betulinus 
Agarico 
mycetes 1 1 
100%_DQ491423_ Piptoporus betulinus                   
strain CBS 378.51 JQ700297 
Polyporus 
gayanus  
Agarico 
mycetes 1 1 
100%_AF518757_ Polyporus gayanus                       
strain CIEFAP136 AF518757 
Strobilurus sp.  
Agarico 
mycetes 1 1 
100%_GQ892818_Strobilurus albipilatus            
voucher TFB11910 GQ892818 
Baeospora sp. * 
Agarico 
mycetes 1 1 95%_EU770252_Baeospora sp. ICMP 16979 EU770252 
Hyphodontia sp.  
Agarico 
mycetes 1 1 
100%_FJ197950_Uncultured Hyphodontia                 
clone Bo2gLR21_A21  FJ197950 
Cryptococcus 
curvatus  
Tremello 
mycetes 1 1 
100%_EU266558_Cryptococcus curvatus                 
strain ATCC 10567 EU266558 
 
Table S2: OTU designation for fungal sequences that were found in sputa, grouped by a: Saccharomycetes; b: 
Ascomycota (non-Saccharomycetes); c: Basidiomycota. Names of teleomorphs have priority. The anamorph 
name is only given if asexual state is reported more frequently from clinical samples. Common synonyms of 
species are given in brackets. Total number of positive (no. pos.) sputum samples and patients are shown and 
respective occurrence frequencies (%) for repeatedly detected OTUs are given in brackets. For each OTU, 
accession numbers of closest described fungus matching the most sequences of ssDNA bands are mentioned 
(number shown in brackets). In representative sequence, accession numbers of sequences used for phylogenetic 
trees (Figure 8 & 9) are shown and matching the sequences given for closest described fungus, unless a 
similarity score and accession number are additionally mentioned.  
* ITS exhibit 100 % sequence similarity with Mucronella sp. PDD 95742   
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S3: Species accumulation curves  
 
 
Figure S3:  Species 
accumulation curves 
are shown for 
bacterial and fungal 
OTUs detected for 
56 CF patients. Only 
the first sample of 
each patient was    
considered. Averaged curves show the number of detected species versus number of samples. Curves for bacteria 
are shown in grey and curves for fungi are shown in black. Full lines show observed species counts (S; Mao Tao) 
and dashed lines show unique species counts (species which occur in only one sample).    
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4.1 Abstract 
Non-invasive diagnostic strategies focusing on the detection of volatile biomarkers in exhaled 
breath are of increasing interest. Volatile organic compounds (VOCs) have the potential to be 
such diagnostic markers. VOCs are released by all organisms, including infectious 
microorganisms colonizing the respiratory tracts of infected hosts. In the current study, a 
breath analytical method was developed to discriminate major pulmonary pathogens 
associated with cystic fibrosis (CF) and the feasibility of the method was tested in a CF 
outpatient clinic in vivo. VOCs were extracted by a sorbent trap and analyzed by gas 
chromatography and mass spectrometry. Specific microbial VOC compositions were used to 
discriminate the bacterial species Pseudomonas aeruginosa, Staphylococcus aureus, 
Achromobacter xylosoxidans and the yeast Candida albicans in vitro. Exhaled breath of CF 
patients was analyzed and allowed distinction of CF patients and controls by the individual in 
vivo VOC compositions. Although none of the specific compounds monitored in vitro were 
detected in exhaled breath of infected CF patients in vivo, the current study support the 
hypothesis that the composition of exhaled VOCs in human breath may be used to identify 
patients with certain microbial infections. 
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4.2 Introduction 
 
Bacteria and fungi are known to produce a broad spectrum of secondary metabolites including 
a wealth of volatile molecules (Schulz & Dickschat 2007) (Brakhage & Schroeckh 2011). A 
large number of these are volatile organic compounds (VOCs) comprising aliphatic and 
aromatic hydrocarbons, esters, ketones, aldehydes, alcohols and mono-, sesqui- and 
diterpenes. Synthesis of VOCs can represent an advantage for the producing organism. 
Ecological functions have been demonstrated in fungi where VOCs defend against competing 
species, act as autoinducer or play an important role in quorum sensing (Kramer & Abraham 
2012). Similar biological effects are also known in bacteria, where VOCs are produced under 
aerobic as well as anaerobic conditions (Kai et al. 2009) (O’Brien & Wright 2011). Because 
of these essential functions, VOCs can be considered to be almost ubiquitously released by 
microorganisms. However, the exact composition of released metabolites and, therefore, also 
of the emitted volatile compounds, varies with different substrates. Most of the microbial 
VOCs are released in very low concentrations but some are familiar to us as special odours of 
food products or even bacterial strains. In the past years, modern analytics enable the 
detection and monitoring of VOCs in the environment even at low concentrations 
(Woolfenden 2010b) (Woolfenden 2010a). Consequently, there is an increasing interest in the 
search for volatile microbial biomarkers and first databases for volatile profiles of 
microorganism have been established, e.g. “SuperScent” (Dunkel et al. 2009). 
 
But not only in environmental or food-related research microbial VOCs are shifting in the 
focus, their potential for medical purposes have been recognized as well (Thomas et al. 2010) 
(Shirasu & Touhara 2011). Already in the 1970s, the use of information on volatile 
compounds for clinical diagnosis was investigated (Liddell 1976) (Zlatkis et al. 1981). First 
techniques for detection of volatiles in exhaled breath of humans were developed in order to 
monitor altered emission of human metabolites from malfunction of organs and tissues 
(Teranishi et al. 1972) (Zlatkis et al. 1973). A diagnostic potential also lies in the smell of 
certain VOCs at high concentrations. If released by inflammation or microbial colonization in 
the mouth they can cause an oral malodour. On that basis the University of the West of 
England started courses for dentists, training their ‘nose’ to differentiate the origins of the 
malodour and then treat appropriately (UWE Bristol 2012). Other technical developments 
intend to extract microbial VOCs from the exhaled air of patients suffering from respiratory 
tract infection. The aim is to detect specific infections by species-specific compounds that are 
released in concentrations high enough to be monitored in larger air volumes like the exhaled 
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breath. Active pulmonary tuberculosis was one of the first infectious diseases screened for 
volatile biomarkers in human exhalation (Phillips et al. 2007) (Syhre & Chambers 2008) 
(Syhre et al. 2009) (Phillips et al. 2010). However, while these studies could greatly show the 
potential for a breath analytical diagnostic tool in tuberculosis, they did not fulfil the needs for 
routine diagnostics or revealed any reliable marker compound. Another promising 
microorganism in this context is the lung infecting fungus Aspergillus fumigatus. A single 
VOC with high potential to act as biomarker was identified and, being not part of the human 
metabolism, detected in the exhaled breath of infected patients but not in healthy individuals 
(Syhre et al. 2008) (Chambers et al. 2009) (Chambers et al. 2011). Likewise, a potential 
breath biomarker was investigated for the diagnosis of Pseudomonas aeruginosa infections in 
cystic fibrosis (CF) patients. 2-Aminoacetophenone has been verified in vitro for its 
specificity and exhaled breath of CF patients was screened for increased levels. Although 
infected patients showed higher levels, the same VOC was also present in breath samples of 
healthy and non-colonized individuals, leaving doubts about its reliability (Scott-Thomas et 
al. 2010a). Nevertheless, particularly in the context of the recessive genetic disorder CF, 
analytical diagnostics for infectious pulmonary diseases using VOCs could be of greater 
interest. CF patients suffer from live-long recurrent microbial colonization of their respiratory 
tracts and pulmonary infections are the main cause of death (Harrison 2007). A vast spectrum 
of pathogens can infect the airways and therefore a rapid, non-invasive diagnostic tool like 
exhaled air analysis would substantially improve the health care of these patients. 
Additionally, lung function tests are already part of routine medical examinations, presumably 
leading to a greater acceptance among patients for an additional breath diagnostic procedure.  
 
The purpose of this study was to validate the discriminative potential of VOCs emitted by 
major respiratory pathogens in vitro and of exhaled VOCs likewise extracted from breath of 
CF patients in vivo. The obtained results suggest that VOCs may be used to identify different 
microorganisms. Furthermore, individual VOCs compositions monitored in exhaled breath 
allowed distinction between CF patients and controls.    
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4.3 Material and Methods 
 
4.3.1 Cell culture and microbial strain preparation  
Precultures of microorganisms were grown overnight in Luria Broth (LB) liquid medium and 
diluted with fresh LB medium. The following strains were allowed to grow until the mid-log 
phase: Staphylococcus aureus strain DSM 20231, P. aeruginosa strain PaO1, Achromobacter 
xylosoxidans strain DSM 2402, and Candida albicans strain SC 5314. Cultures were allowed 
to grow until the mid-log phase. All liquid LB cultures were incubated at 37°C on a shaking 
platform at 120 rpm. Microbial suspensions were used to determine colony-forming units 
(CFU) and in vitro VOCs extractions. For determination of CFUs, suspensions were diluted to 
appropriate concentrations and triplicates of 200 µl each were plated on LB agar plates. Agar 
plates were incubated at 37°C overnight or 3 days for A. xylosoxidans before colonies were 
counted. 
The A549 human epithelial cell line was maintained in Dulbecco’s modified Eagle’s medium 
(DMEM; PAA, Pasching, Austria), with 10% foetal bovine serum (FCS) and 2 mM L-
glutamine without antibiotics. Cells were incubated in culture flasks with growth area of 25 
cm² at 37°C in a humidified atmosphere with 5% CO2. Before reaching confluency, cells were 
trypsinized and sub-cultured.  
 
4.3.2 Microbial in vitro models for measurements of VOC emissions 
Biofilm models were defined as monocultures in agar slants using precultures of 
microorganisms grown overnight in LB liquid medium. 100 µl of the cultures in stationary 
phase were taken and plated on angular LB agar in a 15 ml glass vial. Vials were closed with 
rubber septa and screw caps. Incubation was done in 37°C overnight, before a SPME fiber 
was exposed through the septum to the headspace of the angular LB agar.  
Host-pathogen interaction cultures were defined as A549 cell cultures inoculated with 
microbial pathogens. Therefore, 1 ml of the bacterial suspensions and 2 ml of the fungal 
suspensions in the mid-log phase were taken and centrifuged at 10,000 rpm for 8 min. 
Supernatant was discarded and the cell pellet resuspended in the same volume using DMEM 
(PAA, Pasching, Austria) with 10% FCS and 2 mM L-glutamine without antibiotics. 200 µl 
and 2 ml of bacterial and fungal suspensions, respectively, were added to a confluent 
monolayer of A549 cells and a SPME fiber was exposed to the headspace of the culture at 
different time points during the course of interaction (Table 1). For overnight incubation, 
bacterial suspensions were further diluted in the same medium by the following factors:  
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1x10
-2
 for P. aeruginosa, 1x10
-2
 for S. aureus and 1x10
-1
 for A. xylosoxidans. 200 µl each was 
given to a confluent monolayer of A549 cells and SPME fiber exposed after 21 to 22.5 hours 
of incubation. For C. albicans, 200 µl of the undiluted suspension were used for overnight 
incubation and the SPME fiber was exposed after 20.5 hours. Initial pathogen inoculum added 
to A549 cells was 7.6x10
8
 (7.6x10
7
) CFUs for A. xylosoxidans, 4.8x10
8
 (4.8x10
6
) CFUs for S. 
aureus, 2.7 x10
7
 (2.7x10
6
) CFUs for C. albicans, and 9.5x10
8
 (9.5x10
6
) CFUs for P. 
aeruginosa (numbers in brackets indicate CFUs injected to overnight incubation cultures). All 
cells were kept at 37°C in a humidified atmosphere with 5% CO2. 
Corresponding monocultures inoculated with pathogens in their mid-log phase, like it was 
done for the host-pathogen interaction cultures, were defined as monocultures in agar slants 
using 100 µl of microbial suspensions (LB medium) and plated on angular LB agar in 15 ml 
glass vials. Vials were closed with rubber septa and screw caps. Incubation was done in 37°C 
overnight, before a SPME fiber was exposed through the septum to the headspace of the 
angular LB agar.  
  
C. albicans   
T0 T1 T2 T3 T4 T5 Tmax 
0 min 95 min 195 min 275 min 390 min 470 min 20.5 h 
P. aeruginosa   
T0 T1 T2 T3 T4 T5 Tmax 
0 min 115 min 215 min 295 min 410 min 520 min 22.5 h 
A. xylosoxidans   
T0 T1 T2 T3 T4   Tmax 
0 min 120 min 210 min 300 min 390 min no extraction 21 h 
S. aureus   
T0 T1 T2 T3 T4   Tmax 
0 min 120 min 210 min 300 min 390 min no extraction 21 h 
 
Table 1: Time points of SPME fiber exposition in host-pathogen interaction cultures. A series of VOCs 
extractions (T0 - Tmax) were performed at different time points post injection (min = minutes; h = hours) for 
each culture. The pathogen of each interaction culture is given in italic letters above corresponding rows.   
 
4.3.3 Imaging of host-pathogen interaction cultures 
To monitor growth of pathogens, cultures were visually controlled and digitally documented 
using Axiovert 200M inverted microscope coupled with AxioCam HRc (Carl Zeiss, 
Göttingen, Germany). Subsequently to SPME fiber exposition, images were taken with 10x 
and 20x objective lenses. To monitor shape and confluence state of A549 cells, cultures were 
washed three times with PBS after VOCs extraction T4 or T5 respectively. Laser scanning 
microscopy (LSM) was performed using the Leica SP5 system (Leica, Heidelberg, Germany). 
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Interaction cultures with C. albicans were stained with green fluorescent nucleic acid stain 
SYTO 13 and chitin binding fluorescent stain Calcofluor-white. Cultures were scanned in 
bidirectional mode using a 63 x 0.9 NA objective lens, laser diode (405 nm) and argon laser 
(488 nm) with scanner frequency of 400 Hz and line averaging of 4.  
 
4.3.4 Solid phase micro-extraction (SPME) 
VOCs were extracted using solid phase microextraction (SPME), where the volatiles are 
trapped on a sorbent coated fiber. Various VOCs extractions were performed in vitro and in 
vivo with healthy individuals and CF patients to select the proper fiber coating for this 
particular application. In addition to the four major criteria for the optimal fiber, (i) molecular 
weight and size of the analytes (ii) polarity (iii) concentration level and (iv) complexity of 
sample (Pawliszyn 2009), also the storage and transport between the clinic (Hannover 
Medical School) and the institute (Helmholtz Centre for Infection Research) had to be 
considered. In order to keep the experimental design as comparable as possible, the same fiber 
coatings were used for in vitro and in vivo applications. These demands were best fulfilled by 
a 75 µm Carboxen/PDMS fiber (Portable Field Sampler) from Supelco (Bellefonte, PA, 
USA). All fibers were preconditioned for 20 min in the injection port at 250°C before using or 
being brought to the clinic. The sorbent coated fiber was exposed for 10 min to the sample 
and, subsequently, VOCs were released by thermal desorption in the injection port of the GC 
at 200°C. Even after preconditioning, an individual peak pattern ubiquitously present in all 
associated chromatograms was observed for each SPME fiber. To minimize bias in the data 
analysis caused by these individual peak patterns, all fibers used for in vivo applications were 
numbered and indicated for each sample. For in vitro experiments the same fiber was taken 
for a series of associated VOCs extraction if possible. 
  
4.3.5 Gas chromatography/mass spectroscopy (GC/MS) parameters 
A Varian 450-GC gas chromatograph coupled with ion-trap mass spectrometer Varian 240-
MS (Varian, Palo Alto, USA) was used to perform GC/MS analysis. Injection of SPME fiber 
was done manually at 200°C and with splitless mode for 2 min, followed by a split ratio of 
100 for another 2 min and a final split ratio of 20. The column was a forte GC Capillary 
Column 50 m x 0.32 mm x 1 µm (SGE Analytical Science, Ringwood, Australia). 
Temperatures of ion trap, manifold and transfer line were 150°C, 50°C and 180°C 
respectively. The GC oven temperature was programmed from 35°C (hold for 2 min) to 
250°C in two steps with a total analysis time of 32 min: first the column was heated to 75°C 
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at 3°C min
-1
, followed by 15°C min
-1
 until final temperature was reached (hold for 5 min). 
Helium flow was set at constant rate of 1 ml min
-1
. Analyses were done in EI full scan mode 
with a mass range from 40 m/z to 205 m/z.  
 
4.3.6 CF cohort  
CF patients were recruited in the CF outpatient clinic of the Hannover Medical School (MHH; 
Hannover, Germany), after ethical approval for this study was granted by the local health 
authority ethics committee. All patients were between 30 - 48 years old and of both genders. 
Breath samples were taken during their routine examination in the ambulance. Anonymized 
clinical data of patients was collected, including culture-based microbiological diagnostics 
(Table S1). Additionally, breath samples of two healthy probands (30 years old; male and 
female) were taken in the Helmholtz Centre for Infection Research (Braunschweig, 
Germany). 
 
4.3.7 In vivo breath sampling 
A commercially available device was used for the breath sampling (BIO-VOC
®
 sampler, 
Markes International Ltd, Rhonda Cynon Taff, UK) (Dyne et al. 1997)(Henderson & 
Matthews 2002). After carrying out a series of exhaled air samplings with healthy probands 
and CF patients to establish a comparable and reliable sampling method, both the equipment 
and the procedure recommended by the manufacturer was modified. Self-made autoclavable 
mouthpieces and an adequate adapter were designed (made of polyvinyl chloride) and 
adjusted to the breath sampler, in order to guarantee a sterile procedure and easy handling for 
the patients and the medical staff. Patients and healthy volunteers were asked to rest and, 
when they feel relaxed, to exhale out completely a single slow breath into the sampler. The 
last portion of the exhaled air, originating from the alveolar space, was trapped (approx. 100 
ml) and a SPME fiber was immediately exposed to the sample as described above. No cross-
contamination of exhaled VOCs was observed when breath sampler was kept unclosed for 
two hours to release the remaining analytes. Additional room samples were taken to measure 
VOCs in the ambient air of the sampling location. For this purpose, SPME fiber was exposed 
to the empty sampler without human breath.   
 
4.3.8 Data processing and statistical analysis 
GC-MS data was analyzed using the MS Data Review (Version 6.9.3) from Varian. Since 
injection was done manually, all peaks had to be compared by retention times and mass 
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spectra to enable alignment of chromatograms. Parameters for peak integration of in vitro data 
were the following: Peak Width. 4.0 sec, Slope Sensitivity 20 SN, Tangent 30%. For the host-
pathogen interaction cultures a minimum peak size of 10,000 units was chosen for most 
microorganisms and 5,000 units for P. aeruginosa respectively. For VOCs extractions from 
biofilms, no specific minimum peak size was defined. Parameters for peak integration of the 
in vivo breath sampling data were: Peak Width. 4.0 sec, Slope Sensitivity 2 SN, Tangent 10% 
and a minimum peak size of 10,000 units. After alignment of integrals from the different 
chromatograms, several peaks were rejected to exclude non-informative data points. For host-
pathogen interaction cultures, peaks were rejected that were not detectable in corresponding 
monocultures on LB agar and appeared additionally (i) just once, (ii) just twice but not in the 
last time points and without an increase of size, or (iii) just thrice but not in consecutive time 
points and not of increasing size. Similarly, peaks were excluded for the in vivo exhaled 
breath data: peaks that appeared in several controls and just with smaller peak size in breath 
samples, peaks detected in controls and just in breath samples of healthy individuals, as well 
as peaks present in all samples without a significant change of peak size. For further analysis 
all data were divided by minimum peak size (5,000 units for in vitro and 10,000 units for in 
vivo data) and overall transformed (individual factors are mentioned). A maximum peak size 
before transformation of 100 was defined for the in vivo exhaled breath data. Heatmaps were 
calculated using the software package R (R Development Core Team 2011) from the colour 
palettes, the topo.colors package was chosen without scaling to either rows or columns.  
Further statistical analyses were carried out using PRIMER (Version.6.1.6, PRIMER-E, 
Plymouth Marine Laboratory, UK). Resemblance matrices were calculated using Euclidean 
distance algorithm, taken all variables of a profile into account and providing the shortest 
statistical distance between every pair of samples. Euclidean distance is the square root of the 
sum of squared differences between profiles, the data of these has to be measured on the same 
scale. The samples were ordinated in non-metric multidimensional scaling (MDS) plots (with 
50 random restarts), distances between samples in these plots reflect differences in the VOC 
compositions monitored for the samples. Trajectories were used to connect associated data 
points in chronological order. For each MDS plot, 2D stress values indicate the differences 
between ideal distances in higher dimensional space and the actual distances in two 
dimensional space. Therefore, 2D stress values are a measure for the reliability of the MDS 
plots. Additional analysis for in vivo data was performed using BEST analysis with BIOENV 
algorithm, which tries all variable combinations to find the ones “best explaining” the 
ordination pattern of the samples.  
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4.4 Results 
 
Volatile organic compounds were monitored in different experimental set-ups, which are 
presented in consecutive order. Further identification of emitted compounds was not considered 
to be necessary for this diagnostic manner. Retention times and mass spectra revealed sufficient 
assessment for peak differentiation.  
 
4.4.1 In vitro VOCs monitoring in biofilms of CF pathogens               
Fig. 1A: 
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Figure 1A, B: VOCs detected from pathogens grown in biofilms on LB agar. A. Chromatograms show 
representative peak profiles in the following order (from top to bottom): P. aeruginosa, S. aureus, C. albicans 
and A. xylosoxidans. Arrows indicate conspicuous individual peaks highlighted for better orientation.                      
B.  Diagrams show integrals from conspicuous individual peaks released in biofilms. Overall transformation 
factors are mentioned in each diagram. Retention times of peaks are given on x-axes. Standard deviations are 
shown by error bars.  
 Fig. 1B: 
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VOCs were extracted from microbes of relevance for CF patients, grown in biofilms on LB 
agar. The resulting chromatograms are shown in Figure 1A. After overnight incubation the 
cultures revealed different peak profiles for each pathogen. In addition, VOCs extractions 
were done as a control before the cultures had been started and used for comparison to 
identify unique or remarkable peaks for each microorganism. By this conspicuous individual 
VOCs were characterized for each biofilm. Just peaks ubiquitously present in all 
chromatograms of one pathogen but not in the controls were considered. Individual intensities 
did vary in different extractions and means of integrals are shown in Figure 1B. The 
following conspicuous VOCs were assessed: Peak at 10.921 min was present in all extractions 
and although also detectable before cultures were started, its intensities increase considerably 
with the presence of a microorganism. For P. aeruginosa, in total five conspicuous individual 
VOCs were detected. Only peaks at 22.456 min and 24.833 min were unique to the biofilm of 
this microorganism the others were likewise detected for the different pathogens. Four VOCs 
were found for C. albicans, from which just the one at 22.581 min was unique to the fungus. 
The peak at 10.221 min was also seen for P. aeruginosa and the one at 3.196 min also for S. 
aureus cultures in which extractions revealed in total nine, mostly unique peaks. A. 
xylosoxidans showed the smallest number of conspicuous VOCs. Just one of the four was 
unique to this betaproteobacterium. VOC at 20.056 min was also detectable in the controls but 
with much less intensities. A remarkable increase was observed for VOC at 10.921 min 
especially in comparison to the other microorganisms: in this biofilm, the peak integral 
(square root transformation) is 6,408 whereas the others show peak areas between 645 and 
1,000. Additionally, VOC at 22.241 min was also present in cultures with P. aeruginosa. In 
summary, comparisons of profiles from monoculture biofilms reveal an individual VOC 
composition for each pathogen in culture, allowing discrimination among the different 
biofilms.   
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4.4.2 In vitro VOCs monitoring in host-pathogen interaction cultures (A549 cells) 
Fig. 2A:     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2B:    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2A, B: Imaging of host pathogen interaction cultures. A. Light microscopy was performed during each 
series of VOCs extractions. Upper pictures: on the left, C. albicans was growing in hyphal form on a confluent 
monolayer of A549 cells. On the right, P. aeruginosa interaction culture, where the cell monolayer showed 
increasing signs of detachment during incubation. Both pictures are done with 10x objective lens. Lower picture: 
on the left, A. xylosoxidans in co-culture with apparently confluent A549 cells. On the right, S. aureus was 
growing in typical clusters in the cell culture medium. A 20x objective lens was used for these images. 
B. LSM imaging for C. albicans on A549 cells. Fungal hyphae appeared in blue and human cells were 
fluorescenting in green. 
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A. Peak profiles 
 
Figure 3: Heatmaps showing peak-integrals of chromatograms from A. xylosoxidans (Axyl), C. albicans (Calb), 
S. aureus (Staph) and P. aeruginosa (PaO). T0 - Tmax are time points of VOCs extraction from the host-
pathogen interaction cultures. Peaks were aligned by their retention times as well as mass spectra and numbered 
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chronologically P1-42. In each heatmap, the last column shows peak compositions from corresponding 
monocultures on LB agar. Peaks are individually labelled and integrated in chronological order according to 
peaks P1-42 for each pathogen. Characteristic VOCs released in both cultures are marked in red, those released 
only in the interaction cultures are marked in blue. Additionally, peaks exhibiting similar retention times and 
mass spectra, in comparison with the monoculture biofilms, were highlighted with *-symbol.     
 
To further verify the individual peak composition of each pathogen, VOCs extractions were 
performed during microbial growth on the human epithelial cell line A549. Growth of 
pathogens and status of the cell monolayer was observed visually by microscopy coupled with 
digital imaging (Figure 2A, B). A549 cells in interaction with P. aeruginosa showed 
increasing signs of damage, by means of decreasing confluency. No such damage was 
observed for interaction with the other pathogens. C. albicans was growing in hyphal form 
and appeared to be attached to the A549 cells, whereas S. aureus grew in its typical clusters. 
Peak profiles, taken from host-pathogen interaction cultures during the course of 
growth/interaction, are shown in Figure 3. Peak intensities were calculated individually for 
each heatmap, therefore, the representing colour gradients are not comparable between the 
different figures. All interaction cultures show a rather complex profile. Strong fluctuations of 
intensities are observed for various peaks throughout a series of VOCs extractions revealing 
no obvious pattern, whereas several other peaks did not show any major change in their 
intensities. Peaks P22, P24, P30 were present in all chromatograms with high intensities. 
Others were not detected in all cultures but gave constantly signals in a series of VOCs 
extractions for one or more interaction cultures (e.g. P38, P39, P30, P28, P29). However, 
major differences in the profile composition were observed for all host-pathogen interactions. 
In order to point out these differences and to weight their significance, samples where 
compared by their peak profiles using the Euclidean distance algorithm after transformation 
(log X+1), results are ordinated in the MDS plot in Figure 4. Logarithmic transformation was 
used to reduce the impact of large values from single peaks in order to keep the complete 
profile in consideration including peaks with relatively small values. Each time point was 
indicated by a symbol according to the pathogen, labelled T0 to Tmax and combined with a 
trajectory in chronological order. The MDS plot revealed an obvious change in the peak 
composition during incubation for each interaction culture. For all four pathogens, starting 
points (T0) were ordinated in the centre of the plot. During incubation, the statistical distances 
between the peak compositions of each sample was increasing and the time points are shifting 
away from each other to different quarters of the MDS plot, indicating a continuous change 
over time for each interaction culture.  
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Figure 4: MDS plot of host-pathogen interaction cultures. Each symbol represents one time point of VOCs 
extraction. Distances between symbols reflect differences in the VOC compositions monitored for each sample 
and time point: the closer the symbols are to each other, the more similar were the VOC compositions. Symbols 
for C. albicans are in red, S. aureus in orange, A. xylosoxidans in blue and P. aeruginosa in black. Trajectories 
combine the different time points of each interaction culture.  
 
 B. Characteristic VOCs 
Except for C. albicans, the trajectories revealed some discrepancies between the changing 
peak composition and the time line. For P. aeruginosa and A. xylosoxidans time points T1 and 
T3 were closer than T2 and T3. For S. aureus time points T3 and Tmax were closer than T4 
and Tmax. In order to reveal which peaks were responsible for the main differences over time, 
it was hypothesized that peaks once they came up and show a steady increase should be 
considered to come from volatile compounds released in interaction between host and 
pathogen or by the growing pathogen alone. To all these peaks was further referred to as 
characteristic VOCs. Peaks P12 and P13 of S. aureus were also considered, although not 
continuously increasing but staying at high levels at later time points. In Figure 3, 
characteristic VOCs are marked according to comparisons with the corresponding 
monoculture on LB agar, shown in the last column of each heatmap. Peaks fulfilling the 
above criteria for characteristic VOCs and released in both, the interaction culture and the 
corresponding monoculture, are marked in red and those just released in the interaction 
culture are marked in blue. Conspicuous peaks already observed in the monoculture biofilms 
(Figure 1A, B) and also meeting peak integration criteria in this experiment were listed in 
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Table 2 and additionally highlighted in Figure 3. Signals constantly considered in all cultures 
and biofilms with the particular pathogen were P33 for C. albicans, P32 for P. aeruginosa and 
P14 for both of these microorganisms. Although ubiquitously present in all monoculture 
biofilms on LB agar, P16 was just observed in the host-pathogen interaction culture of A. 
xylosoxidans. Notably, none of the characteristic VOCs detected in the interaction culture 
with S. aureus was observed in the monoculture biofilm on LB agar. 
 
Microorganism Signals in biofilms      
Signals in interaction cultures & 
corresponding monocultures 
A. xylosoxidans 10.921 min P16   
  20.056 min   LB_A8 
  22.241 min /   
C. albicans 3.196 min   LB_C2 
  10.221 min P14   
  10.921 min   LB_C5/LB_C6 
  22.581 min P33   
S. aureus 3.196 min   LB_S3 
  10.921 min   LB_S9 
  14.192 min   LB_S11 
  19.811 min   LB_S14 
  23.250 min   LB_S17 
  25.536 min   LB_S18 
  27.471 min /   
  27.553 min   LB_S20 
  29.705 min /   
P. aeruginosa 10.211 min P14   
  10.921 min /   
  22.241 min /   
  22.456 min P32   
  24.833 min /   
 
Table 2: Matching conspicuous peaks detected for pathogens under different in vitro conditions. Signals from 
monoculture biofilms were given by their retention times in minutes (min) and signals from host-pathogen 
interaction cultures or corresponding monocultures were mentioned according to their labels in Figure 3. Peaks 
in one row were matching in the different cultures and biofilms whereas the slash indicates no matching peak 
within parameters of integration.  
 
To further test the hypothesis of characteristic VOCs, a new MDS plot was calculated taken 
only these peaks into account (Figure 5A). The trajectories revealed that composition of 
characteristic VOCs was changing continuously in the samples throughout a series of VOC 
extractions. Each time point was more distant to T0 than the previous ones. One exception has 
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to be mentioned here: the first three time points (T0-T2) in P. aeruginosa were overlapping 
and therefore showed no distance to each other at all. For all microorganisms characteristic 
VOCs did make the main differences during incubation. The final composition of 
characteristic VOCs from each host-pathogen interaction culture, one day post infection, were 
shown in Figure 5B. Several of these VOCs were detected for more than one pathogen but 
their intensities did vary when compared with other peaks released in the same interaction 
culture. Signals P13, P14, P15 were detected in all cultures, except for A. xylosoxidans 
interaction cultures, and P7 was likewise only not detected for P. aeruginosa. Characteristic 
VOCs unique to one interaction culture are P16 and P23 for A. xylosoxidans, P11 and P33 for 
C. albicans and P32 for P. aeruginosa. S. aureus did not show any unique signal in the host-
pathogen interaction cultures but different relative intensities of the emitted VOCs in 
comparison to other the host-pathogen cultures.  
Summing up, not just presence and absence of released VOCs but also the relative intensities 
were characteristic for each host-pathogen interaction culture, allowing discrimination 
between the different pathogens in vitro and even between different time points during 
incubation of the interaction cultures. 
  
 
Figure 5A, B: Discriminative characteristic VOC compositions. A. MDS plot was calculated just considering 
discriminative characteristic VOCs of each sample. Trajectories combine the series of VOCs extractions from 
each host-pathogen interaction culture. B. The heatmap was calculated with characteristic VOCs detected in the 
last time points Tmax. Relative intensities of peaks are indicated by the colour gradient.  
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4.4.3 In vivo VOCs monitoring in exhaled breath of CF patients 
Since volatile organic compounds allowed discrimination between major CF pathogens in 
vitro, the next step was to investigate the diagnostic potential of these characteristic VOCs for 
clinical diagnostic purposes in vivo. Therefore, a breath analytical procedure was established 
based on the same principles like the in vitro VOCs extractions. After adaptation to clinical 
needs, this method was integrated in the routine ambulance examinations for CF patients. 
Furthermore, the individual microbiome was elucidated by culture independent methods for 
each patient, taken at same day as the exhaled air samples, thus allowing correlation between 
both clinical samples. Comparable peak profiles were generated for nine CF patients and two 
healthy individuals. Additionally, four air room samples were taken and three profiles were 
generated from SPME fibers stored in the sampling locations without exposition. 
Identification under defined parameter revealed in total 36 peaks for all profiles showing 
differences in retention times and mass spectra. They were numbered hP1-hP36 and the last 
peak was assessed at a retention time of 26.739 min (Figure 6). Again, rather complex 
profiles for all extractions were observed. Remarkable peaks were hP3 and hP5, which were 
present in high intensities in all exhaled breath extractions, whereas controls showed no 
signals or just in low intensities. Peaks hP4 and hP6 were detected in all samples extracted at 
the clinic, but never in those made at the institute. Signal hP10 was ubiquitously present in all 
profiles and intensities were higher in all samples stored or transported for more than 1 hour 
after exposition. Furthermore, SPME fibers showed individual peak patterns detected in all 
chromatographic runs made with one specific fiber (e.g. hP32 and hP25 for fiber #7). Several 
peaks were just detected in one or more profiles of exhaled breath from CF patients, although 
mostly with low intensities. Since none of these peaks were matching with the characteristic 
VOCs or conspicuous individual VOCs of the in vitro extractions, by means of retention times 
and mass spectra, the exhaled air profiles were further analysed beyond the previously defined 
parameters of peak integration. Using the MS Data Review, chromatographic runs from in 
vivo VOCs extractions were re-examined by displaying chromatograms generated by the 
particular mass-charge ratios (m/z) of the discriminative VOCs detected in the in vitro 
experiments. Thus, clean chromatograms for those compounds could have been provided out 
of the full scan runs giving a higher resolution for the peaks of interest. However, none of the 
discriminative VOCs were detected in the exhaled breath profiles. 
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Figure 6: VOCs composition from exhaled air of CF patients. VOCs extractions from exhaled breath are marked 
in red, whereupon ProA / ProB are healthy non-CF individuals. Room samples are indicated in blue and SPME 
fibers without exposition are marked in black. Peaks are identified under given parameter and numbered hP1-
hP36. The colour gradient is indicating the peak intensities relative to each other.    
 
For a detailed analysis of the peak profiles, resemblance matrices were calculated with in vivo 
data and samples were accordingly ordinated in a MDS plot (Figure 7). Although none of the 
characteristic VOCs or conspicuous individual peaks was detected, the MDS plot revealed a 
clear clustering of all exhaled breath profiles, clearly separating the healthy individuals from 
the CF patients. Similarly, all control samples ordinated closely together. Furthermore, the 
MDS plot showed a separation between samples extracted in the clinic (grey box) and those 
extracted at the institute. Comparisons with clinical or microbial data sets from the patients 
revealed no further correlations explaining the pattern in the MDS plot. Based on the 
assumption that distances in the resemblance matrix were dominated by a few peaks that were 
independent from microbial or clinical data sets, “BEST” routine analysis was performed on 
the distance matrix in order to identify the main peaks, responsible for the ordination pattern 
shown in the MDS plot, with a maximum number of five variables. Thus every peak, given in 
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a subset of five with a Spearman rank coefficient higher than 0.940, was considered. A new 
distance matrix was calculated without the dominant peaks hP3-hP6, hP8, hP20, hP31 and 
displayed in a new MDS plot (data not shown). Again, comparisons between microbial and 
clinical data with the pattern in the MDS plot revealed no correlation.        
 
 
 
Figure 7: MDS plot of VOCs extraction from in vivo experiments. Peak compositions of different samples were 
compared: human exhaled air is marked in red, whereupon ProA / Pro9B are healthy non-CF individuals. Room 
samples are indicated in blue and SPME-fibers without exposition are marked in black. The numbers indicate 
each of the four individual SPME fibers of the type 75 µm Carboxen/PDMS, which were used for the 
extractions. Locations of sampling were mentioned with MHH/mhh for clinical samples and HZI/hzi for 
extractions performed in the institute.    
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4.5 Discussion  
 
In this study, the emitted VOCs of different microorganisms from the vast spectrum of 
microbial pulmonary pathogens were investigated to assess if they could be used for species 
discrimination and further clinical diagnostic purposes. In vitro experiments with different 
growth conditions were combined with in vivo exhaled breath analysis of CF patients 
suffering from microbial respiratory tract colonization. Microorganisms included in this study 
were the major CF pathogens P. aeruginosa and S. aureus, the emerging innately multi-
resistant betaproteobacterium A. xylosoxidans and the polymorphic fungus C. albicans.  
 
4.5.1 Relevance of appropriate statistical methods in VOC emission analysis 
Fast developing bio-analytical technologies such as the extraction and analysis of microbial 
VOCs in vitro and exhaled VOCs in vivo are generating large data sets requiring advanced 
mathematical tools for comparative studies. Thus, bio-statistical methods are of increasing 
importance in VOCs profiling with a particular emphasis on data exploration by visualization 
and identification of grouping trends (Boots et al. 2012). The multidimensional scaling 
(MDS) plots used in this study have the advantages to feature multivariant similarity 
measurements and simultaneously allow information about the variables that are responsible 
for certain groupings. In this study, the rather complex VOC emission profiles generated in 
vitro and in vivo were simplified by reducing the information to Euclidean distances between 
all samples. The resulting MDS plots clearly revealed discriminative VOC emissions, enable 
differentiation between species in vitro and even visualized a specific diversification as a 
function of time. Similarly, grouping of in vivo exhaled breath samples clearly separated from 
control samples could be illustrated. Multivariant analysis using (distance) resemblance 
matrices and MDS plots are therefore an appropriate statistical tool to analyze and compare 
VOC profiles. This is in accordance with another recent study using this statistical strategy to 
differentiate between microbial VOCs emissions in vitro (Thorn et al. 2011). 
 
4.5.2 Application of in vitro VOC emission models for microbial discrimination  
In vitro microbial VOCs profiles were studied and compared using two different model 
systems: (i) monoculture biofilms and (ii) host-pathogen interaction cultures. Biofilm 
formation is considered to be a major factor in recurrent and chronic pulmonary infections, 
especially in CF patients (Liu & Post 2009). Rather simple monoculture biofilms were grown 
in vitro and used to verify the potential of VOCs to discriminate between different pathogens. 
To achieve conditions more similar to the human respiratory tract, the host-pathogen 
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interaction culture system was established. To this end, the human lung epithelial cell 
monolayer was inoculated with high amounts of pathogens to mimic infection conditions. In 
bronchoalveolar lavage (BAL) studies a threshold to discriminate infection from colonization 
was defined as 10
4
 or 10
5
 CFU ml
-1
 (American Thoracic Society & Infectious Diseases 
Society of America 2005), which is well below the numbers used in this study even when 
taken the dilution factor of BAL diagnostics into account. Only the A549 monolayer 
inoculated with P. aeruginosa showed visible signs of damage but all pathogens showed 
typical growing behaviours, therefore this system was considered to be more an interaction 
rather than infection culture. VOC extractions from biofilms showed individual emissions, 
allowing differentiation between the pathogenic species included in this study. The host-
pathogen interaction cultures revealed a similar picture: VOC emissions allow differentiation 
of species and even of different time points during incubation. However, most of the detected 
volatiles were released by more than one microorganism. Studies in the past concentrated on 
the search of single biomarker molecules for a certain respiratory pathogen (Chambers et al. 
2009) (Phillips et al. 2010) (Scott-Thomas et al. 2010a), which is accompanied by several 
difficulties that are further discussed below in the context of this study. Comparisons of 
profiles from the same pathogen in biofilm and host-pathogen interaction culture showed 
major differences. Only for P. aeruginosa and C. albicans, one unique VOC could be 
observed in all experimental set-ups. The profiles extracted in biofilms and corresponding 
monocultures showed little differences as well, these compounds had been detected but were 
not fulfilling the parameter of peak integration and were therefore not considered in the 
profiles of the corresponding monocultures. S. aureus is of particular interest, since rather 
different volatile metabolites were observed in the biofilm and during various time points of 
interaction with A549 cells. This might be due to different physiological states of the 
bacterium during VOCs extractions and profiles might get more similar the longer they are 
incubated (O’Hara & Mayhew 2009) or due to the different atmospheres with unequal oxygen 
and CO2 levels. Since cultures on LB agar grew in closed vials, oxygen supply is limited and 
this might influence the metabolism and production of VOCs in particular. Transcriptional 
and metabolic changes in S. aureus, adapting to different oxygen concentrations were well 
described in several studies (Fuchs et al. 2007) (Sun et al. 2012).  
For all microorganisms in this study, certain differences in the VOC emissions were observed 
when biofilm and interaction cultures were compared. Furthermore, VOCs emissions were 
shown as a function of time during interaction with host cells with variable but specific 
compositions for each microorganism. It was previously shown that production of VOCs is 
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directly linked with the physiological state of bacteria or fungi and therefore, temporal 
variability of VOC emissions have to be taken into account for the search of volatile marker 
compounds (Bunge et al. 2008). Furthermore, the substrates available for the microorganisms 
also alter the VOC production, intensity and even the type of compound are strongly 
influenced by the growth media (Scotter et al. 2005). Several studies investigated VOCs 
released by P. aeruginosa and S. aureus in vitro (Cox & Parker 1979) (Labows et al. 1980) 
(Zechman & Labows Jr. 1985) (Barbieri et al. 2005) (Carroll et al. 2005). Different culture 
conditions, extraction methods and analysis strategies revealed numerous compounds in the 
headspace of these microorganisms with partly divergent results (Allardyce et al. 2006a) 
(Preti et al. 2009) (Zhu et al. 2010) (Shestivska et al. 2011) (Goeminne et al. 2012) (Filipiak et 
al. 2012). Furthermore, since metabolic pathways underlie similar principles throughout all 
microorganisms other sources for several microbial VOCs are found including mammalian 
breath (Korpi et al. 2009). Recently, 2-aminoacetophenone was getting in the focus as 
biomarker molecule for P. aeruginosa and was used in a first breath analysis study to 
discriminate P. aeruginosa-colonized CF patients from others (Scott-Thomas et al. 2010b). 
However, other studies detected this compound also in the headspace of different respiratory 
pathogens such as S. aureus and Burkholderia cepacia (Allardyce et al. 2006b) (Thorn et al. 
2011). Taken together, results of this study go in accordance with the literature showing that 
identification of reliable single molecule biomarker in vitro, unique for each pathogen, 
seemed to be highly disputable. Growth of microorganisms was observed in vitro by their 
specific VOC compositions. Only for P. aeruginosa and C. albicans unique compounds 
released under all tested conditions were observed, but their species-specificity and universal 
emission under the specific conditions in the human lung remains to be demonstrated. 
 
4.5.3 Feasibility of exhaled VOCs analysis for diagnostics of pulmonary infections  
None of the VOCs from in vitro cultures were detected in exhaled breath of CF patients 
although colonization of patients with pathogens was assessed. This highlights the importance 
of performing studies in humans to identify true biomarkers. Difficulties in the search for 
single volatile biomarker are discussed in detail above. Further explanations, could be very 
low concentrations of the compounds and the relatively healthy status of the studied 
individuals from the CF ambulance centre. For SPME, an individual detection limit for each 
compound has to be considered. Exhaled human endogenous VOCs are considered to be 
present in levels of parts-per-billion (ppb) with higher levels of metabolites associated with 
diseased states (Amann et al. 2007). Also a possible overrepresentation of VOCs from the 
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ambient air has to be considered. Further data mining procedures like the search for particular 
mass-charge ratios of microbial VOCs or “BEST” routine analysis to exclude ambient air or 
ubiquitous human endogenous VOCs did not reveal any positive correlations. Far more than 
500 different VOCs from diverse origins and biochemical pathways have been detected with 
various methods in human exhaled air (Miekisch et al. 2004). Just small subsets of them were 
detected in this study, revealing already complex profiles for each sample. Data exploration 
by MDS plots revealed well defined groupings of breath samples and controls. However, a 
strong influence by the ambient air was observed and may have a strong influence on the 
separation of exhaled air samples of healthy individuals and CF patients. In a comparative 
study investigating concentrations of 12 VOCs in exhaled breath from 20 CF patients versus 
20 healthy individuals, slightly altered compositions were observed between both groups and 
gave no unambiguous correlations (Barker et al. 2006). Barker et al. also observed increased 
n-pentane levels, which are discussed as a marker for inflammatory diseases, including lung 
diseases (Olopade et al. 1997) (Schubert et al. 1998). However, a strong correlation between 
room and exhaled n-pentane was likewise observed, suggesting to take increased hydrocarbon 
levels cautiously (Gorham et al. 2009). Nevertheless, in this study differences in exhaled air 
profiles were observed and resulted in a certain grouping of VOCs profiles from CF patients. 
To assess further correlations with the entire individual microbiome, medications or health 
conditions, the cohort needs to be expanded. Robroeks et al. recently considered 1099 VOCs 
in the breath of paediatric CF patients and achieved 100% identification of CF patients and 
healthy individuals by using 22 VOCs (Robroeks et al. 2010). Even further discrimination of 
P. aeruginosa colonized patients was achieved by the use of 14 compounds. These results 
strongly support the hypothesis that rather a composition of exhaled compounds than single 
molecules might allow the differentiation between respiratory infections. To validate the 
suitability and importance of VOCs for the purpose of exhaled breath diagnostics, their 
biosynthetic pathways and origins have to be further elucidated (Miekisch et al. 2004) 
(Buszewski et al. 2008). For the methodology, a key issue is the breath sampling and exhaled 
VOCs extraction procedure. On the one hand it has to be easy-to-use for clinical purposes and 
on the other hand cross-contaminations have to be avoided. A similar strategy with the 
commercial BIO-VOC sampler and SPME fiber was also used in other diagnostic research 
approaches for respiratory diseases (Poli et al. 2005) (Poli et al. 2010). To bind exhaled 
VOCs, the choice of the adsorbent material on the sorbent trap strongly depends on the 
compounds of interest. Caldeira et al. further compared different sampling strategies and 
showed advantages of Tedlar
®
 bags in terms of number and peak area of collected compounds 
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(Caldeira et al. 2011). However, their handling and cleaning requires more training making an 
implementation in clinics more difficult.  
 
 
4.6 Conclusion and perspectives 
Exhaled VOCs analysis for the detection of pulmonary infectious diseases is still in the 
research phase but evidence is accumulating that it could be a rapid and efficient diagnostic 
tool in the future. This study showed that the presence and relative intensities of VOCs 
allowed differentiation of microbial species and support the hypothesis that the composition 
of exhaled VOCs in human breath delivers information to identify patients with certain 
infections. A major challenge will be the development of a standard breath sampling and 
VOCs extraction method suitable for clinical diagnostics. Statistical methods, like MDS plots, 
are essential tools for this purpose to measure multivariant similarities and to visualize 
correlation patterns. The more exhaled VOCs samples are considered the more powerful these 
statistic approaches will be.  
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4.8 Supplementary Material 
 
patient 
sampling 
date 
gender 
date of 
birth 
FEV1 
value 
clinical diagnostics 
tso 01.11.2011 ♀ 03.06.1975 / P. aeruginosa; Candida albicans 
dst 02.11.2011 ♂ 29.08.1966 36 % P. aeruginosa; Candida albicans 
han 15.11.2011 ♂ 17.11.1979 56 % P. aeruginosa; S. aureus; Penicillium 
rth 15.11.2011 ♂ 31.12.1970 46 % 
P. aeruginosa; S. aureus;                
Aspergillus fumigatus 
rsi 16.11.2011 ♀ 05.12.1968 / P. aeruginosa; Yeast species 
ech 23.11.2011 ♂ 23.06.1963 25 % P. aeruginosa; Pseudallescheria boydii 
eni 23.11.2011 ♀ 08.04.1970 19 % P. aeruginosa; Streptococci 
nyu 06.12.2011 ♂ 19.06.1981 29 % 
P. aeruginosa; S. aureus;                     
Candida albicans 
ual 07.12.2011 ♂ 20.07.1978 26 % 
P. aeruginosa; S aureus;                    
Candida albicans; Enterococcus spec. 
 
Table S1: Clinical data of CF patients reported from the CF outpatient clinic of the MHH. Anonymized 
identification code for each patient is given. FEV1 value (forced expiratory volume in 1 second; predicted) 
indicates lung function for the respective patient: FEV1 70 - 89 % shows mild lung malfunction, 40 - 69 % 
indicates moderate lung malfunction and less than 40 % is a sign of severe lung malfunction. Microorganisms 
detected in the individual sputum samples by the routine clinical diagnostics are mentioned.   
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Chapter V 
General Discussion 
 
 
 
 
5.1 Diagnostic methods for lower respiratory infections 
Diagnostics of infectious diseases are critical to initiate the appropriate treatment. Clinical 
microbiological laboratories have already undergone important changes in the past decades 
and further improvements are needed to cope with new challenges and aspects elucidated in 
respective research, such as microbial community profiling (Raoult et al. 2004). For lower 
respiratory infections in CF, detection and monitoring of pathogens over time are key issues 
in health management. Clinical microbial diagnostics for CF lung diseases are based on 
cultivation methods. Though, in comparison with next generation sequencing (NGS), high 
accuracy was demonstrated for the detection of major pathogens, it only allowed a limited 
view of the community in terms of richness and diversity (Chapter II). Interestingly, profound 
contamination of sputum samples by oral cavity bacteria were not observed and the same 
species were found in lung tissue and in sputum taken prior to the lung explantation (Rogers 
et al. 2006) (Rudkjøbing et al. 2011). Therefore, communities in sputum samples assumingly 
display well the lower respiratory communities. Microbial community profiling, however, has 
attracted more interest in the past years by using a variety of approaches (Bittar & Rolain 
2010). Hereby, culture-independent methods are necessary to explore the diversity of the 
communities and to establish compositional analyses (Rogers et al. 2009). Although well 
established in research, conventional fingerprinting methods are technically too complicated 
to be applied in routine diagnostics. However, they facilitate accurate profiling of the 
abundant species in complex communities for research purposes (Chapter II) (Chapter III) 
(Pedrós-Alió 2012). Commercially available NGS platforms may facilitate the translation of 
microbial profiling into clinical diagnostics. NGS technologies, like Illumina, offer high 
reproducibility and are capable to analyse large numbers of samples (Chapter II). However, 
drawbacks of these methods are time-consuming sample preparation and the bioinformatic 
effort. These issues substantially complicate the translation into routine diagnostics. 
Additionally for all sputum-based methods, it applies that bias may occur due to uneven 
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spatial distribution of certain bacteria in the sample and in the different compartments of the 
human lungs (Willner et al. 2012) (Goddard et al. 2012).  
 
Analytical, sputum-independent diagnostic approaches, like the detection of volatile microbial 
biomarker in exhaled breath, may represent a future alternative in diagnostics (Chapter IV). In 
particular, volatile organic compounds (VOCs) were extracted from exhaled air and their 
potential to differentiate subgroups of CF patients by microbial infections was elucidated 
(Robroeks et al. 2010). Monitoring and discrimination of different pathogens in vitro was 
successfully approached by extraction and analyses of emitted microbial VOCs (Chapter IV). 
However, this approach implies characterization of specific compounds which might be a 
major drawback in comparison to NGS. Molecular microbial profiling methods, including 
fingerprinting, reveal the entire structure and composition of microbial communities without 
previous selection (Chapter II) (Chapter III). Discrimination of specific pathogens requires 
knowledge about respective marker compounds beforehand. In this term, a selection has to be 
done in exhaled breath analysis. Nevertheless, detection of universal inflammatory markers, 
which might include VOCs, may be used for indirect detection of infectious agents (Paredi et 
al. 1999) (Paredi et al. 2000). Finally, the characterization of exhaled endogenous or microbial 
VOCs, including knowledge about their origins or even ecological functions, will contribute 
to a more profound and comprehensive understanding of lower respiratory tract infections and 
reinforce the great potential of exhaled air analyses for diagnostic purposes.   
 
5.2 Microbial community structure and composition in CF sputum 
Microbial communities observed in sputum samples from CF patients consist mostly only of a 
few species, whereas the entire community observed in a cohort appears to be more complex 
with greater variation between patients (Chapter II) (Chapter III). Therefore, each community 
that colonizes the lower respiratory tract might be considered to be rather unique (Stressmann 
et al. 2012). The principles for this specification are following a universal pattern: in a review, 
focussing on marine microbial communities, Fuhrmann (Fuhrman 2009) discussed the classic 
dictum about microbial distribution “everything is everywhere” and that the environment 
selects those organisms best fitted to the individual conditions in one site. Assumingly, the 
same principle applies in the lower respiratory tracts of CF patients. The observation, that the 
more widespread bacteria are also the most abundant ones in individual samples was made in 
environmental microbiology and recently also in CF sputum (Pommier et al. 2007) (Guss et 
al. 2011) (Zhao et al. 2012). This phenomenon was becoming more apparent for CF 
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respiratory tracts with structural and compositional analyses in a large number of patients 
(Chapter II) (Chapter III). Assumingly, abundant species are more likely to be detected 
whereas rare bacteria might mostly be present in samples but more likely under the detection 
limit (Fuhrman 2009). Only in certain cases, these rare bacteria find an ecological niche and 
grow. Therefore, this observation might be another argument for the universal principle 
underlying microbial colonization of CF respiratory tracts.  
 
The origin of these species is of particular interest to evaluate their colonization abilities. 
Most species observed in CF sputum are either widespread organism, that are commonly 
found in soil or water, or species known to be normal inhabitants of oral cavities and upper 
respiratory tracts in humans (The Human Microbiome Project Consortium 2012) (Chapter 
III). Oral cavities potentially act as a reservoir and ‘stepping stone’ for bacterial immigration 
into the CF lung (Rogers et al. 2006). Those immigrations are further reported for distinct 
clones of P. aeruginosa which were demonstrated to migrate from the paranasal sinuses, 
where they evolve and gain growth advantages, into lower airways to which they had become 
well adapted (Hansen et al. 2012). Likewise, the oral fungal microbiome is known to consist 
not only of bacteria but also of different yeast species, in particular from the genus Candida 
(Ghannoum et al. 2010). Saccharomycetes and other yeasts also make a large proportion of 
fungi observed in sputum samples (Müller & Seidler 2010). Similar migration routes are 
suggested for these species (Chapter III). For most other fungi, aerial dispersion is more likely 
the driver of distribution (Fröhlich-Nowoisky et al. 2009). Considering the higher number of 
fungal species, in comparison to bacteria, observed in a broad CF cohort and a considerably 
large number of species only detected in one sample, the colonization abilities of these fungi 
are assumingly not as adapted to the lung environment as those of bacteria (Chapter III).  
 
In this regard, resilience of microbial communities has informative character about the 
colonization abilities. Dynamics of communities were analyzed and revealed great differences 
between fungi and bacteria considering the number of species observed in repeatedly 
collected sputum samples from one patient (Chapter III). Bacterial richness is rather constant 
in comparison to fungi and even the bacterial community composition exhibits great stability 
over time (Chapter II). Therefore, bacterial communities are apparently less influenced by 
environmental factors, like seasonal variation and its accompanied change in vegetation or the 
change in life styles of patients. All human body sites and the respiratory tract in particular, 
are exposed to different species during the year. The vegetation plays an obvious role in this 
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change but also the different activities of the human hosts in different seasons have to be 
considered. Certain numbers of bacteria are always present in the sputum, whereas fungi are 
generally less represented or even not detectable (Chapter III). Therefore, greater variation in 
the respective richness for individual samples might be explained by the changing exposition 
in different seasons of the year.  
 
However, whereas bacterial colonization of the lower respiratory tracts in CF patients might 
be considered to be permanent, persistent fungal colonization assumingly depends on special 
conditions which only occur in rare cases (Chapter II) (Chapter III). Therefore, the majority of 
fungi is rather transient than persistent in the CF airways. In contrast, bacterial species 
assumingly find a broader range of ecological niches. Considering the presence of a thick 
mucus layer with a resulting oxygen gradient, even anaerobic conditions and respective 
ecological niches for anaerobic bacteria are logical consequences. Accordingly, compositional 
analysis even revealed persistently high relative abundances of strict anaerobic species in 
sputum samples of CF patients, like the S. millerii group or F. nucleatum (Chapter II). Thus, 
also infrequently observed bacteria can become dominant members of microbial communities 
under respective conditions and might influence the health of the host. 
 
5.3 Impact of communities on microbial infections 
The exploration of the human microbiome shifted the point of view on infectious research. 
Not only the introduction of a highly pathogenic organism to the human body causes a 
disease, likewise important seems to be the response of the microbial community to the 
presence of the intruder (Casadevall & Pirofski 2000) (Jenkinson & Lamont 2005). To 
understand the processes accompanying an infection, to initiate the correct treatment and to 
predict confidently the outcome of a disease, the importance of microbial community 
profiling is becoming more apparent. Because of the diagnostic challenges, the impact of the 
microbial community on lower respiratory infections in CF patients might be under-evaluated. 
Accordingly, recent molecular studies elucidated a growing number of emerging pathogens 
and a broad spectrum of bacteria associated with CF sputum, including anaerobic species 
(Tunney et al. 2008) (Bittar et al. 2008) (Rogers et al. 2009) (Guss et al. 2011). A general 
correlation between the colonization by anaerobic bacteria and P. aeruginosa infections was 
suggested but respective studies revealed ambiguous results (Tunney et al. 2008) (Worlitzsch 
et al. 2009) (LiPuma 2010). However, in communities with persistently dominant anaerobes, 
P. aeruginosa frequently appeared to be more abundant (Chapter II). In this context, the 
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observation of increased co-colonization from P. aeruginosa and S. millerii species in CF is 
of particular interest (Parkins et al. 2008). Enhanced virulence was suggested for this bacterial 
consortium. How such mutual influences on the growing behaviour of different species might 
occur is further demonstrated for F. nucleatum, which forms co-aggregates and mixed 
biofilms (Bolstad et al. 1996). In oral cavities, it enables growth of other pathogens by 
creating specialized microenvironments and benefits from exchange of metabolites (Diaz et 
al. 2002). S. millerii and F. nucleatum were both observed in persistently high relative 
abundances together with P. aeruginosa in CF sputum (Chapter II). The concept of 
polymicrobial consortia as one pathogenic entity was introduced by Rogers et al. (Rogers et 
al. 2010) in CF research. Consequentially, the entire microbial community may be regarded as 
opportunistically pathogenic (Jenkinson & Lamont 2005). In this regard, strongly reduced 
lung functions may not always be correlated with the abundances of single pathogens and 
health conditions may be better predicted by the determination of polymicrobial consortia 
(Chapter II). P. aeruginosa as the major pathogen assumingly has a great impact on these 
consortia. This microorganism is not only known to adapt well to the environment of the CF 
lung, with the mucoid phenotype being the most studied adaptation, also several mutual 
interactions with other microorganisms are reported (Hauser et al. 2011). Respective bacterial 
studies were described previously but besides bacteria also the growth of fungal species is 
influenced by P. aeruginosa. Several studies included the yeast Candida albicans which 
mutually interferes in biosynthetic pathways and growth of P. aeruginosa (Cugini et al. 2007) 
(McAlester et al. 2008) (De Sordi & Mühlschlegel 2009). Furthermore, also the biofilm 
formation of the filamentous fungi Aspergillus fumigatus can be altered by the bacterial CF 
pathogen (Mowat et al. 2010). All mentioned species were observed in CF sputum, thus it can 
be assumed that respective colonization abilities of fungi and bacteria are influenced by each 
other (Chapter III). Consequentially, also fungi have to be included in the polymicrobial 
approach to study lower respiratory infections. The still unknown pathogenicity of most 
fungal species in CF illustrates the relatively poor knowledge about these pathogens (Pihet et 
al. 2009). However, considering the low number of respective reports and the high exposure 
rate, their pathogenic potential can assumingly considered to be rather low. Further ecological 
studies might reveal the conditions that promote fungal growth and increase the risk of fungal 
pulmonary infections. 
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5.4 Outlook and Conclusion 
Elucidation of 72 sputum samples from 56 CF patients revealed that individual respiratory 
microbial communities are rather unique (Chapter II) (Chapter III). The number of abundant 
bacteria is comparably small regarding other environmental habitats but community structure 
and composition vary strongly between CF patients. Little is known about the individual 
drivers of colonization and respective ecological studies will substantially improve our 
knowledge about lower respiratory infections. For fungi, high exposure rates together with the 
large number of observed species is disproportionate to the reports of respective pulmonary 
infections which suggest a generally low colonization and infection ability for these 
organisms (Chapter III). Elucidation of the respective conditions to promote fungal growth 
would enable a more effective prevention of those life-threatening infections. Mutual 
interactions between bacteria facilitate polymicrobial consortia which in turn might influence 
substantially the virulence of species. Determination of these consortia appears to be 
challenging but may reveal and explain new emerging pathogens not considered previously, 
such as F. nucleatum (Chapter II). These observations will further influence the clinical 
microbiological laboratories. Routine diagnostics detect well the major pathogens, mainly 
Proteobacteria and S. aureus, but only allow a limited view in the microbial community 
(Chapter II). NGS technology will facilitate a more profound knowledge and assumingly 
broaden the spectrum of microorganisms to be detected in routine diagnostics. The translation 
of the technology itself into routine diagnostics appears to be challenging due to time und 
labour consuming preparations or analyses. However, alternatives for conventional based 
diagnostics are needed and exhaled breath analyses might be an appropriate candidate. 
Pathogen discrimination in vitro together with a first successful implementation in the clinics 
was promising (Chapter IV). Considering the feasibility of exhaled air analyses based on 
VOCs in routine diagnostics of CF lung diseases, major challenges have to be coped with. 
Origins and physiological functions of VOCs have to be elucidated to define their 
discriminative potential. Breath sampling methods as well as extraction of exhaled VOCs 
have to be improved and standards developed which are adapted to clinical needs, like the 
ease of operation.  
 
Overall, compositional microbial studies including bacteria and fungi will further increase the 
knowledge about the pathogenicity of species and will enable a better prediction on the 
outcome of infections. In particular, the identification of pathogenic polymicrobial consortia 
may be a crucial step in the development of advanced diagnostics for respiratory infections. 
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Critical factors that promote growth of the individual pathogens will be elucidated with a 
more profound knowledge of the human airway microbial ecology and together with 
innovative diagnostic approaches, such as exhaled breath analysis, it will further improve the 
life expectancy and quality of CF patients.  
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